Sentence,class,file
2011. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737421314 52.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
2012. http://www.health.gov.au/internet/publications/publishing.nsf/Content/oatsih-hpf-2012-toc~tier2~hlth- beh~215 62.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
2010. http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificRegulatoryCoherence.pdf 69.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
Availablefrom: http://www.iisd.org/itn/2011/07/12/philip-morris-v-uruguay-will-investor-state-arbitration-send-restrictions-on-tobacco-marketing-up-in-smoke/ 72.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
http://www.cancercouncil.com.au/65841/news-media/blog/healthy-living-cancer-prevention/out-with-traffic-lights-in-with-stars-%E2%80%93-next-steps-for-food-labelling-by-kathy-chapman/84.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
Available from: h https://ahha.asn.au/ sites/default/files/docs/policy-issue/20120615_deeble_institute_evidence_brief_food_labelling.pdf 89.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
"Report finds medicine affordability, public health policies at risk in Trans Pacific Partnership[media release] 3 March 2015. https://www.phaa.net.au/documents/item/512 90.",Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
"Trans Pacific Partnership poses grim risks: Fairfax Media [newspaper online], 3 March 2015. http://www.brisbanetimes.com.au/video/video-news/video-federal-politics/trans-pacific-partnership-poses-grim-risks-20150302-3rb85 92.",Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
http://thomas.loc.gov/cgi-bin/query/D?r112:66:./temp/∼r1129vJddO:: 93.,OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
Australia Financial Review 2015 4 Oct. http://www.afr.com/news/politics/national/us-australia-drug-dispute-is-holding-up-settlement-of-the-trans-pacific-trade-deal-20151003-gk0r65 94.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
2016. http://dfat.gov.au/trade/agreements/tpp/outcomes-documents/Pages/outcomes-health.aspx 95.,OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
2015. https://tpplegal.files.wordpress.com/2015/12/ep2-amokura-kawharu.pdf 97.,Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
"http://ccsi.columbia.edu/2015/11/18/the-tpps-investment-chapter-entrenching-rather-than-reforming-a-flawed-system/ Hirono K, et al.BMJ Open 2016; 6:e010339.",Non-OADS,/arxiv_data1/oa_pdf/8b/ed/bmjopen-2015-010339.PMC4823461.pdf
To view these files pleasevisit the journal online (http://dx.doi.org/10.1136/ bmjopen-2015-010215).,Non-OADS,/arxiv_data1/oa_pdf/8e/2d/bmjopen-2015-010215.PMC4823462.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 010109).,Non-OADS,/arxiv_data1/oa_pdf/42/c6/bmjopen-2015-010109.PMC4823464.pdf
2015. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf(accessed 1 Jul 2015).,OADS,/arxiv_data1/oa_pdf/42/c6/bmjopen-2015-010109.PMC4823464.pdf
2015. http://www.livingwellwithcopd.com/ en/home.html (accessed 12 Jan 2015).,Non-OADS,/arxiv_data1/oa_pdf/42/c6/bmjopen-2015-010109.PMC4823464.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-008985).,Non-OADS,/arxiv_data1/oa_pdf/e3/bd/bmjopen-2015-008985.PMC4823465.pdf
"Printex Impresores Ltda, Bogotá Colombia.ISBN: 978-958-8164-31-1. http://pdf.usaid.gov/pdf_docs/Pnady407.pdf 22.",Non-OADS,/arxiv_data1/oa_pdf/e3/bd/bmjopen-2015-008985.PMC4823465.pdf
"Bogotá D.C., 2007. http://www.dane.gov.",Non-OADS,/arxiv_data1/oa_pdf/e3/bd/bmjopen-2015-008985.PMC4823465.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015-011012).,Non-OADS,/arxiv_data1/oa_pdf/59/55/bmjopen-2015-011012.PMC4823468.pdf
"Respondents were also asked about their willingness to take placebos inTable 1 Participants ’characteristics Participants (n=853) Sex Female 524 (61%)Male 329 (39%) Age Mean age (SD) 45.1 (15.7) Race/ethnicityBased on OMB categorieshttp://www.whitehouse.gov/sites/default/files/omb/assets/information_and_regulatory_affairs/re_app-a-update.pdf White non-Hispanic 486 (58%)African-American/Other black 82 (10%)Hispanic/Latino 132 (16%)Asian non-Hispanic 121 (14%)American Indian or Alaska Native 4 (0.5%)Native Hawaiian or other Pacific Islander 7 (1%)Mixed 10 (1%) Educational level Less than high school graduate 13 (2%)High school graduate 107 (13%)Some college 316 (37%)College degree or beyond 372 (44%) OMB, Office of Management and Budget.",OADS,/arxiv_data1/oa_pdf/59/55/bmjopen-2015-011012.PMC4823468.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/59/55/bmjopen-2015-011012.PMC4823468.pdf
DOI  of  original  article:  http://dx.doi.org/10.1016/j.ijscr.2014.11.077 .,OADS,/arxiv_data1/oa_pdf/97/1d/main.PMC4823469.pdf
http://dx.doi.org/10.1016/j.ijscr.2016.03.031 2210-2612/© 2014  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/97/1d/main.PMC4823469.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/97/1d/main.PMC4823469.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"5),  the  tail  of  the  pancreas  and  the http://dx.doi.org/10.1016/j.ijscr.2016.03.011 2210-2612/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"Green,  Impalement  injuries,  J. Trauma  25 (1985) 914–916  (accessed  22.02.16)  http://www.ncbi.nlm.nih.",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"[4] J.P. Salomone, More  than  skin deep: use  caution  when  treating  impalement injuries, JEMS 36  (2011)  40–43,  http://dx.doi.org/10.1016/S0197- 2510(11)70146-2 .",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
16  (1995)  81–83  (accessed  22.02.16)  http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"41  (2011)  495–498,  http://dx.doi.org/10.1016/j.jemermed.2008.03.033 .",OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"5 (2012)  173–178,  http://dx.doi.org/10.7707/hmj.v5i2.171 .",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"17  (2009)  50,  http://dx.doi.org/10.1186/1757-7241-17-50 .",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"73  (2012)  S321–S325,  http://dx.doi.org/10.1097/TA.",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
3  (1999)  648–653  (accessed  22.02.16)  http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
(1996)  56–57  (accessed  22.02.16)  discussion  57–8  http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
"Altman,  D.  Moher,  H.  Sox,  D.  Riley,  The  CARE guidelines: consensus-based  clinical  case  reporting  guideline  development, BMJ  Case  Rep.  (2013),  http://dx.doi.org/10.1136/bcr-2013-201554 .",Non-OADS,/arxiv_data1/oa_pdf/fa/00/main.PMC4823470.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/d3/main.PMC4823473.pdf
For http://dx.doi.org/10.1016/j.ijscr.2016.03.029 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/ed/d3/main.PMC4823473.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/d3/main.PMC4823473.pdf
This  is  an  open access article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/b4/main.PMC4823474.pdf
2)  was  noted http://dx.doi.org/10.1016/j.ijscr.2016.03.030 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/08/b4/main.PMC4823474.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e9/ca/main.PMC4823475.pdf
"The  patient’s  abdomen  was  explored,  and  the large  and  sticky  solid  mass  attached  to  the  ileum  with  the  mesen- http://dx.doi.org/10.1016/j.ijscr.2016.03.025 2210-2612/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/e9/ca/main.PMC4823475.pdf
This  is  an  open access article under the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e3/a3/main.PMC4823476.pdf
"Fluorodeoxyglucose positron  emission  tomography-CT  (FDG-PET/CT)  showed  abnor- mal ﬂuorodeoxyglucose-uptake  in  both  lesions  of  the  pancreas and  ileum  alone,  without  evidence  of  other  metastatic  deposits http://dx.doi.org/10.1016/j.ijscr.2016.03.028 2210-2612/© 2016  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/e3/a3/main.PMC4823476.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e3/a3/main.PMC4823476.pdf
http://www.uis.unesco.org/Education/Pages/ international-standard-classification-of-education.aspx (accessed 23Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/92/d6/openhrt-2015-000367.PMC4823543.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/openhrt-2015-000366).,Non-OADS,/arxiv_data1/oa_pdf/31/86/openhrt-2015-000366.PMC4823544.pdf
This trial was registered at http://www.clinicaltrials.gov(NCT01187823).,Non-OADS,/arxiv_data1/oa_pdf/31/86/openhrt-2015-000366.PMC4823544.pdf
"All statistical analyses were performed using JMP V .11 (SAS Institute Inc, Cary, North Carolina, USA) and R software (http://www.r-project.org/).",OADS,/arxiv_data1/oa_pdf/31/86/openhrt-2015-000366.PMC4823544.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/lupus-2016-000147).,Non-OADS,/arxiv_data1/oa_pdf/c7/37/lupus-2016-000147.PMC4823547.pdf
"Fluorescence-activated cell sorting (FACS) analyses were performed using a FACS ARIA IIIU ﬂow cytometer and FACSDiva software V .6.1.3 (Becton Dickinson, New Jersey, USA) or an iCyte Synergy (Sony Biotechnology,San Jose California, USA) and WINLIST V .8 (Verty Software House, http://www.vsh.com) software.",OADS,/arxiv_data1/oa_pdf/c7/37/lupus-2016-000147.PMC4823547.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a2/f9/main.PMC4823566.pdf
The authors have no commercial associations or sources of support that might pose a con ﬂict of interest.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.006 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/a2/f9/main.PMC4823566.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a2/f9/main.PMC4823566.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
"Study population Eighty healthy subjects with normal EPS results (40 women and 40 men; 2 different age groups [20 –30 and 30 –40 years]), who were referred to our EPS laboratory for various reasons, such asContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.006 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
http://dx.doi.org/10.1111/echo.12702 [Epub ahead of print].,Non-OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
http://dx.doi.org/10.1046/j.1540 –8167.2002.00801.x .,Non-OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/77/26/main.PMC4823567.pdf
"Furthermore, this approach was also proveneffective in the prevention of non-communicable diseases such asContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.003 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/cc/c1/main.PMC4823569.pdf
"Clinical practice guideline: management of ischemic stroke, 2nd edition; 2012 〈http://www.moh.gov.my/attachments/ 7496.pdf 〉[accessed 06.05.15].",Non-OADS,/arxiv_data1/oa_pdf/cc/c1/main.PMC4823569.pdf
BMC Fam Pract 2010;11:47. http://dx.doi.org/10.1186/1471-2296-11-47 .,Non-OADS,/arxiv_data1/oa_pdf/cc/c1/main.PMC4823569.pdf
"It is a short, synthetic peptide that is a reversible inhibitorContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.004 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/de/e1/main.PMC4823570.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.008 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/bb/ab/main.PMC4823571.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/bb/ab/main.PMC4823571.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.joa.2015.11.008 .,OADS,/arxiv_data1/oa_pdf/bb/ab/main.PMC4823571.pdf
Left and right EEPVIs were performedContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.001 1880-4276/ &2015 Japanese Heart Rhythm Society.,OADS,/arxiv_data1/oa_pdf/55/93/main.PMC4823572.pdf
"The primary end point was set as the acute isolation rate of targeted PVs and complications related to the procedure itself, as well as symptomatic AF recurrence during the follow-up period, were analyzed.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.09.011 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/1f/ea/main.PMC4823573.pdf
J Cardiovsc Electophysiol 2015 .http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/1f/ea/main.PMC4823573.pdf
A previous study showedContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.10.002 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/a6/60/main.PMC4823574.pdf
"The antiarrhythmic effects of β-blockers are well- known, although their negative inotropic and even proarrhythmic action in some cases with advanced HF [10] may be non- negligible.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.09.002 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/4d/ed/main.PMC4823575.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.joa.2015.09.002 .,OADS,/arxiv_data1/oa_pdf/4d/ed/main.PMC4823575.pdf
TheContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.08.004 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/df/82/main.PMC4823576.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9b/aa/main.PMC4823577.pdf
"Subsequent to the updated ESC Clinical Guide-lines for the Management of Atrial Fibrillation in 2010 [6],aContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.001 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/9b/aa/main.PMC4823577.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9b/aa/main.PMC4823577.pdf
2014 .http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9b/aa/main.PMC4823577.pdf
http://dx.doi.org/10.1111/pace.12588 [Epub ahead of print].,Non-OADS,/arxiv_data1/oa_pdf/9b/aa/main.PMC4823577.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/41/main.PMC4823578.pdf
"Adenosine- or adenosine triphosphate (ATP)-sensitive atrial tachycardia (AT) (ATP-AT) with the earliest activation site (EAS) in the atrioventricular (AV) node vicinity was reported to be due to reentry [7], and catheter ablation performed for this speci ﬁcA T has targeted the EAS with some risk of AV conduction impairment.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.004 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/af/41/main.PMC4823578.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/41/main.PMC4823578.pdf
"Recent studies, however, demonstrated that not only didContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.09.007 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC4823579.pdf
J Cardiovasc Electrophysiol 2015;Sep:16. http://dx.doi.org/10.1111/jce.12838 [Epub ahead of print].,Non-OADS,/arxiv_data1/oa_pdf/10/94/main.PMC4823580.pdf
Int J Cardiol 2014;177:619 –20.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.002 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/10/94/main.PMC4823580.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/10/94/main.PMC4823580.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f2/24/main.PMC4823581.pdf
This depends critically on the orderly activation and recovery of electrical excitation through the myocardium.Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.003 1880-4276/ &2015 Japanese Heart Rhythm Society.,Non-OADS,/arxiv_data1/oa_pdf/f2/24/main.PMC4823581.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f2/24/main.PMC4823581.pdf
"InMedtronic devices, when this option is on, a sensed signal duringContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.09.003 1880-4276/ &2015 Japanese Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/79/7c/main.PMC4823583.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ rmdopen-2016-000263).,Non-OADS,/arxiv_data1/oa_pdf/ef/c8/rmdopen-2016-000263.PMC4823584.pdf
"Received 13 February 2016 Revised 6 March 2016Accepted 9 March 2016 ▸http://dx.doi.org/10.1136/ rmdopen-2015-000143 Division of Rheumatology- Fondazione Gemelli, Instituteof Rheumatology and Affine Sciences, School of Medicine, Catholic Universityof the Sacred Heart, Rome, Italy Correspondence to Professor Gianfranco Ferraccioli; gf.ferraccioli@rm.unicatt.itOver the past 10 years, the clinical and thera- peutic approach to rheumatoid arthritis (RA) has tremendously improved the out- comes of patients, thanks to the recommen-dations on how to deal with early RA, 1on how to treat and monitor patients,2and on how to assess predictors of response or ofprogression and non-response to initial therapy with conventional synthetic disease modifying antirheumatic drugs(csDMARDs).",Non-OADS,/arxiv_data1/oa_pdf/ef/c8/rmdopen-2016-000263.PMC4823584.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ 2 Ferraccioli G, et al.RMD Open 2016; 2:e000263.",Non-OADS,/arxiv_data1/oa_pdf/ef/c8/rmdopen-2016-000263.PMC4823584.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/rmdopen-2015- 000214).,Non-OADS,/arxiv_data1/oa_pdf/f0/5b/rmdopen-2015-000214.PMC4823585.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/rmdopen-2015- 000143).,Non-OADS,/arxiv_data1/oa_pdf/68/57/rmdopen-2015-000143.PMC4823586.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/68/57/rmdopen-2015-000143.PMC4823586.pdf
To view please visit the journal (http://dx.doi.org/ 10.1136/rmdopen-2015- 000230).,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
25 February 2014. http://www.ameli.fr/assures/ soins-et-remboursements/combien-serez-vous-rembourse/consultations/les-consultations-en-metropole/dans-le-cadre-du-parcours-de-soins-coordonnes.php 13.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
Institut de recherche et de documentation en économie de la santé.28 July 28 2014. http://www.irdes.fr 14.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
"April 2014, 2014.http://www.ecosante.fr/index2.php?base=FRAN&langh=FRA&langs=FRA&sessionid= 15.",Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
http://vidalfrance.com 16.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
16 February 2015. http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/ donnees-statistiques/medicament/medic-am-2008 –2012.php 17.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
2013. http://stats.atih.sante.fr/mco/catalogmco.php 18.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
2013. http://www.atih.sante.fr/?id=0001000021FFmorey 19.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
http://www.inflation.eu/inflation-rates/france/historic-inflation/cpi-inflation-france.aspx 20.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
http://www.insee.fr/fr/themes/theme.asp?theme=4 21.,Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
"http://www.insee.fr/fr/mobile/etudes/document.asp?reg_id=0&ref_id=T13F041 Harvard S, et al.RMD Open 2016; 2:e000230.",Non-OADS,/arxiv_data1/oa_pdf/65/2e/rmdopen-2015-000230.PMC4823587.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fd/ac/main.PMC4823606.pdf
"Thereafter, a 64-pole basket catheter (BC), consisting of 8 splines with 8 elec-trodes each (Boston Scienti ﬁc, Natick, MA, USA), was placed in theContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/joaJournal of Arrhythmia http://dx.doi.org/10.1016/j.joa.2015.11.010 1880-4276/ &2016 Japanese Heart Rhythm Society.",OADS,/arxiv_data1/oa_pdf/fd/ac/main.PMC4823606.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fd/ac/main.PMC4823606.pdf
Supplementary material Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.joa.2015.11.010 .,OADS,/arxiv_data1/oa_pdf/fd/ac/main.PMC4823606.pdf
The NCBI BLAST (blastn) program  (http://www.ncbi.nlm .nih.gov/BLAST/ ) was used to search homologues of vOX 2 protein.,OADS,/arxiv_data1/oa_pdf/84/82/IJBMS-19-2.PMC4823611.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commer cial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Libyan J Med 2016, 11: 31018 - http://dx.doi.org/10.3402/ljm.v11.31018 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
"In fact, in the rats cotreatedwith Pb and TQ, the renal activities of SOD, GPX, CAT,and GR significantly increased ( pB0.05) by 70.57, 78.85, 106.5, and 73.91%, respectively, in relation to the Pb- intoxicated rats.Aymen Mabrouk and Hassen Ben Cheikh 2 (page number not for citation purpose)Citation: Libyan Journal of Medicine 2016, 11: 31018 - http://dx.doi.org/10.3402/ljm.v11.31018",Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
"Student’s t-test: * pB0.05 versus control; #pB0.05 versus TQ-treated rats;$pB0.05 versus Pb-treated rats.Thymoquinone attenuates renal antioxidant depletion Citation: Libyan Journal of Medicine 2016, 11: 31018 - http://dx.doi.org/10.3402/ljm.v11.31018 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
"2006; 19: 167 /C175.Aymen Mabrouk and Hassen Ben Cheikh 4 (page number not for citation purpose)Citation: Libyan Journal of Medicine 2016, 11: 31018 - http://dx.doi.org/10.3402/ljm.v11.31018",Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
2015; 2015: 859383. doi: http://dx.doi.org/10.1155/ 2015/859383 42.,Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
"2003; 26: 87 /C198.Thymoquinone attenuates renal antioxidant depletion Citation: Libyan Journal of Medicine 2016, 11: 31018 - http://dx.doi.org/10.3402/ljm.v11.31018 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/07/LJM-11-31018.PMC4823626.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"2 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"Campylobacter Identification All presumptive Campylobacter isolates were confirmed initially by Gram staining (3% w/v KOH, Sigma-Aldrich,Arklow, Wicklow, Ireland) and a series of biochemical tests (Oxidase test) (Oxoid, Cambridge, UK) and the L-ALA test (Sigma-Aldrich, Arklow, Co. Wicklow, Ireland) followed by streaking on Campy Food ID chromogenic agar (Biomerieux, Durham, NC).Campylobacter growth rates Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"4 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"Int J FoodMicrobiol 2006; 108: 226 /C132.Campylobacter growth rates Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"6 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2016, 6: 31217 - http://dx.doi.org/10.3402/iee.v6.31217",Non-OADS,/arxiv_data1/oa_pdf/8b/cf/IEE-6-31217.PMC4823627.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/53/bf/ehv466.PMC4823634.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/  Volume 18  |  Number 4  |  April 2016  |  GeneticS in medicine",Non-OADS,/arxiv_data1/oa_pdf/0a/e6/gim201592a.PMC4823637.pdf
"bPreviously reported in familial CRC.2 cNot reported in dbSNP , 1000 Genomes, and NHLBI GO Exome Sequencing Project (http://evs.gs.washington.edu/ EVS/), or found in 500 alleles of Spanish origin.18 dPhyloP100way_vertebrate annotations in dbNSFP v.2.8.",OADS,/arxiv_data1/oa_pdf/8b/46/gim201575a.PMC4823640.pdf
11 Structural analysis The human 3D model of POLD1 was obtained from ModBase (http://modbase.compbio.ucsf.edu/) and improved by the  RepairPDB and Optimize commands of FoldX (http://foldx.crg.es).,OADS,/arxiv_data1/oa_pdf/8b/46/gim201575a.PMC4823640.pdf
"For the identified variants,  protein stability calculations were performed using CUPSAT  (http://cupsat.tu-bs.de), I-Mutant 2.0  (http://folding.biofold.",Non-OADS,/arxiv_data1/oa_pdf/8b/46/gim201575a.PMC4823640.pdf
"org/i-mutant/i-mutant2.0.html), ERIS (http://troll.med.unc.edu/eris/), and PoPMuSiC (http://dezyme.com).Loss of heterozygosity Six microsatellite flanking POLD1 and spanning 2.06  Mb,  three centromeric (D19S867, D19S585, D19S904) and three telomeric (D19S246, D19S907, and D19S601), were used to  assess loss of heterozygosity (LOH) in DNA extracted from   formalin-fixed paraffin-embedded tissue.",OADS,/arxiv_data1/oa_pdf/8b/46/gim201575a.PMC4823640.pdf
"SUPPLEMENTARY MATERIAL Supplementary material is linked to the online version of the paper  at http://www.nature.com/gim ACKNOWLEDGMENTS This work was supported by the Spanish Ministry of Economy and Competitiveness (State Secretariat for Research, Develop-ment, and Innovation; SAF2012-38885 and SAF2010-21165,  Ramón y Cajal contract to L.V., fellowship to F.B., and RTICC  (Red Temática de Investigación Cooperativa en Cáncer) networks RD12/0036/0031, RD12/0036/0008, and RD12/0036/0067), the Scientific Foundation Asociación Española Contra el Cáncer, the Government of Catalonia (2014SGR-338), and the EU FP7 project ASSET (grant agreement 259348 to A.V.).",Non-OADS,/arxiv_data1/oa_pdf/8b/46/gim201575a.PMC4823640.pdf
"The com- plete exome sequencing data of these three samples are available  at the Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra)  under the codes SRX667201 (patient), SRX667384 (mother), and  SRX667386 (father).",OADS,/arxiv_data1/oa_pdf/14/ae/gim2015100a.PMC4823641.pdf
Available at http://mouse.brain-map.org/).,Non-OADS,/arxiv_data1/oa_pdf/14/ae/gim2015100a.PMC4823641.pdf
We first confirmed that  JMJD1C was expressed in different brain regions by examining  the Allen Brain Atlas Database (http://www.brain-map.org/)  (Figure  4a).23 We also validated the widespread expression of  JMJD1C throughout distinct regions of the mouse (Figure 4b)  and human (Figure 4c) brain by quantitative RT-PCR.,OADS,/arxiv_data1/oa_pdf/14/ae/gim2015100a.PMC4823641.pdf
"SUPPLEMENTARY MATERIAL Supplementary material is linked to the online version of the paper  at http://www.nature.com/gim ACKNOWLEDGMENTS This study was supported by the European Community’s Sev-enth Framework Program (FP7/2007–2013) under grant agree-ment PITN-GA-2012–316758 of the EPITRAIN project and   PITN-GA-2009–238242 of DISCHROM; ERC grant agreement  268626 of the EPINORC project; the E-RARE EuroRETT network (Carlos III Health Institute project PI071327); the Fondation Lejeune (France); MINECO projects SAF2011-22803 and  CSD2006-00049;  the Cellex Foundation; the Botín Foundation; the Catalan Associa-tion for Rett Syndrome; Fundación Alicia Koplowitz 2011 Grant AKO- PLOWITZ11_006; the FIS project PI1002512; Grants PI10/01422,  PI13/00285, CA10/01474, RD06/0020/1050, RD12/0036/008, and 2009-SGR293; and the Health and Science Departments of the Catalan government (Generalitat de Catalunya).",Non-OADS,/arxiv_data1/oa_pdf/14/ae/gim2015100a.PMC4823641.pdf
"To view a copy of this license, visit   http://creativecommons.org/licenses/by-nc-nd/4.0/ GeNeTICs in MeDICINe  |   Volume 18  |  Number 4  |  April 2016",Non-OADS,/arxiv_data1/oa_pdf/14/ae/gim2015100a.PMC4823641.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ 472 Pediatric RESEARCH       Volume 79  |  N umber 3  |  March 2016",Non-OADS,/arxiv_data1/oa_pdf/c9/94/pr2015239a.PMC4823642.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Volume 79  |  N umber 3  |  March 2016       Pediatric RESEARCh  431",Non-OADS,/arxiv_data1/oa_pdf/e6/c8/pr2015235a.PMC4823643.pdf
"To view  a copy of this license, visit http://creativecommons.org/   licenses/by-nc-sa/4.0/ Volume 79  |  N umber 3  |  March 2016       Pediatric RESEARCH 481",Non-OADS,/arxiv_data1/oa_pdf/4a/89/pr2015233a.PMC4823644.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b2/9b/omw014.PMC4823761.pdf
"Human protein sequences and respective codes were  obtained by querying UNIPROT (Universal Protein Resource) (www.uniprot.org) (last accessed on March 24, 2015, tutorial at http://www.uniprot.org/help/).",OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
"In addition, the human sequence in FASTA for - mat was aligned with BLAST (Basic Local Alignment Search Tool) (http://blast.ncbi.nlm.nih.gov) with default settings (last accessed on March 24, 2015, tutorial at ftp://ftp.ncbi.nlm.nih.gov/pub/factsheets/HowTo_BLASTGuide.pdf) for the taxa required (human, swine, rat, others).",OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
The term “partially conserved” will be used throughout for substitutions of amino acids between groups of strongly similar properties with scoring >0.5 in the Gonnet PAM 250 matrix (see http://www.uniprot.org/help/sequence-alignments) (Mount 2008).,Non-OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
"Epitope prediction modeling was used in selected cases  with the IEDB Analysis Resource platform (http://tools.immuneepitope.org/bcell/) (last accessed on March 24, 2015, tutorial at http://tools.immuneepitope.org/bcell/help/).",OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
"Public repositories of cDNA microarray data (BioGPS, http://biogps.org) (last accessed on October 2nd, 2014) report ALK expression in adrenal tissue (GeneAtlas U133A, gcrma; probe 208212_s_at), in astrocytes (Primary Cell Atlas; probe 208212_s_at) and heterogeneously at low levels in normal tissue, including the brain (Barcode on nor - mal tissues).",OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
The legend is drawn from http://www.uniprot.org/help/sequence-alignments and http://www.ebi.ac.uk/Tools/msa/clustalo/help/faq.html#24.,Non-OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
"The color-coding sequence display was obtained by sequence alignment with Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/)  (last accessed on March 24, 2015).",OADS,/arxiv_data1/oa_pdf/e6/ae/10.1369_0022155415597738.PMC4823807.pdf
Clinical Trial Registration—URL: http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/4b/40/cir-133-1472.PMC4823823.pdf
"Key Words: angioplasty ◼ drug-eluting stents ◼ paclitaxel ◼ peripheral artery disease ◼ stents Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.115.016900Received April 10, 2015; accepted February 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/4b/40/cir-133-1472.PMC4823823.pdf
"Global strategy for the diagnosis, management and prevention of COPD (2015) Available at http://www.goldcopd.org/http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html Accessed 10 November 2015.",Non-OADS,/arxiv_data1/oa_pdf/25/c6/npjpcrm201610.PMC4823919.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplemental Information accompanies the paper on the npj Primary Care Respiratory Medicine website (http://www.nature.com/npjpcrm)Multi-component assessment of COPD RC Jones et al 7 © 2016 Primary Care Respiratory Society UK/Macmillan Publishers Limited npj Primary Care Respiratory Medicine (2016) 16010",Non-OADS,/arxiv_data1/oa_pdf/25/c6/npjpcrm201610.PMC4823919.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non- commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b3/17/evv195.PMC4823973.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/ff/evv260.PMC4823975.pdf
"Next, using BLAST (http://blast.ncbi.nlm.nih.gov/ ) with default parameters, output scaffolds/contigs larger than 1,000 bp were mappedto the four plastid reference genomes of Alismatales: Colocasia esculenta (NC_016753), Elodea canadensis (NC_018541), Lemna minor (NC_010109), and Spirodela polyrhiza (NC_015891).",OADS,/arxiv_data1/oa_pdf/82/ff/evv260.PMC4823975.pdf
Available from: http://www.mobot.org/MOBOT/research/APweb/ .,Non-OADS,/arxiv_data1/oa_pdf/82/ff/evv260.PMC4823975.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/98/bb/evv262.PMC4823976.pdf
Supplementary Material Supplementary ﬁgures S1 and S2 a r ea v a i l a b l ea t Genome Biology and Evolution online ( http://www.gbe.oxfordjour- nals.org/ ).,Non-OADS,/arxiv_data1/oa_pdf/98/bb/evv262.PMC4823976.pdf
"Tel: (919) 843-6864; Fax: (919) 966-7911; E-mail: rfry@unc.edu, http://orcid.org/0000-0003-0899- 9018 †Elizabeth M. Martin, http://orcid.org/0000-0001-8428-7034 Abstract A biological mechanism by which exposure to environmental contaminants results in gene-speciﬁc CpG methylation patterning is currently unknown.",Non-OADS,/arxiv_data1/oa_pdf/37/e6/dvv011.PMC4824001.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/e6/dvv011.PMC4824001.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4b/8e/evw029.PMC4824008.pdf
"2015 ;http://www.girinst.org/repbase/ , last accessed February 19, 2016).",Non-OADS,/arxiv_data1/oa_pdf/4b/8e/evw029.PMC4824008.pdf
"This work was also supported by “Marco Polo” grant to F.P., and Canziani Bequest to M.P.Supplementary Material Supplementary tables S1 and S2 andﬁgure S1 are available at Genome Biology and Evolution online (http://www.gbe.",Non-OADS,/arxiv_data1/oa_pdf/4b/8e/evw029.PMC4824008.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/18/evw030.PMC4824009.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/42/f8/evw031.PMC4824010.pdf
This region was then searched for predicted open reading frames (ORFs) using NCBI ORF Finder ( http://www.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/42/f8/evw031.PMC4824010.pdf
"1.7.1 ( http://beast.bio.ed.ac.uk/beast , last accessed March 2, 2016) with the following assumptions: An uncorrelated relaxed molecular clock, lognormal rate distribution, HKY model of nucleotide substitution with four gamma categories, normally distributed priors, a Yule process tree model, andUPGMA starting tree.",Non-OADS,/arxiv_data1/oa_pdf/42/f8/evw031.PMC4824010.pdf
Supplementary Material Supplementary tables S1–S7 andﬁgures S1–S3 are available atGenome Biology and Evolution online (http://www.gbe.,OADS,/arxiv_data1/oa_pdf/42/f8/evw031.PMC4824010.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0f/10/evw032.PMC4824011.pdf
"trimmed and reads containing more than 5% of undeter- mined bases ( N) or more than 15% of low-quality bases (Qphred /C2020) were removed, the remaining reads were aligned against the chicken reference genome by usingTopHat 2.0.1 ( https://ccb.jhu.edu/software/tophat/index.",OADS,/arxiv_data1/oa_pdf/0f/10/evw032.PMC4824011.pdf
"The corresponding SNPs in homol- ogous regions were used to construct a neighbor-joining treeby using MEGA4 ( http://www.megasoftware.net/mega4/ mega.html , last accessed February 26, 2016) modeled on thep-distance between different chicken populations ( Hall 2013 ).",OADS,/arxiv_data1/oa_pdf/0f/10/evw032.PMC4824011.pdf
"DEGs were an- alyzed using DESeq ( https://bioconductor.org , last accessed February 26, 2016).",OADS,/arxiv_data1/oa_pdf/0f/10/evw032.PMC4824011.pdf
Supplementary Material Supplementary tables S1–S7 andﬁgures S1–S15 are available atGenome Biology and Evolution online (http://www.gbe.,OADS,/arxiv_data1/oa_pdf/0f/10/evw032.PMC4824011.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a6/f2/evw023.PMC4824031.pdf
"The mapping results were visualized in Geneious version 6.18 (http://www.geneious.com/ , last accessed February 23, 2016; Kearse et al.",OADS,/arxiv_data1/oa_pdf/a6/f2/evw023.PMC4824031.pdf
"variegatus ), a vermilinguan ( Tamandua tetradactyla ), and a cingulate (Dasypus novemcinctus ) downloaded from GenBank using the MUSCLE ( Edgar 2004 ) algorithm implemented in Geneious v 8.0.4 ( http://www.geneious.com; Kearse et al.",OADS,/arxiv_data1/oa_pdf/a6/f2/evw023.PMC4824031.pdf
"We ensured that both runs had converged bychecking that potential scale reduction factor scores had de- creased to ~1 ( Gelman and Rubin 1992 ), and by visual inspec- tion of trace plots in the program Tracer v 1.6 ( http://tree.bio.",OADS,/arxiv_data1/oa_pdf/a6/f2/evw023.PMC4824031.pdf
Supplementary Material Supplementary tables S1–S5 and references are available at Genome Biology and Evolution online (http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/a6/f2/evw023.PMC4824031.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0a/8a/evw024.PMC4824032.pdf
Supplementary Material Supplementary ﬁgure S1 andtables S1–S3 a r ea v a i l a b l ea t Genome Biology and Evolution online ( http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/0a/8a/evw024.PMC4824032.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/4f/evw025.PMC4824033.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
"The genome and annotation were submitted to the European Nucleotide Archive, ENA at http://www.ebi.ac.",OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
Annotation of CSEPs SignalP version 4.1 was used for signal peptide prediction and ProtComp 9.0 (online version) for localization prediction(http://linux1.softberry.com/berry.phtml ).,OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
Supplementary Material Supplementary ﬁgures S1–S7 and tables S1–S5 are available atGenome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
Available from: http://CRAN.R-project.org/package= agricolae .,Non-OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
Available from: http://repeatmasker.org .,Non-OADS,/arxiv_data1/oa_pdf/2e/5a/evw026.PMC4824034.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"Culture Collection of Algae of th e Charles University in Prague (CAUP; http://botany.natur.cuni.cz/algo/caup.html ,l a s t accessed February 19, 2016).",Non-OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"2011 ), but a scaffold representing a major portion of the mitogenome (scaffold_85) could bedownloaded from the A. anophagefferens genome database at the Joint Genome Institute ( http://genome.jgi-psf.org/ Auran1/Auran1.home.html , last accessed February 19, 2016).",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"We used the original Sanger WGS reads availablefrom the Trace Archive ( http://www.ncbi.nlm.nih.gov/Traces/ wgs/ [last accessed February 19, 2016], preﬁx ACJI01) and Illumina-sequenced transcripto mic data available in Sequence Read Archive ( http://www.ncbi.nlm.nih.gov/sra/SRX275708 , last accessed February 19, 2016) to iteratively ﬁll gaps in the scaffold and to extend its ends.",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"Genome Annotation and Analyses Initial annotation of the newly sequencedeustigmatophyte mitogenomes was obtained using MFannot ( http://megasun.bch.umontreal.ca/cgi-bin/mfannot/ mfannotInterface.pl , last accessed February 19, 2016).",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"Multiple alignments of all protein se- quences were obtained using the program MAFFT version 7(http://mafft.cbrc.jp/alignment/server/ [last accessed February 19, 2016], Katoh and Standley 2013 ) with either default set- tings or (in case of Nad11 and Rps3) the L-INS-i iterative re- ﬁnement method.",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"Sequences were aligned using MAFFT and unreliably ali gned positions were removed using program GBLOCKS 0.91b program ( Castresana 2000 ) on the Gblocks server ( http://molevol.cmima.csic.es/castre- sana/Gblocks_server.html , last accessed February 19, 2016), and the alignments were concatenated using FASconCAT (Ku¨ ck and Muesemann 2010 ).",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"All phylogenetic trees we re displayed by iTOL ( http://itol.embl.de/ [last accessed February 19, 2016]; Letunic and Bork 2011 ).",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"2014 ;http://pfam.xfam.org/ ) are shown above the alignment, the meaning of the domain labels i s explained at the bottom of the scheme.Mitochondrial Genomes in Eustigmatophyte Algae GBE Genome Biol.",OADS,/arxiv_data1/oa_pdf/3a/1e/evw027.PMC4824035.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecom-mons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original workis properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/10/nlw017.PMC4824036.pdf
6(1): 44-56 ISSN: 2226-4485 (Print)ISSN: 2218-6050 (Online) 44Review Article DOI: http://dx.doi.org/10.4314/ovj.v6i1.7 Submitted: 13/12/2015 Accepted: 04/03/2016 Published: 28/03/201 6 Integrative veterinary medical education and consensus guidelin es for an  integrative veterinary medicine curriculum within veterinary co lleges M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
"2011:67649. http://dx.doi.org/10.1093/ecam/nep044 Evans, R. 2009.",OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
"17, 10. http://doi.org/10.1186/1746-1340-17-10 Haussler, K.K.",Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://www.openveterinaryjournal.com M.A.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
http://dx.doi.org/10.1155/2015/983621.,Non-OADS,/arxiv_data1/oa_pdf/ee/58/OpenVetJ-6-44.PMC4824037.pdf
"E-mail : antonio.torres@correo.uady.mxOriginal Article DOI: http://dx.doi.org/10.4314/ovj.v6i1.8 Submitted: 03/12/2015 Accepted: 19/03/2016 Published: 28/03/201 6 First molecular evidence of Toxoplasma gondii  in opossums ( Didelphis  virginiana ) from Yucatan, Mexico M. Torres-Castro1,*, H. Noh-Pech1, R. Puerto-Hernández1, B. Reyes-Hernández1, A. Panti-May2,  S. Hernández-Betancourt3, A. Yeh-Gorocica1, L. González-Herrera4, J. Zavala-Castro1 and F.I.",OADS,/arxiv_data1/oa_pdf/c5/75/OpenVetJ-6-57.PMC4824038.pdf
http://www.openveterinaryjournal.com M. Torres-Castro et al.,OADS,/arxiv_data1/oa_pdf/c5/75/OpenVetJ-6-57.PMC4824038.pdf
http://www.openveterinaryjournal.com M. Torres-Castro et al.,OADS,/arxiv_data1/oa_pdf/c5/75/OpenVetJ-6-57.PMC4824038.pdf
http://www.openveterinaryjournal.com M. Torres-Castro et al.,OADS,/arxiv_data1/oa_pdf/c5/75/OpenVetJ-6-57.PMC4824038.pdf
http://www.openveterinaryjournal.com M. Torres-Castro et al.,OADS,/arxiv_data1/oa_pdf/c5/75/OpenVetJ-6-57.PMC4824038.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/50/f4/evw033.PMC4824065.pdf
Both Illumina and PacBio reads were mapped back tothe scaffolds using Geneious (Biomatters; http://www.gen- eious.com/ )t oﬁ l lg a p s .,OADS,/arxiv_data1/oa_pdf/50/f4/evw033.PMC4824065.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/cc/evw034.PMC4824066.pdf
"Materials and Methods Datasets We used data from the 1000 Genomes Project, phase 1, that are available through public ftp site ftp://ftp-trace.ncbi.nih.",OADS,/arxiv_data1/oa_pdf/d0/cc/evw034.PMC4824066.pdf
"Availability All our programs, their instruction manuals and notes, sup- porting ﬁles, and results ﬁles are available in supplementary ﬁle“Data”, Supplementary Material online, and also from our web site ( http://bpg.utoledo.edu/~afedorov/lab/atlas_vrGV.",OADS,/arxiv_data1/oa_pdf/d0/cc/evw034.PMC4824066.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"2014 ), except for the gymnosperm P. abies version from ConGenIE 1.0 (http://congenie.org/start , last accessed February 29, 2016; Nystedt et al.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"Additionally, the most current and nonre- dundant protein sequences of Homo sapiens (e!Ensembl re- lease 78, http://asia.ensembl.org/Homo_sapiens/Info/Index ,l a s t accessed February 29, 2016), Saccharomyces cerevisiae (SGD release R64.2, http://www.yeastgenome.org/ , last accessed February 29, 2016) and Escherichia coli K-12 (EcoGene v3.0, http://ecogene.org/ , last accessed February 29, 2016; Zhou et al.",Non-OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"The exon/intron structures of individual FRO and NOX genes wereobtained through the online Gene Structure Display Server(GSDS, http://gsds.cbi.pku.edu.cn , last accessed February 29, 2016; Hu et al.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"2015 ) by aligning the coding or cDNA se- quences with their corresponding genomic DNA sequencesfrom Phytozome v9.1 ( http://www.phytozome.net/ ,l a s t accessed February 29, 2016; Goodstein et al.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"Cis-Regulatory Elements, In Silico Expression Profiles The 1,500 bp upstream of the transcription start site of all NOX genes in Arabidopsis and rice were obtained from Phytozome v9.1 ( http://www.phytozome.net/ ), and the cis- regulatory elements were identiﬁed using the PlantCARE pro-gram ( http://bioinformatics.psb.ugent.be/webtools/plantcare/ html/, last accessed February 29, 2016; Lescot et al.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"2007 ) and RiceFREND (version 2.0, http://ricefrend.dna.affrc.go.jp/ , last accessed February 29, 2016; Sato 2012) coexpression data- bases, respectively.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
The Cytoscape v3.2.1 software ( http://www.cytoscape.,Non-OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"Moreover, a search for NOX paralogs using the Plant Genome Duplication Database (PGDD; http://chibba.agtec.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"Essentially identical develop- mental expression proﬁles for the AtNOX andOsNOX genes were also obtained with data from the Arabidopsis and rice eFP browsers in the Bio-Analytic Resource ( http://bar.utoronto.ca/welcome.htm , last accessed February 29, 2016) database (Winter et al.",OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
Supplementary Material Supplementary ﬁgures S1–S9 and tables S1–S5 are available atGenome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/3b/c6/evw035.PMC4824067.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"(2008) *These sequence data were produced by the US Department of Energy Joint Genome Institute, A. coerulea Genome Sequencing Project, http://www.phytozome.net/ .",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Domain architecture searches with AtMLO4 as a query in NCBI CDART ( http://www.ncbi.nlm.nih.gov/ Structure/lexington/lexington.cgi [last accessed March 1, 2016], Geer et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
The following databases were used for these searches: NCBI http://blast.ncbi.nlm.nih.gov/Blast.cgi (Altschul et al.,OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"1997 ),http://solgenomics.net/ (N. benthamiana Genome v. 1.0.1), Phytozome v10.2 http://phytozome.jgi.doe.gov/pz/ portal.html (A. coerulea v1.1, P. patens v3.0, S. moellendorﬁi v.1.0, S. italica v2.1), http://congenie.org/ (P. abies v1.0, P. taeda v1.0), http://www.amborella.org/ (Amborella genome scaffold v1.0), http://webblast.ipk-gatersleben.de/barley/ (H. vulgare v1).",Non-OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Further, motif searches were conducted on amino acid sequence alignments using the MEME tool from the MEME suite ( http://meme-suite.org/ ,Bailey and Elkan 1994 ;Bailey et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Motifs identiﬁed by this procedure ( supplementary ﬁles 4–6 ,Supplementary Material online ) were subjected to analysis viathe FIMO search tool from the MEME suite against the Ensembl Genomes database for S. cerevisiae (http://meme-suite.org/ tools/ﬁmo ,Grant et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"The resulting gene list was an- alyzed for over-representation of GO terms by Generic GOTerm Finder ( http://go.princeton.edu/cgi-bin/GOTermFinder , Boyle et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Domain Architecture Searches Using a clade I MLO protein sequence as the query ( AtMLO4), we searched the databases CDART ( http://www.ncbi.nlm.nih.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"2002) and InterPro ( http://www.ebi.ac.uk/interpro/ ,Jones et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Protein Topology Prediction The topology of the nonland plant MLOs was analyzed via TOPCONS 2.0 ( http://topcons.cbr.su.se/pred/ ,Tsirigos et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
"Land plant MLOs were mined for ID protein regions by IUPred (http://iupred.enzim.hu/ ,Doszta ´nyi et al.",OADS,/arxiv_data1/oa_pdf/fd/ed/evw036.PMC4824068.pdf
GSE26328 and GSE30263) were downloaded fromthe GEO website at http://www.ncbi.nlm.nih.gov/geo/ query/acc .,OADS,/arxiv_data1/oa_pdf/2f/7b/gkv1300.PMC4824072.pdf
The ‘my5C-primer’ and ‘my5C-heatmap’ bioin- formatics tools are found at http://3dg.umassmed.edu/ my5Cheatmap/heatmap.php .,OADS,/arxiv_data1/oa_pdf/2f/7b/gkv1300.PMC4824072.pdf
"The published 5C data were obtained and visualized using the UCSC genome browser (GM12878; wgEn-codeEH001665, H1-hESC; wgEncodeEH001666, HeLa- S3; wgEncodeEH001667, K562; wgEncodeEH001668) (http://genome.ucsc.edu )(49).",OADS,/arxiv_data1/oa_pdf/2f/7b/gkv1300.PMC4824072.pdf
ACCESSION NUMBER RawandprocessedRNAsequencingdataforMSCmuscle differentiation are available at GEO ( http://www.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/25/0e/gkw032.PMC4824105.pdf
ACCESSION NUMBERS The sequencing data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (60) and are accessible through GEO Series acces- sion number GSE73210 ( http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE73210 ).,OADS,/arxiv_data1/oa_pdf/ca/1a/gkw040.PMC4824107.pdf
Sequencing and Bioinformatics analysis Small RNA libraries were prepared from 5 /H9262g of RNA us- ing the Small RNA Sample Preparation Alternative v1.5Protocol (Illumina) according to the manufacturers’ in- structionsandsequencedatGeneworks(Adelaide)usingan IlluminaGAIIxplatform.ReadswerealignedwithBowtie2(12) on hg19 and miRNA expression was quantified us- ingSeqMonk( http://www.bioinformatics.babraham.ac.uk/ projects/seqmonk/ )withaloessnormalisation.NovelmiR- NAs were investigated using a sliding window of 20 bp across the aligned reads on the genome.,OADS,/arxiv_data1/oa_pdf/c0/fc/gkw041.PMC4824108.pdf
Pseudogenes and predicted genes were removed based on Gencode annotation ( http://www.gencodegenes.,OADS,/arxiv_data1/oa_pdf/c0/fc/gkw041.PMC4824108.pdf
Gene expression array Differential expression of mRNAs was assessed using the GeneChip R/circlecopyrtPrime ViewTMHuman Gene Expression Ar- ray (Affymetrix) at the Ramaciotti Centre for Genomics (Sydney)accordingtothemanufacturer’sinstructions.Thearrays were normalised using the justRMA suite of algo- rithms from Bioconductor ( http://www.bioconductor.org ) and analysed as previously described ( 16).,OADS,/arxiv_data1/oa_pdf/c0/fc/gkw041.PMC4824108.pdf
"The reduction of mascRNA after TALAM1-ASO1 and ASO2 treatment was estimated byquantifying and normalizing the signal intensity of mascRNA to U6, via ImageJ software ( http://rsb.info.nih.gov/ij/index.html ).",OADS,/arxiv_data1/oa_pdf/e0/22/gkw047.PMC4824109.pdf
Protein structure predictions StructuralpredictionswereperformedwiththePhyre2web server(49).Comparisonsbetweendifferenttopoisomerases modelswereconductedwiththePyMOLMolecularGraph- ics System ( http://www.pymol.org ).,OADS,/arxiv_data1/oa_pdf/d2/30/gkw097.PMC4824112.pdf
"Stabilin-2 is expressed in low levels in several human tissues ( http://www.gtexportal.org/ home/(33)), but highly expressed in non-continuous sinu- soidal endothelium of liver, lymph node, spleen and bone marrow––tissueswhichrepresentsitesofhighaccumulationfor PS ASOs in animals ( 8).",Non-OADS,/arxiv_data1/oa_pdf/50/f3/gkw112.PMC4824115.pdf
The ChIP-seq peak gene assignment and peak overlap were analyzed using HOMER soft- ware (http://homer.salk.,OADS,/arxiv_data1/oa_pdf/c3/fb/gkw126.PMC4824118.pdf
"MATERIALS AND METHODS Proteins Streptococcus pyogenes proteins Cas9 (SpCas9) wild-type (wt) and catalytically inactive dCas9 harboring point mu- tations D10A /H840A were expressed in Escherichia coli BL21(DE3) using the expression plasmids pMJ806 andpMJ841,respectively,(Addgene, https://www.addgene.org/ ) and purified essentiallyas previouslydescribed( 8).",OADS,/arxiv_data1/oa_pdf/91/a2/gkw138.PMC4824121.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a2/a9/evw043.PMC4824122.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/8b/evw050.PMC4824123.pdf
Availability and implementation: CASSIS and SMIPS are freely available at https://sbi.hki-jena.de/ cassis.Contact: thomas.wolf@leibniz-hki.de or ekaterina.shelest@leibniz-hki.de Supplementary information :Supplementary data are available at Bioinformatics online.,OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
"1138 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
"The genome sequences, protein sequences and corresponding gene annotations were downloaded from the Broad Institute (http://www.broadinstitute.org) or Aspergillus Genome Database ( Cerqueira et al., 2014 ).",OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
"For the latter, SMIPS accepts the formatsof InterProScan or the JGI tables (for details see https://sbi.hki-jena.de/smips/Help.php#Input).",OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
"2009 (suite); http://www.meme-suite.org), required for the next two steps, are not incorporated into CASSISand should be therefore pre-installed on the system.",Non-OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
5 Implementation and availability The CASSIS method is implemented in a tool with the same name.User-friendly online versions of both SMIPS and CASSIS (the‘CASSIS suite’) are available at https://sbi.hki-jena.de/cassis.,OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
The source codes as well as executeable files forLinux and Windows are freely available at https://sbi.hki-jena.de/cassis/Download.php.,OADS,/arxiv_data1/oa_pdf/4e/6a/btv713.PMC4824125.pdf
"The Kipper data store format makes publishing curated FASTA databases convenient since in most cases it can store a range of ver- sions into a ﬁle marginally larger than the size of the latest version.Availability and implementation: Kipper v1.0.0 and the Galaxy Versioned Data tool are written in Python and released as free and open source software available at https://github.com/Public- Health-Bioinformatics/kipper and https://github.com/Public-Health-Bioinformatics/versioned_data,respectively; detailed setup instructions can be found at https://github.com/Public-Health- Bioinformatics/versioned_data/blob/master/doc/setup.md Contact : Damion.Dooley@Bccdc.Ca or William.Hsiao@Bccdc.Ca Supplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
"1275 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
ftp://ftp.ncbi.nih.gov/genbank/daily-nc/) but no publically available client-side system exists for version update and retrieval.,OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
"Git (http://git-scm.com), a file and code versioning tool, was evaluated as apossible solution but was found to be inefficient at versioning largeFASTA files.",OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
"As noted by Ram (2013) Git does not handle large datasets well, and must externalize them as separate files using toolslike git-annex (https://git-annex.branchable.com).",OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
Recently the BioMAJ teamintroduced a Galaxy tool that connects current BioMAJ downloads(https://www.e-biogenouest.org/resources/1397/download/AnthonyBretaudeau_Galaxy_Day_IFB_2014_BioMAJ2Galaxy.pdf).,OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
"Acknowledgements More information about the project can be found at http://www.irida.ca.Funding This work was supported by the Genome Canada/Genome BC Grant 172PHM ‘A Federated Bioinformatics Platform for Public Health Microbial Genomics’ under Fiona Brinkman, Gary Van Domselaar and William Hsiao.",Non-OADS,/arxiv_data1/oa_pdf/17/a0/btv724.PMC4824126.pdf
"1163 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/99/ef/btv725.PMC4824127.pdf
More details about the molecular dynamics simulation parameters are available at: http://arianna.med.uniroma1.it/neutraldrugs/.,OADS,/arxiv_data1/oa_pdf/99/ef/btv725.PMC4824127.pdf
"1996 ) [http://www.R-project.org], the results of which are shown in Supplementary Figure S2 .",Non-OADS,/arxiv_data1/oa_pdf/99/ef/btv725.PMC4824127.pdf
The scripts for running the simulations and perform the ana-lysis are available at: http://arianna.med.uniroma1.it/neutraldrugs/.2.5 Statistical analysis and comparison with other methods The program used to analyze the molecular dynamics trajectories and to build the histograms was written in Fortran90.,OADS,/arxiv_data1/oa_pdf/99/ef/btv725.PMC4824127.pdf
"The R pack-age ( Ihaka and Gentleman, 1996 ) [http://www.R-project.org] was used to analyze the histograms.",Non-OADS,/arxiv_data1/oa_pdf/99/ef/btv725.PMC4824127.pdf
It is maintained and available for download at http://BioFVM.MathCancer.org and http://BioFVM.sf.netunder the Apache License (v2.0).,Non-OADS,/arxiv_data1/oa_pdf/c9/e4/btv730.PMC4824128.pdf
"1256 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c9/e4/btv730.PMC4824128.pdf
Source code and docu- mentation are at http://www.bioconductor.org/packages/paxtoolsr.,OADS,/arxiv_data1/oa_pdf/6d/1b/btv733.PMC4824129.pdf
2 Implementation and functionality PaxtoolsR is implemented using the rJava R package (http://www.rforge.net/rJava/) which allows R code to call Java methods.,OADS,/arxiv_data1/oa_pdf/6d/1b/btv733.PMC4824129.pdf
"1262 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6d/1b/btv733.PMC4824129.pdf
BioPAX representations for databases aggregated by Pathway Commons canbe downloaded from the project website (http://www.pathwaycommons.org).,OADS,/arxiv_data1/oa_pdf/6d/1b/btv733.PMC4824129.pdf
"2.1.3 Extensible markup language BioPAX file validation and search results of Pathway Commons resultsare returned as R XML (http://www.omegahat.org/RSXML/) objectswhere further data can be extracted using XPath expressions in R. 2.2 Convert, merge and validate local BioPAX files A number of BioPAX-related functions are available in PaxtoolsR.These functions can both operate on local BioPAX files and thoseretrieved from Pathway Commons.",OADS,/arxiv_data1/oa_pdf/6d/1b/btv733.PMC4824129.pdf
"Availability and implementation: The DNAshapeR software package was implemented in the stat- istical programming language R and is freely available through the Bioconductor project at https:// www.bioconductor.org/packages/devel/bioc/html/DNAshapeR.html and at the GitHub developer site, http://tsupeichiu.github.io/DNAshapeR/.Contact: rohs@usc.edu Supplementary information: Supplementary data are available at Bioinformatics online.",OADS,/arxiv_data1/oa_pdf/cb/5b/btv735.PMC4824130.pdf
"1211 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cb/5b/btv735.PMC4824130.pdf
"1238 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/85/btv748.PMC4824132.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
"Based on the vascular smooth muscle contraction sig- naling pathway ( http://www.genome.jp/kegg/ ) (KO: 04270), several candidate vasoconstrictors and receptors have been identiﬁed, including endothelin-1, -2, and -3 ( EDN1 ,EDN2 , EDN3 ); endothelin receptors type A and B ( EDNRA and EDNRB )(Masaki 2000 ); angiotensin II receptor type 1 and 2 (AGTR1 andAGTR2 )(Ardaillou 1999 ); adrenergic receptor a- 1A, B, and D ( ADRA1A ,ADRA1B ,a n d ADRA1D )(Wright et al.",OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
The information on gene function and related disease was searched from UniProtKB/Swiss-Prot ( http://www.uni- prot.org/ ) and GeneCards website ( http://www.genecards.,OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
"Gene sequences from other mammalian orders, including artiodactyls, carnivores, primates, lagomorphs, ro- dents, and afrotheria, were downloaded from GenBank (http://www.ncbi.nlm.nih.gov ), the Ensemble Genome data- base ( http://www.ensembl.org ), or UCSC genome data (http://genome.ucsc.edu/ ) with accession numbers listed in supplementary table S4 ,Supplementary Material online .T h e nucleotide and deduced amino acid sequences of each gene were aligned using MUSCLE in MEGA6 ( Tamura et al.",OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
The sec- ondary structures of each gene were identiﬁed using UniProt(http://www.uniprot.org/ ).,OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
"Furthermore, the 3D structures of genes were either searched from Protein Data Bank, which is a database containing experimentally determined 3D structures of proteins, nucleic acids, and other biological macromole- cules ( http://www.rcsb.org/pdb/ ), or constructed by the I-TASSER (Threading ASSEmbly Reﬁnement), a hierarchical protein structure modeling approach based on the secondarystructure enhanced Proﬁle–Proﬁle threading Alignment and the iterative implementation of the TASSER programEvolutionary Genetics of Hypoxia Tolerance GBE Genome Biol.",OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
Supplementary Material Supplementary tables S1–S10 and ﬁgures S1–S5 are available atGenome Biology and Evolution online (http://www.gbe.,OADS,/arxiv_data1/oa_pdf/66/8d/evw037.PMC4824146.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cd/8f/evw038.PMC4824147.pdf
Supplementary Material Supplementary tables S1–S3 andﬁgures S1–S8 are available atGenome Biology and Evolution online (http://www.gbe.,OADS,/arxiv_data1/oa_pdf/cd/8f/evw038.PMC4824147.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/a5/evw040.PMC4824148.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2f/e8/evw042.PMC4824149.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"( http://www.broadinstitute.org/software/gaemr/ , last accessed June 6, 2015).",OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"1997 ), SeqTK 1.0 ( https://github.com/lh3/ seqtk/ , last accessed August 13, 2014), and FastQC 0.10.1 (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/ ).",Non-OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"2009 ), and concatenated using publically available scripts available through https://github.com/tatumdmortimer/core- genome-alignment , last accessed September 8, 2014.",OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"The resulting gene content was visualized in a Venn diagram using nml_par- se_orthomcl.pl script ( https://github.com/apetkau/orthomcl- pipeline/tree/master/scripts , last accessed October 22, 2014).Detection of Horizonta lly Transferred Genes A customized version of HGTector (Z hu et al.",OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
2014 ; available through https://github.com/ecg-lab/hgtector ) was used to identify putatively horizontally transferred genes in the E. tra- cheiphila genome.,OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"45–56, http://mira-assembler.sourceforge.net/docs/ DeﬁnitiveGuideToMIRA.html .",Non-OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
Available from: http://www.paciﬁcbiosciences.,Non-OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
Retrieved from https://www.R-project.org/ .,Non-OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"Available from:http://tree.bio.ed.ac.uk/software/ﬁgtree/ Rand FV, Cash LC.",OADS,/arxiv_data1/oa_pdf/a1/32/evw016.PMC4824170.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
"All raw RNAseq data are available in the NCBI Sequence Read Archive data- base under accession numbers http://www.ncbi.nlm.nih.gov/ bioproject/PRJNA274856/ (S. aenigmaticum ),http://www.ncbi.",OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
"nlm.nih.gov/bioproject/?term=PRJNA274852 (S. minutum ), http://www.ncbi.nlm.nih.gov/b ioproject/?term=PRJNA274855 (S. pseudominutum ), and http://www.ncb i.nlm.nih.gov/ bioproject/?term=PRJNA274854 (S. psygmophilum ).",Non-OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
The assembled and annotated transcriptome sequences for each species are avail- able at http://reefgenomics.org .,OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
R package version 2.2.0. http://bioconductor.uib.no/2.7/bioc/ html/topGO.html Last accessed: January 2014.,Non-OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
Available from: http://www.broadinstitute.org/ cancer/software/GENE-E/index.html .,OADS,/arxiv_data1/oa_pdf/4f/ec/evw019.PMC4824173.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/49/evw020.PMC4824201.pdf
"In brief, we used a stand-alone PERL script underlying the ORF prediction avail- able at http://bioinformatics.ysu.ed u/tools/OrfPredictor.html , last accessed February 29, 2016 where transcripts were trans- lated into the six reading frames.",Non-OADS,/arxiv_data1/oa_pdf/6c/49/evw020.PMC4824201.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"Materials and Methods Sequence Availability Whole genome-wide primary transcript sequences of G. max , P. vulgaris ,M. truncatula , and 34 nonlegume species were downloaded from Phytozome v10 ( http://www.phytozome.",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"Sequences of L. japonicus were obtained from Kazusa DNA Research Institute ( http:// www.kazusa.or.jp/lotus , last accessed March 1, 2015), and those of C. cajan and C. arietinum were downloaded from the International Crops Research Institute for the Semi-Arid Tropics ( http://www.icrisat.org , last accessed March 1, 2015).",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"The phylogeny of the involved plant species was derived from Cogepedia ( http://genomevolution.org/wiki/index.php/ Sequenced_plant_genomes , last accessed March 1, 2015) and APG III ( Angiosperm Phylogeny Group 2009 ).",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"Ancestral character state reconstruction was performed with the Markov k-state 1 parameter m odel (Mk1) in Mesquite 3.03 (http://mesquiteproject.org , last accessed March 1, 2015).",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"Gene Structure Analysis CDS length, intron number, and intron length covering the CDS of the identiﬁed LLGs in nonlegume species were obtained fromgff3 proﬁles downloaded fro m Phytozome v10 and TAIR10 (http://www.arabidopsis.org , last accessed March 1, 2015).",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"The expression data of the identiﬁed LLGs’ orthologs in response to biotic stresses in tomato were taken from the Tomato Functional Genomics data- base ( http://ted.bti.cornell.edu/ , last accessed March 1, 2015), and related data of rice and grape were extracted from theGene Expression Omnibus database ( http://www.ncbi.nlm.nih.",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
Protein sequences of genes coexpressed with each LLG were submitted to KOBAS 2.0 ( http://kobas.cbi.pku.edu.,OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"GO enrichment analysis was performed on AGRIGO v1.2 ( http://bioinfo.cau.edu.cn/agriGO , last accessed March 1, 2015), with the reference genome locus obtained from TAIR10.",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"Protein–Protein Interaction Prediction The identiﬁed LLGs in Arabidopsis were submitted to the A. thaliana section of STRING 10 ( http://string-db.org ,l a s t accessed March 1, 2015) to generate protein–protein interac- tion (PPI) networks.",OADS,/arxiv_data1/oa_pdf/93/f1/evw021.PMC4824202.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/11/71/evw022.PMC4824203.pdf
Gon is P. troglodytes verus (http://www.shigen.,Non-OADS,/arxiv_data1/oa_pdf/11/71/evw022.PMC4824203.pdf
Supplementary Material Supplementary table S1 andﬁgures S1–S4 a r ea v a i l a b l ea t Genome Biology and Evolution online (http://www.gbe.,Non-OADS,/arxiv_data1/oa_pdf/11/71/evw022.PMC4824203.pdf
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/ CIRCULATIONAHA.114.013258/-/DC1 .,Non-OADS,/arxiv_data1/oa_pdf/87/f3/emss-62197.PMC4824279.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph padolescent health, Medicine and Therapeutics 2016:7 37–42submit your manuscript | www.dovepress.co m Dove press  37 http: //dx.doi.org/10.2147/AHMT .S9185 3adverse obstetrical and perinatal outcome in  adolescent mothers associated with first birth:  a hospital-based case-control study in a tertiary  care hospital in north-east india robin Medhi Banani Das arpana Das Mansur ahmed sonika Bawri suditi rai Department of Obstetrics and  gynaecology, silchar Medical college  and hospital, silchar, assam, india correspondence: Banani Das   silchar Medical college, ghungoor,   silchar 788014, assam, india   Tel +91 98 6402 6537   email drbananiz85@gmail.co mPurpose:  To analyze the adverse obstetrical and perinatal outcome of adolescent mothers  associated with first birth.",Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
"Available  from: http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_12-en.pd f.  Accessed November 19, 2015.",Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
"Available  from: http://data.worldbank.org/indicator/SP .ADO.TFR T. Accessed  November 19, 2015.",OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
Available from:  http://www.unfpa.org/sites/default/files/pub-pdf/EN-SWOP2013-final.,Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
"Adolescent Health, Medicine and Therapeutics Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/adolescent-health-medicine-and-therapeutics-journa lAdolescent Health, Medicine and Therapeutics is an international,  peer-reviewed, open access journal focusing on health, pathology,  and treatment issues specific to the adolescent age group.",Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/07/66/ahmt-7-037.PMC4824280.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Biologics: Targets and Therapy Biologics: Targets and Therapy 2016:10 67–73Dove press submit your manuscript | www.dovepress.co m Dove press  Original researchopen access to scientific and medical research Open access Full T ext article 67 http: //dx.doi.org/10.2147/BTT .S9698 2cost-effectiveness of routine measuring of serum  drug concentrations and anti-drug antibodies in  treatment of rheumatoid arthritis patients with  TnF-α blockers Juha laine1 T sakari Jokiranta2,3 Kari K eklund4,5 Merja Väkeväinen1 Kari Puolakka6 1Pfizer Oy, helsinki, 2United Medix  laboratories ltd, espoo, 3research   Programs Unit, immunobiology,   4Department of rheumatology,   University of helsinki, 5helsinki  University central hospital, helsinki,   6Department of Medicine, south  Karelia, Finland correspondence: Juha laine   Pfizer Oy, Tietokuja 4, 00330 Helsinki,  Finland   T el +358 9 4300 40   email juha.laine@pfizer.co mAbstract:  Monitoring of anti-drug antibodies (ADAbs) or serum concentrations of biologicals  in treatment of rheumatoid arthritis could provide an explanation for a loss of efficacy and help  in the choice of subsequent medication.",Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
"Biologics: Targets & Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/biologics-targets--therapy-journa lBiologics: Targets & Therapy is an international, peer-reviewed journal  focusing on the patho-physiological rationale for and clinical applica - tion of Biologic agents in the management of autoimmune diseases,  cancers or other pathologies where a molecular target can be identified.",Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
"Available from: http://www.kora.dk/media/272051/ dsi-3225.pd f. Accessed August 26, 2015  20.",Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
Available from: http://urn.fi/URN:NBN:- fi-fe20120419417 8.,Non-OADS,/arxiv_data1/oa_pdf/cf/d3/btt-10-067.PMC4824281.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/02/0f/dhps-8-039.PMC4824282.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug, Healthcare and Patient Safety 2016:8 39–48Drug, Healthcare and Patient Safety Dove press submit your manuscript | www.dovepress.co m Dove press  39Original reSearcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DHPS.S9539 9Seasonality in acute liver injury?",Non-OADS,/arxiv_data1/oa_pdf/02/0f/dhps-8-039.PMC4824282.pdf
"Drug, Healthcare and Patient Safety Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-healthcare-and-patient-safety-journa lDrug, Healthcare and Patient Safety is an international, peer-reviewed  open-access journal exploring patient safety issues in the healthcare  continuum from diagnostic and screening interventions through to treat - ment, drug therapy and surgery.",Non-OADS,/arxiv_data1/oa_pdf/02/0f/dhps-8-039.PMC4824282.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/02/0f/dhps-8-039.PMC4824282.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).international Journal of cOPD 2016:11 697–709submit your manuscript | www.dovepress.co m Dove press  697 http: //dx.doi.org/10.2147/COPD.S10025 0cOPD exacerbations by disease severity in  england evie Merinopoulou1 Mireia raluy-callado1 sreeram ramagopalan1 sharon Maclachlan1 Javaria Mona Khalid2 1real-World evidence, evidera,   2Takeda Development centre europe  ltd, london, UKObjectives:  Exacerbations of chronic obstructive pulmonary disease (COPD) are associated  with accelerated disease progression and are important drivers of health care resource utiliza - tion.",Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
"Additionally, the health  care resource use associated with the management of COPD in primary and secondary  care results in a substantial economic burden borne by national health care systems.3 In the UK, COPD is the most common respiratory condition with an estimated  prevalence of 33 cases per 1,000 persons in 2013.4 We recently showed using UK  primary care data that 26.2% of patients with COPD on December 31, 2013 had one correspondence: Mireia raluy-callado real-World evidence, evidera, Metro  Building, 6th Floor, 1 Butterwick, london,  W6 8Dl, UK Tel +44 20 857 65000 Fax +44 20 857 65195 email mireia.raluy@evidera.co mJournal name: International Journal of COPD Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Merinopoulou et al Running head recto: COPD exacerbations in England DOI: http://dx.doi.org/10.2147/COPD.S100250",Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
Available from: http://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
Available from: http://www.goldcopd.org /.,Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
Available from: http://www.cprd.,Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
Available from: http://www.hscic.,Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
"Available from:  http://apps.who.int/classifications/icd10/browse/2016/e n. Accessed  March 10, 2016.",OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/32/d1/copd-11-697.PMC4824283.pdf
"Automated Intraretinal Layer Segmentation Ten intraretinal layers (11 surfaces) from the macular SD-OCT volumes were automatically detected by applying our previously reported automated graph- based segmentation method, the Iowa ReferenceAlgorithms (available in the public domain fromhttps://www.iibi.uiowa.edu/content/shared-software- download/ ).",OADS,/arxiv_data1/oa_pdf/23/7b/i2164-2591-5-2-14.PMC4824284.pdf
"Statistical computing software(R version 2.15.2, R Development Core Team;provided in the public domain by R Foundation forStatistical Computing, Vienna, Austria, available athttp://www.r-project.org/ , ‘randomForest’ package) was used for the random forest regression.",OADS,/arxiv_data1/oa_pdf/23/7b/i2164-2591-5-2-14.PMC4824284.pdf
E-mail  address:  Arun.Samidurai@vcuhealth.org  (A.  Samidurai) Available  online  6  November  2015 http://dx.doi.org/10.1016/j.ihj.2015.08.028 0019-4832/ #  2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/40/21/main.PMC4824326.pdf
E-mail  address:  ozcanozeke@gmail.com  (O.  Ozeke).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0280019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/07/8f/main.PMC4824327.pdf
E-mail  address:  drsupriyabhu@gmail.com  (S.  Kushwah).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.09.0130019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/4a/ed/main.PMC4824328.pdf
E-mail  address:  senguptasp@gmail.com  (S.  Sengupta).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.06.0420019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/18/c4/main.PMC4824329.pdf
E-mail  address:  prashanthp_69@yahoo.co.in  (P.  Panduranga).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.11.0190019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/06/fd/main.PMC4824330.pdf
Lyon).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2016.01.0220019-4832/ # 2016  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/c2/ff/main.PMC4824331.pdf
This  is  an  open  access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c2/ff/main.PMC4824331.pdf
Mehra).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2016.01.0170019-4832/ # 2016  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/38/d0/main.PMC4824332.pdf
This  is  an  open  access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/38/d0/main.PMC4824332.pdf
Available  at:  https://clinicaltrisl.gov/ct2/show/NCT01452802 .,Non-OADS,/arxiv_data1/oa_pdf/38/d0/main.PMC4824332.pdf
"Suvro  Banerjee Consultant  Cardiologist,  Department  of  Cardiology, Apollo  Gleneagles  Hospital,  Kolkata,  India E-mail  address:  drsuvrob@gmail.com  (S.  Banerjee) Available  online  12  November  2015 http://dx.doi.org/10.1016/j.ihj.2015.07.018 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/02/23/main.PMC4824333.pdf
E-mail  address:  melvingeorge2003@gmail.com  (M.  George).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.07.0060019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/8b/17/main.PMC4824334.pdf
"Sundeep  Mishra Department  of  Cardiology,  AIIMS,  New  Delhi,  India E-mail  address:  sundeepmishraihj@gmail.com Available  online  11  January  2016 http://dx.doi.org/10.1016/j.ihj.2015.12.012 0019-4832/ #  2016  Published  by  Elsevier,  a  division  of  Reed  Elsevier  India, Pvt.",Non-OADS,/arxiv_data1/oa_pdf/8a/7f/main.PMC4824335.pdf
E-mail  address:  lmure_san@yahoo.com  (M.  Lucian).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.09.0250019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/37/53/main.PMC4824336.pdf
Anker).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.11.0180019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/94/af/main.PMC4824338.pdf
Available  at:  http://www.who.int/ mediacentre/factsheets/fs317/en/ ;  Accessed  26.09.15.,Non-OADS,/arxiv_data1/oa_pdf/94/af/main.PMC4824338.pdf
Available  at:  http://www3.weforum.org/docs/WEF_ EconomicNonCommunicableDiseasesIndia_Report_2014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/94/af/main.PMC4824338.pdf
Available  at:  https://clinicaltrials.gov/ct2/show/ NCT01953874?term=CAT-HF&rank=1 ;  Accessed  13.08.15.67.,Non-OADS,/arxiv_data1/oa_pdf/94/af/main.PMC4824338.pdf
"Abbreviations:  HF,  heart  failure;  AHF,  acute  heart  failure;  UF,  ultraﬁltration.Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.10.386 0019-4832/ #  2015  Cardiological  Society  of  India.",Non-OADS,/arxiv_data1/oa_pdf/35/fa/main.PMC4824339.pdf
2014.  https://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/35/fa/main.PMC4824339.pdf
Sudharshana  Murthy).Available  online  at  www.sciencedirect.com ScienceDirect journal  homepage:  www.elsevier.com/locate/ihj http://dx.doi.org/10.1016/j.ihj.2015.09.0030019-4832/ # 2015  Cardiological  Society  of  India.,Non-OADS,/arxiv_data1/oa_pdf/2e/31/main.PMC4824340.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4d/db/jpr-9-177.PMC4824363.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",OADS,/arxiv_data1/oa_pdf/4d/db/jpr-9-177.PMC4824363.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Journal of Pain Research 2016:9 177–186submit your manuscript | www.dovepress.co m Dove press  177 http: //dx.doi.org/10.2147/JPR.S8357 4Management of chronic pain in osteoporosis:  challenges and solutions T eresa Paolucci* vincenzo Maria Saraceni Giulia Piccinini* Physical Medicine and Rehabilitation  Unit, Azienda Policlinico Umberto i,   Rome, italy *These authors contributed equally to  this work Correspondence:  T eresa Paolucci   Complex Unit of Physical Medicine  and Rehabilitation, Azienda Policlinico  Umber to i, Piazzale Aldo Moro 5, 00185  Rome, italy   T el +39 347 933 8625   Fax +39 06 4991 4552   email teresapaolucci@hotmail.co mAbstract:  Osteoporosis (OP) is a pathological condition that manifests clinically as pain,  fractures, and physical disability, resulting in the loss of independence and the need for long- term care.",Non-OADS,/arxiv_data1/oa_pdf/4d/db/jpr-9-177.PMC4824363.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/4d/db/jpr-9-177.PMC4824363.pdf
Visit  http://www.dovepress.com/testimonials.php to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4d/db/jpr-9-177.PMC4824363.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/ijn-11-1383.PMC4824364.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 1383–1394International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1383OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9632 4gelatin-methacrylamide gel loaded with  microspheres to deliver gDNF in bilayer collagen  conduit promoting sciatic nerve growth hai Zhuang1–3 shoushan Bu1 lei hua1 Mohammad a Darabi2,3 Xiaojian cao4 Malcolm Xing2,3 1Department of stomatology, The  First affiliated hospital with Nanjing  Medical University, Nanjing, Jiangsu  Province, People’s republic of  china; 2Department of Mechanical  engineering, Biochemistry & Medical  genetics, 3children’s hospital  research Institute of Manitoba,   University of Manitoba, Winnipeg, MB,   canada; 4Department of Orthopedics,   The First affiliated hospital with  Nanjing Medical University, Nanjing,   Jiangsu Province, People’s republic  of chinaAbstract:  In this study, we fabricated glial cell-line derived neurotrophic factor (GDNF)-loaded  microspheres, then seeded the microspheres in gelatin-methacrylamide hydrogel, which was finally  integrated with the commercial bilayer collagen membrane (Bio-Gide®).",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/ijn-11-1383.PMC4824364.pdf
"So far,  existing problems in repairing PNS include (1) difficulty in building appropriate  microenvironment for nerve regeneration, such as lack of required growth factors, and  (2) diminishing neuronal apoptosis and muscle atrophy.1 For peripheral nerve repair,  nerve autograft has been considered as the “gold standard” for the restoration of nerve  regeneration.2 But autograft is limited by the short age availability of donor nerves,  wound pain, increased morbidity, and scar formation at the donor site.3correspondence: shoushan Bu Department of stomatology, The First  Affiliated Hospital with Nanjing Medical  University, Nanjing, Jiangsu, 210029,  People’s republic of china Tel +86 138 1388 8277 email bushsh@vip.sina.co m  Malcolm Xing Department of Mechanical engineering,  Biochemistry & Medical genetics,  children’s hospital research Institute  of Manitoba, University of Manitoba,  715 McDermot ave, Winnipeg, MB, r3e  3P4, canada Tel +1 204 474 6301 email malcolm.xing@umanitoba.c a Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Zhuang et al Running head recto: Delivery of GDNF using microsphere-loaded GelMA DOI: http://dx.doi.org/10.2147/IJN.S96324",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/ijn-11-1383.PMC4824364.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/ijn-11-1383.PMC4824364.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/ijn-11-1383.PMC4824364.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d2/07/opth-10-603.PMC4824365.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 603–608Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  603Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10268 3Comparison of Scheimpflug imaging parameters  between steep and keratoconic corneas of  Caucasian eyes T ukezban huseynova1 Farah abdulaliyeva2 Michele lanza3 1Briz-l eye Clinic, 2national  Ophthalmology Center, Baku,   azerbaijan; 3second University of  naples, Caserta, Campania, italyPurpose:  To compare the keratometric and pachymetric parameters of healthy eyes with those  affected by steep cornea and keratoconus (KC) using Scheimpflug camera.",Non-OADS,/arxiv_data1/oa_pdf/d2/07/opth-10-603.PMC4824365.pdf
"As the cornea steepens, the amount of astigmatism increases, caus - ing a distortion of the image which reduces visual acuity of affected patients.4 Although  KC can be easily diagnosed with corneal topography, it is rather more difficult to rule  out subclinical KC before surgery.5 Detection of subclinical KC or forme fruste KC  among refractive surgery candidates is important because kerato-refractive procedures Correspondence: Tukezban huseynova  Briz-l eye Clinic,  Maqsud alizadeh 46, aZ1106, Baku, azerbaijan Tel +994 50 308 2662 email tukezban@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Huseynova et al Running head recto: Corneal parameters between steep and keratoconic corneas DOI: http://dx.doi.org/10.2147/OPTH.S102683",Non-OADS,/arxiv_data1/oa_pdf/d2/07/opth-10-603.PMC4824365.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/d2/07/opth-10-603.PMC4824365.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/07/opth-10-603.PMC4824365.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8e/e9/ijn-11-1367.PMC4824366.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 1367–1382International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1367OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S10129 4The role of well-defined nanotopography of  titanium implants on osseointegration: cellular  and molecular events in vivo Dimitrios Karazisis1–3 ahmed M Ballo1,2,4 sarunas Petronis2,5 Hossein Agheli1,2 lena emanuelsson1,2 Peter Thomsen1,2 Omar Omar1,2 1Department of Biomaterials, Institute  of Clinical Sciences, Sahlgrenska  Academy, University of Gothenburg,   Gothenburg, Sweden; 2BIOM aTcell,   VINN excellence center of  Biomaterials and Cell Therapy,   Gothenburg, Sweden; 3Department  of Oral and Maxillofacial Surgery,   Sahlgrenska Academy, University of  Gothenburg, Sweden; 4Department  of Oral Health Sciences, Faculty  of Dentistry, University of British  Columbia, Vancouver, BC, Canada;   5Department of Chemistry, Materials  and surfaces, sP Technical research  Institute of sweden, Borås, swedenPurpose:  Mechanisms governing the cellular interactions with well-defined nanotopography  are not well described in vivo.",Non-OADS,/arxiv_data1/oa_pdf/8e/e9/ijn-11-1367.PMC4824366.pdf
"Keywords:  nanofabrication, gene expression, immunohistochemistry, energy dispersive X-ray  spectroscopy, inflammatory cytokines, bone formation Introduction Osseointegration is a complex phenomenon and a prerequisite for the clinical suc - cess of bone-anchored dental and orthopedic implants.1 Experimental studies provide  evidence that bone formation could be promoted by implant surface modifications,  largely dependent on the alterations of surface topography and roughness.2 While it is  established that surface roughness at the microscale plays influential roles for tissue  healing and implant fixation,3,4 the role of surface topography at the nanoscale has correspondence: Omar Omar Department of Biomaterials, Institute of  Clinical Sciences, Sahlgrenska Academy,  University of Gothenburg, Box 412,  SE-405 30 Gothenburg, Sweden Tel +46 31 786 2951 Fax +46 31 786 2941 email omar.omar@biomaterials.gu.s e Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Karazisis et al Running head recto: Cellular and molecular events at well-defined nanotopography DOI: http://dx.doi.org/10.2147/IJN.S101294",Non-OADS,/arxiv_data1/oa_pdf/8e/e9/ijn-11-1367.PMC4824366.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/8e/e9/ijn-11-1367.PMC4824366.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8e/e9/ijn-11-1367.PMC4824366.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5b/ba/ndt-12-737.PMC4824367.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2016:12 737–743Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  737OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S9263 7Demographic variables, clinical aspects, and  medicolegal implications in a population of  patients with adjustment disorder annalisa anastasia1 chiara colletti1 Valentina cuoco1 adele Quartini1 stefania Urso2 raffaella rinaldi2 giuseppe Bersani1 1Department of Medical- surgical  sciences and Biotechnologies, Faculty  of Pharmacy and Medicine, sapienza  University of rome, 2Department of  anatomical, istological, Forensic and  locomotor system sciences, sapienza  University of rome, rome, italyIntroduction:  Although adjustment disorder (AD) is considered as residual diagnosis and  receives little attention in research, it plays an important role in clinical practice and also assumes  an increasingly important role in the field of legal medicine, where the majority of diagnostic  frameworks (eg, mobbing) often refer to AD.",Non-OADS,/arxiv_data1/oa_pdf/5b/ba/ndt-12-737.PMC4824367.pdf
"Within these studies,  the most shared concept is that diagnostic criteria are vague and not so helpful in clini - cal practice.1,2 AD has been regarded as one of the most ill-defined mental disorders.3  Conceptually, it is an intermediate category between healthy normal responses to  stress and affective conditions such as anxiety and mood disorders.4,5 At present,  it is included in the “Trauma and Stress Related Disorder” category of Diagnostic correspondence: annalisa anastasia Department of Medical-surgical sciences  and Biotechnologies, Faculty of Pharmacy  and Medicine, sapienza University of  rome, corso della repubblica 79, 04100  latina, italy Tel +39 0773 175 7210 Fax +39 0773 175 7219 email annalisa.anastasia@yahoo.i tJournal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2016 Volume: 12 Running head verso: Anastasia et al Running head recto: Patients with adjustment disorder DOI: http://dx.doi.org/10.2147/NDT.S92637",Non-OADS,/arxiv_data1/oa_pdf/5b/ba/ndt-12-737.PMC4824367.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/5b/ba/ndt-12-737.PMC4824367.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/ba/ndt-12-737.PMC4824367.pdf
"The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/63/ec/jbm-7-027.PMC4824368.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Journal of Blood Medicine 2016:7 27–38Journal of Blood Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  27Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S8152 0New developments in the management of  moderate-to-severe hemophilia B Moniba Nazeef1,2 John P Sheehan1,2 1Department of Medicine, Division  of Hematology/Oncology, 2Uw  Carbone Cancer Center, University  of wisconsin School of Medicine and  Public Health, Madison, wi, USA Correspondence: John P Sheehan   Uw Carbone Cancer Center, University  of wisconsin School of Medicine and  Public Health, 600 Highland Ave, K5/622,  Madison, wi 53705, USA   T el +1 608 262 1964   Fax +1 608 265 8133   email jps@medicine.wisc.ed uAbstract:  Hemophilia B is an X-linked genetic deficiency of coagulation factor IX (FIX) activity  associated with recurrent deep tissue and joint bleeding that may lead to long-term disability.",Non-OADS,/arxiv_data1/oa_pdf/63/ec/jbm-7-027.PMC4824368.pdf
"Journal of Blood Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/Journal-of-blood-medicine-journa lThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects  of all topics pertaining to blood based medicine including but not limited to:  Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,  and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of  blood related medicine; Legal aspects of blood medicine; Historical perspec - tives.",Non-OADS,/arxiv_data1/oa_pdf/63/ec/jbm-7-027.PMC4824368.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/63/ec/jbm-7-027.PMC4824368.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7a/50/opth-10-593.PMC4824369.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 593–602Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  593Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S8367 6Limbal stem cell transplantation: current  perspectives Marwan Raymond Atallah Sotiria Palioura victor L Perez Guillermo Amescua Department of Ophthalmology,   Bascom Palmer eye institute,   University of Miami Miller School  of Medicine, Miami, FL, USAAbstract:  Regeneration of the corneal surface after an epithelial insult involves division,  migration, and maturation of a specialized group of stem cells located in the limbus.",Non-OADS,/arxiv_data1/oa_pdf/7a/50/opth-10-593.PMC4824369.pdf
"Lineage Correspondence: Guillermo Amescua Department of Ophthalmology,  Bascom Palmer eye institute, 900 Nw  17th Street, Miami, FL 33136, USA Tel +1 305 326 6000 email gamescua@med.miami.ed u Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Atallah et al Running head recto: Limbal stem cell transplantation DOI: http://dx.doi.org/10.2147/OPTH.S83676",Non-OADS,/arxiv_data1/oa_pdf/7a/50/opth-10-593.PMC4824369.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/7a/50/opth-10-593.PMC4824369.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7a/50/opth-10-593.PMC4824369.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2016:9 1921–1926OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1921Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S10139 0survival analysis in second-line and third-line  chemotherapy with irinotecan followed by  topotecan or topotecan followed by irinotecan  for extensive-stage small-cell lung cancer patients:  a single-center retrospective study gokmen aktas1 T ulay Kus1 Mehmet emin Kalender1 alper sevinc1 celaletdin camci1 seval Kul2 1Division of Medical Oncology,   Department of internal Medicine,   school of Medicine, gaziantep  Oncology hospital, gaziantep  University, gaziantep, T urkey;   2Department of Biostatistics, school  of Medicine, gaziantep University,   gaziantep, T urkeyPurpose:  The number of patients who make it to receive third-line chemotherapy is increasing  owing to the improvements in adverse-event management of chemotherapy for small-cell lung  cancer (SCLC).",Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
"Despite the high sensitivity to initial chemotherapy,  most patients develop quick relapses, and tumor responses severely decrease after  the first-line therapy.2 According to Veterans Administration Lung Study Group’s correspondence: gokmen aktas Division of Medical Oncology,  Department of internal Medicine,  school of Medicine, gaziantep Oncology  hospital, gaziantep University,  Tr-27310 gaziantep, Turkey Tel +90 342 472 0711 Fax +90 342 472 0718 email aktas_gokmen@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2016 Volume: 9 Running head verso: Aktas et al Running head recto: Survival analysis in second-line and third-line chemotherapy DOI: http://dx.doi.org/10.2147/OTT.S101390",Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
Available from: http://seer.cancer.gov/csr/1975_2011 /.,Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/de/22/ott-9-1921.PMC4824370.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2016:11 1349–1366International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  1349OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S9525 3Theranostic multimodular potential of zinc-doped  ferrite-saturated metal-binding protein-loaded  novel nanocapsules in cancers sishir K Kamalapuram1 rupinder K Kanwar1 Kislay roy1 rajneesh chaudhary1 rakesh sehgal2 Jagat r Kanwar1 1Nanomedicine laboratory of  Immunology and Molecular  Biomedical research, school of  Medicine, centre for Molecular and  Medical research, Faculty of health,   Deakin University, geelong, VIc ,   australia; 2Department of Medical  Parasitology, Postgraduate Institute  of Medical education and research,   chandigarh, IndiaAbstract:  The present study successfully developed orally deliverable multimodular zinc (Zn)  iron oxide (Fe3O4)-saturated bovine lactoferrin (bLf)-loaded polymeric nanocapsules (NCs),  and evaluated their theranostic potential (antitumor efficacy, magnetophotothermal efficacy  and imaging capability) in an in vivo human xenograft CpG-island methylator phenotype  (CIMP)-1+/CIMP2−/chromosome instability-positive colonic adenocarcinoma (Caco2) and  claudin-low, triple-negative (ER−/PR−/HER2−; MDA-MB-231) breast cancer model.",Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
"Due to these characteristics, cancer researchers are in search of  novel noble therapeutic compounds as nanotheranostic platforms for cancer.1 Cancer  has evolved as an increasingly complex disease, due to the innumerable cancer-growth  mechanisms escaping the normal growth patterns that lead to severe disease states.2  Due to these growth trends, it is very difficult for conventional chemotherapeutic  drugs and traditional therapeutic platforms to achieve effective treatment of cancers.3–5  Iron-saturated bovine lactoferrin (Fe-bLf) has been extensively studied for its promi - nent ability in helping the immune system to combat cancer and also in generation of  immune cells, such as B lymphocytes, increasing antitumor macrophage activity, and  increased production of wide range of interleukins.3,6–9 Fe-bLf-derived nanotherapeutics  exhibit apoptotic signaling mechanisms, and further Fe-bLf had a crucial role in the correspondence: Jagat r Kanwar Nanomedicine laboratory of Immunology  and Molecular Biology, school of  Medicine, centre for Molecular and  Medical research, Faculty of health,  school of Medicine, Deakin University,  75 Pigdons road, Waurn Ponds, geelong,  VIc 3217, australia Tel +61 3 5227 1148 Fax +61 3 5227 2539 email jagat.kanwar@deakin.edu.a u Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2016 Volume: 11 Running head verso: Kamalapuram et al Running head recto: Zn-Fe bovine lactoferrin NCs for cancer DOI: http://dx.doi.org/10.2147/IJN.S9525 3",Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
"Appendix F: Calculate the  Percent Daily Value for the Appropriate Nutrients) Available from:  http://www.fda.gov/Food/GuidanceRegulation/ GuidanceDocuments   RegulatoryInformation /LabelingNutrition/ucm064928.ht m. Accessed  November 10, 2015.",Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/2a/ijn-11-1349.PMC4824375.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a2/40/opth-10-587.PMC4824378.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 587–592Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  587Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10163 2laser-induced corneal cross-linking upon  photorefractive ablation with riboflavin igor M Kornilovskiy1 elmar M Kasimov2 ayten i sultanova2 alexander a Burtsev1 1Department of eye Diseases, Federal  state Budgetary institution “ national  Pirogov Medical surgical Centre”,   Ministry of health, Moscow, russia;   2Department of eye Diseases, Zarifa  aliyeva national Ophthalmology  Center, Ministry of health, Baku,   azerbaijanAim:  To estimate the biomechanical effect of the laser-induced cross-linking resulting from  photorefractive ablation of the cornea with riboflavin.",Non-OADS,/arxiv_data1/oa_pdf/a2/40/opth-10-587.PMC4824378.pdf
"This is because riboflavin not only forms oxy compounds and additional cross-links Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Kornilovskiy et al Running head recto: Biomechanical properties of corneal samples DOI: http://dx.doi.org/10.2147/OPTH.S101632 Correspondence: igor M Kornilovskiy Department of eye Diseases, Federal  state Budgetary institution “national  Pirogov Medical surgical Centre”,  nizhnyaya Pervomayskaya 65, 105203  Moscow, russia email kornilovsky51@yandex.r u",Non-OADS,/arxiv_data1/oa_pdf/a2/40/opth-10-587.PMC4824378.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/a2/40/opth-10-587.PMC4824378.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a2/40/opth-10-587.PMC4824378.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/93/56/opth-10-571.PMC4824379.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2016:10 571–576Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  571Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S10077 0impact of corneal cross-linking combined with  photorefractive keratectomy on blurring strength georgios labiris1,2 haris sideroudi2 Dimitris angelonias2 Kimonas georgantzoglou2 Vassilios P Kozobolis1,2 1Department of Ophthalmology,   University hospital of  alexandroupolis, 2eye institute of  Thrace, alexandroupolis, greecePurpose:  The aim of this study was to evaluate the impact of corneal cross-linking combined  with photorefractive keratectomy (PRK) on blurring strength.",Non-OADS,/arxiv_data1/oa_pdf/93/56/opth-10-571.PMC4824379.pdf
"Moreover, in an  attempt to (partially) reverse KC’s impact on visual capacity, CxL has been combined Correspondence: georgios labiris Department of Ophthalmology,  University hospital of alexandroupolis,  68100 Dragana, alexandroupolis, greece Tel +30 25 5103 9891 email labiris@usa.ne t Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2016 Volume: 10 Running head verso: Labiris et al Running head recto: Impact of CxL combined with PRK on blurring strength DOI: http://dx.doi.org/10.2147/OPTH.S100770",Non-OADS,/arxiv_data1/oa_pdf/93/56/opth-10-571.PMC4824379.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/93/56/opth-10-571.PMC4824379.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/93/56/opth-10-571.PMC4824379.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2016:10 435–441Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  435Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S8346 9varenicline for smoking cessation: a narrative  review of efficacy, adverse effects, use in at-risk  populations, and adherence Michael v Burke J Taylor Hays Jon O ebbert Mayo Clinic, Rochester, MN, USAAbstract:  Treating tobacco dependence is the most effective way to reduce tobacco-related  death and disability.",Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
"Nicotine replacement therapy (NRT) used in combination (eg, patch + gum or  patch + nasal spray) improve abstinence outcomes compared with single NRT.12,13 Correspondence: Jon O Ebbert Mayo Clinic, 200 First Street SW,  Rochester, MN 55905, USA Tel +1 585 266 1944 Fax +1 585 266 7900 email ebbert.jon@mayo.ed u Journal name: Patient Preference and Adherence Article Designation: Review Y ear: 2016 Volume: 10 Running head verso: Burke et al Running head recto: A review of varenicline for smoking cessation DOI: http://dx.doi.org/10.2147/PPA.S83469",Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm276737.ht m. Accessed August 2015.,Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm330367.ht m. Accessed August 2015.,Non-OADS,/arxiv_data1/oa_pdf/5a/ee/ppa-10-435.PMC4824380.pdf
"To view a copy of this license, visit http://cre - ativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto)",Non-OADS,/arxiv_data1/oa_pdf/a3/6e/mto201523.PMC4824560.pdf
http://globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/6f/1a/mto20163.PMC4824561.pdf
http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/6f/1a/mto20163.PMC4824561.pdf
"To view a copy of this license, visit http://   creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto)",Non-OADS,/arxiv_data1/oa_pdf/6f/1a/mto20163.PMC4824561.pdf
"To view a copy of this license, visit http://creativecommons.org/   licenses/by-nc-sa/4.0/",Non-OADS,/arxiv_data1/oa_pdf/c5/48/mto20167.PMC4824564.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto)",Non-OADS,/arxiv_data1/oa_pdf/3c/07/mto20161.PMC4824565.pdf
"To view a copy of this license, visit http://   creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Molecular Therapy— Oncolytics  website (http://www.nature.com/mto)",Non-OADS,/arxiv_data1/oa_pdf/aa/f4/mto201524.PMC4824566.pdf
"The SPRY domain of TRIM5speciﬁcally binds the tertiary structure of target protein HIVp24 and not simian immunodeﬁciency virus p24, leading to© Chandra B Lebovitz, Lindsay DeVorkin, Damien Bosc, Katharina Rothe, Jag- bir Singh, Marcel Bally, Xiaoyan Jiang, Robert N Young, Julian J Lum, andSharon M Gorski *Correspondence to: Sharon M. Gorski; Email: sgorski@bcgsc.ca Submitted: 07/10/2015; Revised: 07/19/2015; Accepted: 07/28/2015http://dx.doi.org/10.1080/15548627.2015.1078962 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Cancer Discov 2014; 4:905-913; PMID:24875860; http://dx.doi.org/10.1158/2159-8290.CD-14-0362 3.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Nature 2014; 509:105-9; PMID:24695223; http://dx.doi.org/ 10.1038/nature13148 4.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Commun 2014; 5:5775; PMID:25503391; http://dx.doi.org/10.1038/ncomms67755.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Cell Death Differ 2014; 21:1432-41; PMID:24769734; http://dx.doi.org/10.1038/ cdd.2014.58 6.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Neurobiol Dis 2015; 76:24- 36; PMID:25583186; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Hum Mol Genet 2014; 23:3166-79; PMID:24459296; http://dx.doi.org/10.1093/hmg/ddu027 8.,OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Trends Neurosci 2015; 38:26-35; PMID:25282404; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Diabetes 2015; 64:36-48; PMID:25071026; http://dx.doi.org/10.2337/db14-0267 10.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Bioorg Med Chem 2015; 23:3237-47;PMID:25979376; http://dx.doi.org/10.1016/j.bmc.,OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
ASSAY Drug Dev Technol 2014; 12:176-89; PMID:24735444; http://dx.doi.org/10.1089/adt.2013.561 12.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
Autophagy 2012; 8:1383-4;PMID:22878685; http://dx.doi.org/10.4161/auto.,Non-OADS,/arxiv_data1/oa_pdf/89/a9/kaup-11-10-1078962.PMC4824567.pdf
"In this context,autophagy has been demonstrated as necessary for BCR-ABL1-induced leukemogenesis, 7,9,10as well as to protect cancer cells from apoptosis induced by antineoplastic drugs such as © David Colecchia, Matteo Rossi, Federica Sasdelli, Sveva Sanzone, Angela Strambi, and Mario Chiariello *Correspondence to: Mario Chiariello; Email: mario.chiariello@ittumori.itSubmitted: 08/26/2014; Revised: 08/07/2015; Accepted: 08/13/2015 http://dx.doi.org/10.1080/15548627.2015.1084454 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
"7,14Importantly, new clinical trials are also investigating the effect of adding hydroxy- chloroquine to Imatinib treatment for CML (CHOICES trial,http://www.cancerresearchuk.org/about-cancer/ﬁnd-a-clinical-trial/a-trial-hydroxychloroquine-with-imatinib-for-choices).",Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Science 1964; 144:1229-31; PMID:14150328; http://dx.doi.org/ 10.1126/science.144.3623.1229 2.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Nature 1985; 315:550-4; PMID:2989692; http://dx.doi.org/10.1038/315550a0 4.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Nature Med 1996;2:561-6; PMID:8616716; http://dx.doi.org/10.1038/ nm0596-561 5.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
"Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-speciﬁc P210bcr/ a b lp r o t e i n .P r o cN a t lA c a dS c iUSA1 9 8 8 ; 85:9312-6; PMID:3143116; http://dx.doi.org/ 10.1073/pnas.85.23.9312 6.",Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Blood 2011; 118:2035- 43; PMID:21693757; http://dx.doi.org/10.1182/ blood-2011-01-3306218.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Acta Haematol 2013; 130:268-78; PMID:23949495; http://dx.doi.org/10.1159/000353163 9.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis.Oncogene 2011; 30:1855-67; PMID:21151168; http://dx.doi.org/10.1038/onc.2010.561 10.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Crit Rev Oncol Hematol 2012; 81:275-85; PMID:21612942; http://dx.doi.org/10.1016/j.critrevonc.2011.03.009 11.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Blood2007; 110:313-22; PMID:17363733; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Cancer Sci 2008; 99:2200-8; PMID:18823378; http://dx.doi.org/10.1111/j.1349-7006.2008.00932.x 13.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Cell Death Differ 2008; 15:1712-22; PMID:18617896; http://dx.doi.org/10.1038/cdd.2008.10714.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Am J Hematol 2011; 86:38-47; PMID:21132731; http://dx.doi.org/10.1002/ajh.21914 16.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Autophagy 2013; 9:317-27; PMID:23242206; http://dx.doi.org/ 10.4161/auto.22923 17.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Biol Chem 2002; 277:16733-43; PMID:11875070;http://dx.doi.org/10.1074/jbc.M112483200 18.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Biol Chem 2006; 281:10567-76; PMID:16484222; http://dx.doi.org/10.1074/jbc.M513397200 21.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Cancer Res 2010; 70:3218-27; PMID:20395206; http://dx.doi.org/10.1158/0008- 5472.CAN-09-4306 22.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Clin Invest 1993; 92:1925-39; PMID:8408645; http://dx.doi.org/; http://dx.doi.org/ 10.1172/JCI116786 25.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Changing the subcellular location of the oncopro- tein Bcr-Abl using rationally designed capture motifs.Pharm Res 2012; 29:1098-109; PMID:22183511; http://dx.doi.org/10.1007/s11095-011-0654-8 26.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Mol Cell 2005; 19:461- 73; PMID:16109371; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Nat Med 2001; 7:228-34; PMID:11175855; http://dx.doi.org/ 10.1038/84683 28.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Biol Chem 2011;286:8507-22; PMID:21190936; http://dx.doi.org/ 10.1074/jbc.M110.179523 30.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Cell Death Dis 2012; 3:e373; PMID:22898871; http://dx.doi.org/ 10.1038/cddis.2012.111 31.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Autophagy 2011; 7:1069-70; PMID:21552009; http://dx.doi.org/ 10.4161/auto.7.9.15886 33.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496 34.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Mol Cell Biol 2003; 23:5979-88; PMID:12917323; http://dx.doi.org/10.1128/MCB.23.17.5979-5988.2003 35.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Cell Biol 2010; 190:575-86;PMID:20733054; http://dx.doi.org/10.1083/jcb.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Cancer Res 2011; 71:3328-40; PMID:21531765; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Science 1990; 247:1079-82; PMID:2408149; http://dx.doi.org/10.1126/science.2408149 38.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
PLoS Genet2014; 10:e1004764; PMID:25393288; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Nat Commun 2015; 6:6666; PMID:25823377; http://dx.doi.org/10.1038/ncomms7666 41.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
EMBO J 2011; 30:3684-700;PMID:21847093; http://dx.doi.org/10.1038/ emboj.2011.253 42.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Blood 2012; 120:3555-62; PMID:22898604; http://dx.doi.org/10.1182/blood-2012-01-402578 43.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
Am J Hematol 2013; 88:455-62; PMID:23440701; http://dx.doi.org/ 10.1002/ajh.23428 44.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
PLoS One 2013; 8:e52011; PMID:23326322; http://dx.doi.org/10.1371/journal.pone.0052011 45.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
PLoS One 2009; 4:e6124;PMID:19568437; http://dx.doi.org/10.1371/ journal.pone.0006124 46.,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Biol Chem 2008; 283:3023-30; PMID:18070886; http://dx.doi.org/10.1074/jbc.M705513200 47.,OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
J Immunol Methods 1991; 139:271-9; PMID:1710634; http://dx.doi.org/10.1016/0022- 1759(91)90198-O 1802 Volume 11 Issue 10 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/2e/6b/kaup-11-10-1084454.PMC4824572.pdf
"7During autophagy, cells create double-membrane-bound compartments called phagophores that engulf cytoplasmic components; the phagophore expands and seals to form a © Yu Wang, Shuyu Cai, Lingling Yin, Kai Shi Xiaojian Xia, Yanhong Zhou, Jingquan Yu, and Jie Zhou *Correspondence to: Jie Zhou; Email: jie@zju.edu.cnSubmitted: 05/06/2015; Revised: 09/05/2015; Accepted: 09/16/2015 http://dx.doi.org/10.1080/15548627.2015.1098798 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
"Expression of autophagy-related (ATG ) genes and formation of autophagosomes under drought stress To analyze whether autophagy involved in HsfA1a-induced drought tolerance, we ﬁrst examined the expression of 26 autoph-agy genes identiﬁed from the Sol Genomics Network (http://solgenomics.net/) in response to drought stress.",OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Cell Death Differ 2013;20:21-30; PMID:22722335; http://dx.doi.org/ 10.1038/cdd.2012.72 2.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Nature 2011; 475:324-32; PMID:21776078; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Cell 2011; 147:728-41; PMID:22078875;http://dx.doi.org/10.1016/j.cell.2011.10.0264.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Nat Immunol 2005; 6:973- 9; PMID:16177805; http://dx.doi.org/10.1038/ni1253 5.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell Environ 2012; 35:259-70; PMID:21486305; http://dx.doi.org/10.1111/j.1365-3040.2011.02336.x 6.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Curr Opin Plant Biol 2011; 14:290-5; PMID:21377404; http://dx.doi.org/ 10.1016/j.pbi.2011.02.0017.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Curr Opin Plant Biol 2007; 10:587-93; PMID:17702643; http://dx.doi.org/10.1016/j.pbi.2007.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Science 2000; 290:1717- 21; PMID:11099404; http://dx.doi.org/10.1126/science.290.5497.1717 9.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
J Plant Biol 2008; 51:313-20; http://dx.doi.org/10.1007/BF03036132 10.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
2012; 34:413-23; PMID:22772908; http://dx.doi.org/ 10.1007/s10059-012-0098-y 11.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Autophagy 2008; 4:851-65; PMID:18670193; http://dx.doi.org/10.4161/auto.6555 12.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plos One 2010; 5(7): e11883; http://dx.doi.org/10.1371/journal.pone.0011883 13.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
"Nat Rev Mol Cell Bio 2010; 11:545-55; http://dx.doi.org/10.1038/nrm2938 16. von Koskull-Doring P, Scharf KD, Nover L. The diver- sity of plant heat stress transcription factors.",OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Cell Stress Chaperon 2001; 6:177-89; http://dx.doi.org/10.1379/1466-1268(2001) 006%3c0177:AATHST%3e2.0.CO;2 19.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2004; 39:98-112; PMID:15200645; http://dx.doi.org/ 10.1111/j.1365-313X.2004.02111.x 20.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell Physiol 2011; 52:933-45; PMID:21471117; http://dx.doi.org/ 10.1093/pcp/pcr045 22.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell Environ 2011; 34:738-51; PMID:21241330; http://dx.doi.org/ 10.1111/j.1365-3040.2011.02278.x 23.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Physiol Biochem 2013; 64:92-8; PMID:23399534; http://dx.doi.org/10.1016/j.plaphy.2012.12.013 25.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell2011; 23:741-55; PMID:21307284; http://dx.doi.org/ 10.1105/tpc.110.076018 26.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Gene Dev 2002; 16:1555-67; PMID:12080093; http://dx.doi.org/10.1101/gad.228802 27.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 1995; 8:603-12; PMID:7496404; http://dx.doi.org/10.1046/j.1365- 313X.1995.8040603.x 28.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2002; 30:107-14; PMID:11967097; http://dx.doi.org/10.1046/j.1365- 313X.2002.01261.x 29.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2004; 39:264-72; PMID:15225290; http://dx.doi.org/ 10.1111/j.1365-313X.2004.02122.x 30.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2002; 31:777-86; PMID:12220268; http://dx.doi.org/10.1046/j.1365-313X.2002.01394.x 31.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
PLoS Genet 2013; 9:e1003196; PMID:23341779; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell 2013; 25:1383- 99; PMID:23564204; http://dx.doi.org/10.1105/tpc.112.108993 33.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Physiol 2013; 161:1722-36; PMID: 23404918; http://dx.doi.org/10.1104/pp.112.208108 34.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Science 2008; 319:607-10; PMID:18239122; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Annu Rev Plant Biol 2002; 53:247-73; PMID:12221975; http://dx.doi.org/10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Annu Rev Plant Biol 2006; 57:781-803; PMID:16669782; http://dx.doi.org/10.1146/annurev.arplant.57.032905.105444 37.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
J Exp Bot 2007; 58:221-7; PMID:17075077; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Trends Plant Sci 2001; 6:431-8; PMID:11544133; http://dx.doi.org/10.1016/S1360-1385(01)02052-0 39.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Curr Opin Biotech 2005; 16:123-32; PMID: 15831376; http://dx.doi.org/10.1016/j.copbio.2005.02.001 40.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Biochem J 2005; 388:151-7; PMID:15631617; http://dx.doi.org/10.1042/BJ20041931 41.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Trends Plant Sci 2004;9:244-52; PMID:15130550; http://dx.doi.org/ 10.1016/j.tplants.2004.03.006 42.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Cell Res 2011; 21:957-69; PMID:21187857; http://dx.doi.org/10.1038/cr.2010.181 43.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
PLoS Genet 2014; 10(1): e1004116; http://dx.doi.org/10.1371/journal.pgen.1004116 44.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Physiol 2005; 139:1597-611; PMID:16339806; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Front Plant Sci 2014; 5:122; http://dx.doi.org/ 10.3389/fpls.2014.00122 46.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
J Mol Med 2011; 89:1175-82; PMID:21818581; http://dx.doi.org/ 10.1007/s00109-011-0795-6 47.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Annu Rev Biochem 2013;82:323-55; PMID:23746257; http://dx.doi.org/ 10.1146/annurev-biochem-060208-092442 48.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Autophagy 2015; 11:200-13; PMID:25714619; http://dx.doi.org/10.1080/15548627.2015.1009776 49.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Bio- chem 1999; 38:3559-69; http://dx.doi.org/10.1021/ bi981774j 51.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2005; 41:1-14; PMID:15610345; http://dx.doi.org/10.1111/ j.1365-313X.2004.02272.x 52.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Genetics 2008; 178:1339-53; PMID:18245858; http://dx.doi.org/10.1534/genetics.107.086199 53.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Physiol 2004; 134:1683-96; PMID:15047901; http://dx.doi.org/10.1104/pp.103.033431 55.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
J Biol Chem 2013; 288:9165-76; PMID: 23386620; http://dx.doi.org/10.1074/jbc.M112.422071 56.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
PMID:19491106; http://dx.doi.org/10.1074/jbc.M109.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell 2014; 26:1764-80; PMID:24728648; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Bio-Technol 1987; 5:726-30; http://dx.doi.org/10.1038/nbt0787-726 59.,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant J 2003; 36:905-17;PMID:14675454; http://dx.doi.org/10.1046/j.1365- 313X.2003.01944.x 60.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
J Exp Bot 2011; 58:1207-17; http://dx.doi.org/10.1093/jxb/erl291 62.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Phys- iol 2008; 147:367-80; PMID:18326788; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262 64.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell 2004;16:2967-83; PMID:15494556; http://dx.doi.org/ 10.1105/tpc.104.025395 65.,OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
Plant Cell 2011; 23:3824-41; PMID:21990940; http://dx.doi.org/10.1105/tpc.111.090571 www.tandfonline.com 2047 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/44/fb/kaup-11-11-1098798.PMC4824577.pdf
"redﬂuorescent protein; EGFP, enhanced greenﬂuorescent protein; FRET, ﬂuorescenceresonance energy transfer; HEK-293T, human embryonic kidney 293; L, lyso- somes; LPD, LysoSensor Yellow/Blue pHdistribution; MAP1LC3B, microtubule-associated protein 1 light chain 3 b; mRFP, monomeric red ﬂuorescent protein; © Giuseppe Maulucci, Michela Chiarpotto, Massimi- liano Papi, Daniela Samengo, Giovambattista Pani, and Marco De Spirito *Correspondence to: Giuseppe Maulucci; Email:giuseppe.maulucci@rm.unicatt.it; GiovambattistaPani; Email: gpani@rm.unicatt.it Submitted: 09/11/2014 Revised: 08/12/2015Accepted: 08/12/2015http://dx.doi.org/10.1080/15548627.2015.1084455 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Cell 2008; 132:27-42; http://dx.doi.org/ 10.1016/j.cell.2007.12.018 2.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nature 2008; 451:1069-75; http://dx.doi.org/10.1038/ nature06639 3.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nature 2006; 443:780-6; http://dx.doi.org/10.1038/nature05291 4.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Sci Rep 2015; 5:9149; http://dx.doi.org/10.1038/srep09149 5.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
J Cell Sci 2004; 117:2805-12; http://dx.doi.org/10.1242/jcs.01131 6.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
EMBO J 2000; 19:5720-8; http://dx.doi.org/10.1093/emboj/19.21.5720 7.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Int J Biochem Cell Biol 2004; 36:2491-502; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Cell 2010; 140:313- 26; http://dx.doi.org/10.1016/j.cell.2010.01.028 9.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Autophagy 2005; 1:23-36; http://dx.doi.org/10.4161/auto.1.1.1495 10.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Autophagy2007; 3:452-60; http://dx.doi.org/10.4161/auto.4451 12.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Autoph- agy 2012; 8:1215-26; http://dx.doi.org/10.4161/ auto.20284 13.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Autophagy 2008; 4:205-13; http://dx.doi.org/ 10.4161/auto.5331 14.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Bio- technol 2002; 20:83-7; http://dx.doi.org/10.1038/nbt0102-83 15.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Chem Biol 2011; 18:1042-52; http://dx.doi.org/ 10.1016/j.chembiol.2011.05.013 16.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Int J Mol Sci 2013; 14:15260-85; http://dx.doi.org/10.3390/ijms140815260 17.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biophys J 1998; 74:1591-9; http://dx.doi.org/10.1016/ S0006-3495(98)77870-120.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biophys J 2000; 79:2199-208; http://dx.doi.org/10.1016/S0006-3495(00)76468-X 21.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biochemistry 2007; 46:5494-504; http://dx.doi.org/10.1021/bi602646r 22.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Methods 2012; 9:1005-12; http://dx.doi.org/ 10.1038/nmeth.2171 23.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biophys J 2005; 88:1224-37; http://dx.doi.org/ 10.1529/biophysj.104.050153 24.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Protein Eng Des Sel 1999; 12:1035-40; http://dx.doi.org/10.1093/ protein/12.12.1035 25.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Meth- ods 2011; 8:771-7; http://dx.doi.org/10.1038/ nmeth.1664 26.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Rev Mol Cell Biol 2014; 15:155-62; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biosens Bioelectron 2009; 25:682-7;http://dx.doi.org/10.1016/j.bios.2009.07.038 31.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Eur Biophys J 2010; 39:993-9; http://dx.doi.org/ 10.1007/s00249-009-0470-9 32.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Autophagy 2013; 9:813-4; http://dx.doi.org/ 10.4161/auto.24359 33.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Commun 2015; 6:7007; http://dx.doi.org/10.1038/ncomms800734.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Physiology 2004; 19:207-15; http://dx.doi.org/ 10.1152/physiol.00005.2004 35.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Cell Biol 2010; 12:831-5; http://dx.doi.org/10.1038/ncb0910-831 36.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
EMBO J 2012; 31:1095-108; http://dx.doi.org/ 10.1038/emboj.2012.32 38.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Rev Mol Cell Biol 2013; 14:283-96; http://dx.doi.org/10.1038/nrm3565 39.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nat Bio- technol 2004; 22:1567-72; http://dx.doi.org/10.1038/nbt1037 41.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Biochem Biophys Res Commun 2001; 289:457-62; http://dx.doi.org/ 10.1006/bbrc.2001.6004 42.,OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
PLoS One 2012; 7:e50804; http://dx.doi.org/10.1371/ journal.pone.0050804 44.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Nature 1998; 394:192- 5; http://dx.doi.org/10.1038/28190 46.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
Bio- chemistry 2002; 41:15477-88; http://dx.doi.org/10.1021/bi026609p 47.,Non-OADS,/arxiv_data1/oa_pdf/8f/e3/kaup-11-10-1084455.PMC4824579.pdf
"© Jian-Da Wang, Yu-Lan Cao, Qian Li, Ya-Ping Yang, Mengmeng Jin, Dong Chen, Fen Wang, Guang-Hui Wang, Zheng-Hong Qin, Li-Fang Hu, and Chun-Feng Liu *Correspondence to: Li-Fang Hu; Email: hulifang@suda.edu.cn, Chun-Feng Liu; Email: liucf@suda.edu.cnSubmitted: 10/15/2014; Revised: 09/08/2015; Accepted: 09/22/2015 http://dx.doi.org/10.1080/15548627.2015.1100930 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Lancet Neurol 2003; 2:715; PMID:14649238; http://dx.doi.org/10.1016/S1474- 4422(03)00601-X 2.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Lancet 2004; 364:1167-9; PMID:15451224; http://dx.doi.org/10.1016/S0140- 6736(04)17103-1 3.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Nat Genet 1998; 18:106-8; PMID:9462735; http://dx.doi.org/10.1038/ng0298- 106 4.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Proc Natl Acad Sci USA 2002; 99:8968-73; PMID:12084935; http://dx.doi.org/ 10.1073/pnas.132197599 5.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
35:2180 e1-5; PMID:24746362; http://dx.doi.org/ 10.1016/j.neurobiolaging.2014.03.024 8.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Brain 2008; 131:1969-78;PMID:18187492; http://dx.doi.org/10.1093/brain/ awm318 10.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Trends Neurosci 2010; 33:541-9; PMID:20947179; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Autophagy 2008; 4:917-9; PMID:18708765; http://dx.doi.org/10.4161/auto.6685 12.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Nat Rev Mol Cell Biol2010; 11:777-88; PMID:20944667; http://dx.doi.org/ 10.1038/nrm2993 13.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Autophagy2012; 8:6-17; PMID:22170155; http://dx.doi.org/ 10.4161/auto.8.1.16645 14.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
The J Neurosci 2009; 29:13578-88; PMID:19864570; http://dx.doi.org/10.1523/JNEUROSCI.4390- 09.2009 16.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Mol Cell Biol2001; 21:6820-32; PMID:11564866; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Oncogene 2009; 28:886-98; PMID:19060920; http://dx.doi.org/10.1038/onc.2008.441 18.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Mol Cell Biol 2009; 29:2594-608; PMID:19289499; http://dx.doi.org/10.1128/MCB.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Cell Metab 2007; 6:472-83; PMID:18054316;http://dx.doi.org/10.1016/j.cmet.2007.11.004 20.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Autophagy 2007; 3:207-14; PMID:17224629; http://dx.doi.org/10.4161/auto.3708 21.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Neurologist 2011; 17:S54-66; PMID:22045327; http://dx.doi.org/ 10.1097/NRL.0b013e31823968fc22.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Curr Opin Pharmacol 2007; 7:100-5; PMID:17174156; http://dx.doi.org/10.1016/j.coph.2006.11.004 23.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Brain Res 1999; 838:51-9; PMID:10446316; http://dx.doi.org/10.1016/S0006-8993(99)01688-1 24.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Phar-macol Ther 2001; 90:231-59; PMID:11578658; http://dx.doi.org/10.1016/S0163-7258(01)00139-5 25.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Neurochem Res2010; 35:1546-56; PMID:20635141; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Biol Chem 2012; 287:38625-36; PMID:23027865; http://dx.doi.org/ 10.1074/jbc.M112.365767 27.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Cell 1988; 54:541-52; PMID:3135940; http://dx.doi.org/ 10.1016/0092-8674(88)90076-1 29.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Naunyn- Schmiedeberg’s Arch Pharmacol 2006; 372:257-66;http://dx.doi.org/10.1007/s00210-005-0025-2 30.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Neuro- pharmacol 2013; 71:264-72; http://dx.doi.org/10.1016/j.neuropharm.2013.03.036 31.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
ColdSpring Harbor Perspectives Med 2012; 2:a009357; http://dx.doi.org/10.1101/cshperspect.a009357 32.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Mol Brain 2009; 2:29; PMID:19754977; http://dx.doi.org/10.1186/1756- 6606-2-29 34.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Trends Neurosci 2006; 29:528- 35; PMID:16859759; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Lancet Neurol 2007; 6:352-61; PMID:17362839; http://dx.doi.org/10.1016/S1474-4422(07)70076-5 36.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Curr Top Dev Biol 2006; 76:89- 101; PMID:17118264; http://dx.doi.org/10.1016/ S0070-2153(06)76003-338.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Neurosci 2004; 24:1888-96; PMID:14985429; http://dx.doi.org/10.1523/JNEUROSCI.3809-03.2004 39.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Neurosci 2012; 32:16503-9;PMID:23152632; http://dx.doi.org/10.1523/ JNEUROSCI.0209-12.2012 40.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Exp Mol Med 2013; 45:e22; PMID:23661100; http://dx.doi.org/10.1038/ emm.2013.45 41.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Autophagy 2014; 10:2171-92; PMID:25484190; http://dx.doi.org/10.4161/ auto.36436 42.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Neurosci 2010; 30:6838-51;PMID:20484626; http://dx.doi.org/10.1523/ JNEUROSCI.5699-09.2010 43.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Cell Calcium 2011; 50:242-50; PMID:21571367; http://dx.doi.org/ 10.1016/j.ceca.2011.04.001 44.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Cell Biol 2010; 190:1023-37;PMID:20855506; http://dx.doi.org/10.1083/jcb.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Science 2004;305:1292-5; PMID:15333840; http://dx.doi.org/ 10.1126/science.1101738 46.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
"Song JX, Lu JH, Liu LF, Chen LL, Durairajan SS, Yue Z, Zhang HQ, Li M. HMGB1 is involved in autoph- agy inhibition caused by SNCA/ a-synuclein overex- pression: a process modulated by the natural autophagyinducer corynoxine B. Autophagy 2014; 10:144-54; PMID:24178442; http://dx.doi.org/10.4161/ auto.26751 47.",Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Mol Neurobiol 2014; 50:685-701; PMID:24833599;http://dx.doi.org/10.1007/s12035-014-8738-1 48.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Neuroimmune Pharmacol 2013;8:356-69; PMID:23325107; http://dx.doi.org/ 10.1007/s11481-012-9431-7 50.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
EMBO Rep 2009; 10:285-92; PMID:19180116; http://dx.doi.org/ 10.1038/embor.2008.246 52.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Hum Mol Genet 2010; 19:2087-98; PMID:20185556; http://dx.doi.org/10.1093/hmg/ddq086 54.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Neuron 1998; 21:13-26; PMID:9697848; http://dx.doi.org/10.1016/S0896-6273(00)80510-3 55.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Recept Signal Transduct Res2004; 24:165-205; PMID:15521361; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Biochem Soc Symp 2007; 74:9-22; PMID:17233576; http://dx.doi.org/10.1042/BSS2007c0257.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Neuroendocrinol2007; 86:243-8; http://dx.doi.org/10.1159/ 000107795 58.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
BMC Pharmacol 2010; 10:2; PMID:20137065; http://dx.doi.org/ 10.1186/1471-2210-10-2 62.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Lancet Neurol 2013; 12:747-55; PMID:23726851; http://dx.doi.org/10.1016/S1474- 4422(13)70117-0 63.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
J Neurochem 2014; 129:827-38;PMID:24673410; http://dx.doi.org/10.1111/jnc.,Non-OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Cell Signal 2013; 25:2255-62; PMID:23872072; http://dx.doi.org/10.1016/j.cellsig.2013.07.010 66.,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
Int J Mol Sci 2013; 14: 24242-54; PMID:24351814; http://dx.doi.org/ 10.3390/ijms141224242 www.tandfonline.com 2073 Autophagy,OADS,/arxiv_data1/oa_pdf/d2/54/kaup-11-11-1100930.PMC4824582.pdf
"5 For both fusion and ﬁssion processes, thesize of the membranes (organelles/vesicles)and their locations relative to each otherKeywords: autophagy, closure, membrane ﬁssion, membrane fusion, membrane neck, membrane scission, nuclear pore, phagophore, sporulation, yeast © Roland L Knorr, Reinhard Lipowsky, and Rumiana Dimova*Correspondence to: Roland L Knorr; Email: knorr@mpikg.mpg.de, Rumiana Dimova; Email: dimova@mpikg.mpg.de Submitted: 02/25/2015Revised: 08/25/2015Accepted: 09/02/2015 http://dx.doi.org/10.1080/15548627.2015.1091552 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Annu Rev Cell Dev Biol 2011; 27:107-32; PMID:21801009; http://dx.doi.org/ 10.1146/annurev-cellbio-092910-154005 2.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Autophagy 2008; 4:151-75; PMID:18188003; http://dx.doi.org/10.4161/auto.5338 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Biol Chem 2014; 395:253-74; PMID:24491948; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Phys Rev Lett 2007; 98; PMID:17677811; http://dx.doi.org/10.1103/PhysRevLett.98.218101 6.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Plos One 2012; 7:e32753; PMID:22427874; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Cell Death Differ 2011; 18:571-80; PMID:21311563; http://dx.doi.org/10.1038/cdd.2010.191 8.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Physiol Rev 2010; 90:1383-435;PMID:20959619; http://dx.doi.org/10.1152/ physrev.00030.2009 9.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Cell 2008; 132:27-42; PMID:18191218;http://dx.doi.org/10.1016/j.cell.2007.12.018 10.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Plos Biol 2006; 4:161- 4; PMID: 16464128; http://dx.doi.org/10.1371/ journal.pbio.0040036 11.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Nat Cell Biol 2009; 11:1433-U102; PMID:19898463; http://dx.doi.org/10.1038/ncb1991 12.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
J Cell Sci 2015; 128:185-92; PMID:25568152;http://dx.doi.org/10.1242/jcs.158758 13.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Mol Cell Biol 2014;34:1695-706; PMID:24591649; http://dx.doi.org/ 10.1128/MCB.01327-1314.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Plos One 2012; 7:e32753; PMID: 22427874; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Genetics 2013; 194:341-61; PMID:23733851; http://dx.doi.org/10.1534/genetics.112.149013 17.,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Cell Microbiol 2013; 15:305-14; PMID:23217081;http://dx.doi.org/10.1111/cmi.12077 18.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
J Cell Sci2004; 117:389-96; PMID:14702385; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
Genetics 2011; 189:737-65; PMID: 22084423; http://dx.doi.org/10.1534/genetics.111.127126 www.tandfonline.com 2137 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/29/70/kaup-11-11-1091552.PMC4824592.pdf
"18In contrast, KSHV encodes several proteins that block autophagy at multiple levels19-21even if autophagy has been shown to be activated and to promote the KSHV lytic cycle.22,23 In this study, besides conﬁrming that autophagy is activated con-comitantly with the KSHV lytic cycle in 2 different PEL cell sys-tems and that autophagy promoted viral lytic gene expression, we © Marisa Granato, Roberta Santarelli, Mariarosaria Filardi, Roberta Gonnella, Antonella Farina, Maria Rosaria Torrisi, Alberto Faggioni, and Mar a Cirone *Correspondence to: Alberto Faggioni; Email: alberto.faggioni@uniroma1.it; Mara Cirone; Email: mara.cirone@uniroma1.itSubmitted: 04/27/2015; Revised: 09/01/2015; Accepted: 09/04/2015 http://dx.doi.org/10.1080/15548627.2015.1091911 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
"Densitometric analysis The quantiﬁcation of proteins bands was performed by densi- tometric analysis using the ImageJ software, which was down- loaded from the NIH web site (http://imagej.nih.gov).",OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
"PhilosTrans Royal Soc London Series B, Biol Sci 2001; 356:517-34; PMID:11313009; http://dx.doi.org/ 10.1098/rstb.2000.0778 3.",Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Nat Med 1996; 2:342-6; PMID:8612236; http://dx.doi.org/10.1038/nm0396-3424.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Gen Virol 1999; 80(Pt 1):83- 90; PMID:9934688; http://dx.doi.org/10.1099/0022- 1317-80-1-83 6.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Virol-ogy 1998; 252:304-12; PMID:9878608; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2003; 77:4205-20; PMID:12634378; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Adv Cancer Res 2007; 97:81-109;PMID:17419942; http://dx.doi.org/10.1016/S0065- 230X(06)97004-3 10.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2009; 83:5869-80; PMID:19321621; http://dx.doi.org/ 10.1128/JVI.01821-08 11.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2008; 82:4562-72; PMID:18305046; http://dx.doi.org/10.1128/JVI.02400-07 1 3 .,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496 15.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Cell Death Differ 2011; 18:571-80; PMID:21311563; http://dx.doi.org/10.1038/cdd.2010.19116.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Cell Host Microbe 2009; 5:527-49; PMID:19527881; http://dx.doi.org/ 10.1016/j.chom.2009.05.016 17.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2014; 88:12715-26; PMID:25142602; http://dx.doi.org/10.1128/JVI.02199-14 18.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Proc Natl Acad Sci U S A 2015; 112:256-61; PMID:25535384; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Sci Rep 2014; 4:4241; PMID:24577500; http://dx.doi.org/10.1038/srep04241 20.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Nat Cell Biol 2009; 11:1355-62; PMID:19838173; http://dx.doi.org/10.1038/ncb1980 21.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
PLoS Pathogens 2009; 5:e1000609; PMID:19816569; http://dx.doi.org/ 10.1371/journal.ppat.1000609 22.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2010; 84:7448- 58; PMID:20484505; http://dx.doi.org/10.1128/ JVI.00024-10 23.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Immunol Res 2015; 2015:546063; PMID:26090494; http://dx.doi.org/10.1155/2015/546063 24.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Mol Cancer Ther 2009; 8:3203-13; PMID:19996277; http://dx.doi.org/ 10.1158/1535-7163.MCT-09-0244 27.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Neurosci: Off J Soc Neurosci 2010; 30:12535-44; PMID:20844148; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Mol Biol Cell 2000; 11:467-80; PMID:10679007; http://dx.doi.org/10.1091/mbc.11.2.467 29.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Biochimica et Biophysica Acta 2013; 1833:503-10; PMID:23220125; http://dx.doi.org/10.1016/j.bbamcr.2012.11.018 30.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Biol Chem 2007; 282:24131-45; PMID: 17580304; http://dx.doi.org/10.1074/ jbc.M702824200 31.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2013; 87:12499-503; PMID:24027317; http://dx.doi.org/10.1128/JVI.01898-13 32.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
J Virol 2014; 88:12133-45; PMID:25122800; http://dx.doi.org/ 10.1128/JVI.02033-14 33.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Bio- chimica et Biophysica Acta 2015; 1853:1586-95; PMID:25827954; http://dx.doi.org/10.1016/j.bbamcr.2015.03.011 34.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
EBioMedicine 2014; 1(2-3):116- 125; PMID:26137519; http://dx.doi.org/10.1016/j.ebiom.2014.11.007 35.,OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
Curr Opin Infect Dis 2011; 24:295- 301; PMID:21666458; http://dx.doi.org/10.1097/QCO.0b013e3283486d04 1986 Volume 11 Issue 11 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/kaup-11-11-1091911.PMC4824593.pdf
"Paradoxically, current clinical trialsseeking to manipulate autophagy include mainly attempts toinhibit the process by antimalarial agents as adjuvant anticancer chemotherapy: by inhibiting lysosomal acidiﬁcation, it is hoped © Yulia Haim, Matthias Bl €uher, Noa Slutsky, Nir Goldstein, Nora Kl €oting, Ilana Harman-Boehm, Boris Kirshtein, Doron Ginsberg, Martin Gericke, Esther Guiu Jurado, Julia Kovsan, Tanya Tarnovscki, Leonid Kachko, Nava Bashan, Yiftach Gepner, Iris Shai, and Assaf Rudich*Correspondence to: Assaf Rudich; Email: rudich@bgu.ac.ilSubmitted: 01/14/2015; Revised: 09/03/2015; Accepted: 09/10/2015 http://dx.doi.org/10.1080/15548627.2015.1094597 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
N Engl J Med 2013; 368:651-62;PMID:23406030; http://dx.doi.org/10.1056/ NEJMra1205406 2.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Autophagy 2014; 10:1415-25; PMID:24991836;http://dx.doi.org/10.4161/auto.29165 3.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
"Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharma- cokinetic, and pharmacodynamic analysis of hydroxy- chloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.Autophagy 2014; 10:1403-14; PMID:24991835; http://dx.doi.org/10.4161/auto.29231 4.",Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Autophagy 2014; 10:1478- 80; PMID:24991829; http://dx.doi.org/10.4161/auto.29428 5.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Autophagy 2014; 10:1369-79; PMID:24991839;http://dx.doi.org/10.4161/auto.29118 7.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Autophagy 2014; 10:1359-68; PMID:24991840; http://dx.doi.org/10.4161/auto.28984 8.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Combined autophagy and proteasome inhi- bition: a phase 1 trial of hydroxychloroquine and borte- zomib in patients with relapsed/refractory myeloma.Autophagy 2014; 10:1380-90; PMID:24991834; http://dx.doi.org/10.4161/auto.29264 9.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
PloS one 2008; 3:e3316; PMID:18830406; http://dx.doi.org/10.1371/journal.pone.0003316 10.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Clin Invest 2009; 119:3329-39; PMID:19855132;http://dx.doi.org/10.1172/JCI35541 11.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
"Zhang Y, Goldman S, Baerga R, Zhao Y, Komatsu M, Jin S. Adipose-speciﬁc deletion of autophagy-relatedgene 7 (atg7) in mice reveals a role in adipogenesis.Proc Natl Acad Sci U S A 2009; 106:19860-5; PMID:19910529; http://dx.doi.org/10.1073/ pnas.0906048106 12.",OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Clin Endocrinol Metab 2011; 96:E268-77; PMID:21047928; http://dx.doi.org/ 10.1210/jc.2010-1681 14.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Mol Med 2010; 16:235-46; PMID:20386866; http://dx.doi.org/ 10.2119/molmed.2010.00023 15.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Endo- crinology 2012; 153:5866-74; PMID:23117929;http://dx.doi.org/10.1210/en.2012-1625 16.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Obes Facts 2012; 5:710-21; PMID:23108431; http://dx.doi.org/10.1159/000343983 2086 Volume 11 Issue 11 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell Metab 2010; 11:467-78; PMID:20519119; http://dx.doi.org/10.1016/j.cmet.2010.04.005 19.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell Res 2010; 20:748-62; PMID:20548331; http://dx.doi.org/10.1038/cr.2010.82 20.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Onco- gene 2008; 27:4860-4; PMID:18408756; http://dx.doi.org/10.1038/onc.2008.117 23.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cancer Biol Ther 2004;3:1208-11; PMID:15662116; http://dx.doi.org/ 10.4161/cbt.3.12.1494 24.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Curr Opin Plant Biol 2009; 12:599-605; PMID:19700366; http://dx.doi.org/10.1016/j.pbi.2009.07.005 25.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Oncogene2005; 24:2810-26; PMID:15838517; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Front Oncol 2013; 3:4; PMID:23355973; http://dx.doi.org/10.3389/fonc.2013.00004 27.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell 1996; 85:549-61; PMID:8653790; http://dx.doi.org/10.1016/S0092-8674(00)81255-6 28.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Dev Cell 2002; 3:39-49; PMID:12110166; http://dx.doi.org/10.1016/S1534-5807(02)00190-9 29.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Obes Rev 2001; 2:239-54; PMID:12119995; http://dx.doi.org/10.1046/j.1467-789X.2001.00042.x 30.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Mol Cell 2000; 6:293-306; PMID:10983977; http://dx.doi.org/ 10.1016/S1097-2765(00)00030-7 31.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Biol Chem 2008; 283:27410-7; PMID:18667418;http://dx.doi.org/10.1074/jbc.M802418200 32.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Cell Physiol 2006; 209:923-34; PMID:16972274; http://dx.doi.org/10.1002/jcp.20802 33.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Nat Cell Biol 2011; 13:1146-52; PMID:21841792; http://dx.doi.org/10.1038/ncb2309 34.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Apoptosis 2009; 14:1165-75; PMID:19657746; http://dx.doi.org/10.1007/s10495- 009-0390-2 35.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Clin Endocrinol Metab 2007; 92:2240-7; PMID:17374712; http://dx.doi.org/10.1210/jc.2006- 1811 36.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Clin Endocrinol Metab 2013; 98:1173-81; PMID:23372170; http://dx.doi.org/10.1210/jc.2012-2745 38.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Circ Res 2005; 96:939-49;PMID:15890981; http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Circulation 1992; 85:37-45; PMID:1728471; http://dx.doi.org/10.1161/01.CIR.85.1.37 40.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Diabetologia 2014; 57:562-71; PMID:24343232; http://dx.doi.org/10.1007/s00125- 013-3139-y 42.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
FEBS Lett 2011; 585:2763-7; PMID:21843524; http://dx.doi.org/10.1016/j.febslet.2011.08.002 43.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
MolCell Endocrinol 2015; 406:10-8; PMID:25697344; http://dx.doi.org/10.1016/j.mce.2015.02.012 45.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
PloS One 2013; 8:e83183; PMID:24358263; http://dx.doi.org/10.1371/journal.pone.0083183 46.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Mol Med 2008; 86:597-608; PMID:18368381; http://dx.doi.org/10.1007/s00109-008-0326-2 47.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Nat Med 2009; 15:267-76;PMID:19252503; http://dx.doi.org/10.1038/nm.1928 48.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Immunity 2010; 32:227-39; PMID:20171125; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Nature 2014; 510:547-51; PMID:24870244; http://dx.doi.org/ 10.1038/nature13267 51.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Annu Rev Pharmacol Toxicol 2008; 48:199- 225; PMID:17883330; http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094606 53.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Curr Genomics 2010; 11:287-96; PMID:21119893; http://dx.doi.org/10.2174/ 138920210791233117 54.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell 2006; 126:121-34; PMID:16839881; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Mol Cancer 2010; 9:95; PMID:20429933; http://dx.doi.org/10.1186/1476-4598-9-95 56.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Hepatology 2012; 56:108-17; PMID:22278336; http://dx.doi.org/10.1002/hep.25609 57.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
PloS one 2012; 7:e43961; PMID:22952826; http://dx.doi.org/10.1371/journal.pone.0043961 58.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Dev Cell 2010; 18:1041-52; PMID:20627085; http://dx.doi.org/ 10.1016/j.devcel.2010.05.005 59.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Nat Cell Biol 2011; 13:303-9; PMID:21336304; http://dx.doi.org/10.1038/ncb2171 60.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell Metab 2007; 6:458-71; PMID:18054315; http://dx.doi.org/10.1016/j.cmet.2007.11.001 www.tandfonline.com 2087 Autophagy,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Biol Chem 2012; 287:39107-14; PMID:22992773; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
FoxO tran- scription factors promote autophagy in cardiomyocytes.J Biol Chem 2009; 284:28319-31; PMID:19696026; http://dx.doi.org/10.1074/jbc.M109.024406 63.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell Cycle 2012; 11:1247-59; PMID:22356768; http://dx.doi.org/10.4161/cc.11.6.19670 64.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Opt Lett 2011; 36:2242-4;PMID:21685980; http://dx.doi.org/10.1364/ OL.36.002242 65.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cancer Res 2009; 69:8844-52; PMID:19903843; http://dx.doi.org/10.1158/0008-5472.CAN-08-4401 6 8 .,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Cell Biochem 2012; 113:695-710;PMID:22006269; http://dx.doi.org/10.1002/jcb.23399 69.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Cell Metab 2007; 6:472-83; PMID:18054316;http://dx.doi.org/10.1016/j.cmet.2007.11.004 70.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
EMBO Mol Med 2013; 5:441-55; PMID:23401241; http://dx.doi.org/10.1002/ emmm.201201475 71.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
J Biol Chem 2009; 284:31484-92; PMID:19758991; http://dx.doi.org/10.1074/jbc.M109.033936 72.,OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
Endocri- nology 2007; 148:2955-62; PMID:17317777;http://dx.doi.org/10.1210/en.2006-1369 74.,Non-OADS,/arxiv_data1/oa_pdf/b9/d7/kaup-11-11-1094597.PMC4824599.pdf
"Hurley’s group previouslyreported the crystal structure ofAtg13 HORMAfrom a budding yeast, Lachancea thermotolerans, which explainsthe lack of necessity of Atg101 for stabili- zation in these species; LtAtg13 HORMA has a 3-strand b-sheet insertion named the “cap” that has never been observed incanonical HORMA domains and utilizesthe cap to stabilize the C-MAD2-like con-formation without the help of Atg101.This insertion is not conserved inATG13 HORMAfrom other eukaryotes that conserve ATG101, explaining the neces- sity of Atg101/ATG101 for stabilizationof Atg13/ATG13 in these species.Keywords: Atg13, Atg101, autophagy ini- tiation, crystal structure, HORMA, ULKcomplex © Hironori Suzuki, Takeshi Kaizuka, Noboru Mizush- ima, and Nobuo N Noda *Correspondence to: Nobuo N Noda; Email: nn@bikaken.or.jp Submitted: 08/19/2015Revised: 08/20/2015Accepted: 09/01/2015 http://dx.doi.org/10.1080/15548627.2015.1091144 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/ec/kaup-11-11-1091144.PMC4824606.pdf
"13,14 Similar to ITPRs, intracellular Ca2C signaling also appears to play a dual role in autophagy, leading to apparently contra- dictory results.5Increase of the cytosolic Ca2Cconcentration ([Ca2C]cyt) triggered by treatment of cells with extracellular ago-nist ATP, the ATP2A/SERCA inhibitorthapsigargin or Ca 2Cionophores such as ionomycin, induce an increase in LC3-IIKeywords: autophagic ﬂux, autophagy, Ca2Cmicrodomains, Ca2Csignaling, ino- sitol 1,4,5-trisphosphate receptor, spatio-temporal Ca 2Csignals Abbreviations: AMPK, adenosine mono- phosphate-activated protein kinase;ATP2A/SERCA, ATPase, Ca 2Ctransport- ing, cardiac muscle, fast twitch; BCL2, B- cell CLL/lymphoma 2; BECN1, Beclin 1, autophagy related; ER, endoplasmic retic-ulum; IP 3, inositol 1,4,5-trisphosphate; ITPR, inositol 1,4,5-trisphosphate recep-tor; LC3, microtubule-associated protein1 light chain 3; TFEB, transcription factorEB; TGM2, transglutaminase 2;TMBIM6/BI-1, transmembrane BAX inhibitor motif containing 6; TPCN, 2 pore segment channel; WIPI1, WD-repeat domain, phosphoinositide interact-ing 1 © Jean-Paul Decuypere, Jan B Parys, and Geert Bultynck *Correspondence to: Jean-Paul Decuypere; Email: jeanpaul.decuypere@cme.vib-kuleuven.be Submitted: 10/02/2014Revised: 07/31/2015Accepted: 08/11/2015 http://dx.doi.org/10.1080/15548627.2015.1083666 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Nat Rev Mol Cell Biol 2003; 4:517–29; PMID:12838335;http://dx.doi.org/10.1038/nrm1155 2.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
BiochimBiophys Acta 2014; 1843:2164–83; PMID:24642269; http://dx.doi.org/10.1016/j.bbamcr.2014.03.007 4.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell Calcium 2006; 40:405–12; PMID:17030366; http://dx.doi.org/10.1016/j.ceca.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell Calcium 2011; 50:242–50; PMID:21571367; http://dx.doi.org/ 10.1016/j.ceca.2011.04.001 6.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
CellDeath Differ 2009; 16:1006–17; PMID:19325567; http://dx.doi.org/10.1038/cdd.2009.34 8.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell 2010; 142:270–83; PMID:20655468; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Biol Chem 2010; 285:16912–20; PMID:20308071; http://dx.doi.org/10.1074/jbc.M110.114207 10.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Mol Cell Cardiol 2013; 54:19–24; PMID:23137780; http://dx.doi.org/ 10.1016/j.yjmcc.2012.10.014 11.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Cell Biol 2005; 170:1101–11; PMID:16186256; http://dx.doi.org/10.1083/jcb.200504035 12.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Mol Biol Cell 2008; 19:691–700; PMID:18077554; http://dx.doi.org/10.1091/mbc.E07-08-0823 13.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
PloS One 2013; 8:e61020; PMID:23565295; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Mol Cell 2007; 25:193– 205; PMID:17244528; http://dx.doi.org/10.1016/j.molcel.2006.12.009 16.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell Signal 2010; 22:914–25; PMID:20114074; http://dx.doi.org/ 10.1016/j.cellsig.2010.01.015 17.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Mol Cell2011; 42:731–43; PMID:21700220; http://dx.doi.org/ 10.1016/j.molcel.2011.04.024 19.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Autophagy 2013; 9:1475–90; PMID:23970164;http://dx.doi.org/10.4161/auto.25900 21.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell Metab 2011; 13:119–20; PMID:21284977; http://dx.doi.org/ 10.1016/j.cmet.2011.01.009 22.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cancer Res 2014; 74:6820–32; PMID:25297632; http://dx.doi.org/ 10.1158/0008-5472.CAN-14-0303 23.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Immunol 2011; 186:1564–74; PMID:21191072; http://dx.doi.org/ 10.4049/jimmunol.1001822 25.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Biochim et Biophys Acta 2014; 1837:461–9; PMID:24211533; http://dx.doi.org/ 10.1016/j.bbabio.2013.10.015 26.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Autophagy 2013; 9:1677–86;PMID:24121707; http://dx.doi.org/10.4161/auto.24795 27.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Mol Cell 1998; 1:337–46; PMID:9660918; http://dx.doi.org/10.1016/S1097-2765(00)80034-9 29.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Biol Chem 2012; 287:2544–57;PMID:22128171; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Sci Signal 2014; 7:pe22;PMID:25227609; http://dx.doi.org/10.1126/scisignal.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Cell Death Dis 2012; 3:e367; PMID:22875004; http://dx.doi.org/10.1038/cddis.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Genes Dev 2012; 26:1041–54; PMID:22588718; http://dx.doi.org/10.1101/gad.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Mol Pharmacol 2011; 80:1066–75; PMID:21896713;http://dx.doi.org/10.1124/mol.111.071761 34.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Cell Biol 2013; 200:789–805; PMID:23479744; http://dx.doi.org/10.1083/jcb.201204078 35.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Cell Sci 2013; 126:60–6; PMID:23108667; http://dx.doi.org/10.1242/ jcs.118836 36.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
J Cell Sci 2013; 126:289–300; PMID:23097044; http://dx.doi.org/ 10.1242/jcs.116103 37.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Nat Cell Biol 2015; 17:288–99; PMID:25720963; http://dx.doi.org/10.1038/ncb3114 39.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Commun Integr Biol2012; 5:308–11; PMID:23060949; http://dx.doi.org/ 10.4161/cib.20076 40.,OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
Blood 2011; 117:2924–34; PMID:21193695; http://dx.doi.org/ 10.1182/blood-2010-09-307405 41.,Non-OADS,/arxiv_data1/oa_pdf/9d/77/kaup-11-10-1083666.PMC4824608.pdf
"Vascular smooth muscle cells (VSMCs) are the major compo- nents of the blood vessel wall and play crucial roles in both physi-ological (e.g., regulation of blood pressure and vascular tone) and © Mandy OJ Grootaert, Paula A da Costa Martins, Nicole Bitsch, Isabel Pintelon, Guido RY De Meyer, Wim Martinet, and Dorien M Schrijvers *Correspondence to: Dorien M Schrijvers; Email: dorien.schrijvers@uantwerpen.beSubmitted: 01/08/2015; Revised: 09/03/2015; Accepted: 09/15/2015 http://dx.doi.org/10.1080/15548627.2015.1096485 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
The microarray data are available via the National Center for Biotechnology InformationGene Expression Omnibus at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token Dytuzumoktdqzpifandacc DGSE54019.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell Res 2014; 24:24-41; PMID:24366339;http://dx.doi.org/10.1038/cr.2013.168 2.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j.cell.2011.10.026 3.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Arterioscler Thromb Vasc Biol 2004; 24:2296-301; PMID:15458974; http://dx.doi.org/ 10.1161/01.ATV.0000146266.65820.a1 4.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Immunol Cell Biol 2006; 84:448-54; PMID:16942488; http://dx.doi.org/10.1111/j.1440-1711.2006.01454.x 5.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Biochem J 2008; 410:525-34; PMID:18052926; http://dx.doi.org/10.1042/BJ20071063 6.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
"Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7 g. Int J Cardiol 2013; 168:1378-85; PMID:23305858; http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Biochem J 2013; 451:375-88; PMID:23421427;http://dx.doi.org/10.1042/BJ20121344 9.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Am J Pathol 2013; 183:626-37; PMID:23770348;http://dx.doi.org/10.1016/j.ajpath.2013.04.028 10.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2009; 104:304-17; PMID:19213965;http://dx.doi.org/10.1161/CIRCRESAHA.108.188318 14.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2001;88:648-50; PMID:11304484; http://dx.doi.org/ 10.1161/hh0701.089955 16.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
JAtheroscler Thromb 2014; 21:381-90; PMID:24717761; http://dx.doi.org/10.5551/jat.23929 17.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
"Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs.Cell Death Differ 2015; 22:377-88; PMID:25257172; http://dx.doi.org/10.1038/cdd.2014.150 18.",Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Oxid Med Cell Longev 2015; 2015:130315; PMID:25866599; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2007; 100:15-26; PMID:17204661; http://dx.doi.org/10.1161/01.RES.0000256837.40544.4a 22.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell Metab 2012; 15:545-53; PMID:22445600;http://dx.doi.org/10.1016/j.cmet.2012.01.022 23.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell 2007; 131:1149-63; PMID:18083104; http://dx.doi.org/10.1016/j.cell.2007.10.035 24.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Cell Biol 2005; 169:425-34; PMID:15866887; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Nature 2006; 441:880-4; PMID:16625205; http://dx.doi.org/ 10.1038/nature04723 27.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell Metab 2008; 8:318-24; PMID:18840362; http://dx.doi.org/10.1016/j.cmet.2008.08.013 28.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Cell Physiol 2006;209:592-97; PMID:17001692; http://dx.doi.org/ 10.1002/jcp.20750 29.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Clin Invest 2013; 123:966-72; PMID:23454759; http://dx.doi.org/10.1172/JCI64098 31.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2012; 111:245-59; PMID:22773427; http://dx.doi.org/ 10.1161/CIRCRESAHA.111.261388 32.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Biosci Rep 2010; 30:11-18; http://dx.doi.org/10.1042/BSR20080128 34.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Clin Invest 2004; 114:1299-307; PMID:15520862; http://dx.doi.org/10.1172/ JCI22475 35.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell 2011; 146:682-95; PMID:21884931; http://dx.doi.org/10.1016/j.cell.2011.07.030 36.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell Cycle 2009;8:1888-95; PMID:19471117; http://dx.doi.org/ 10.4161/cc.8.12.8606 37.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cell Cycle 2009; 8:1901-4; PMID:19471118;http://dx.doi.org/10.4161/cc.8.12.8810 38.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Insufﬁcient autophagy promotes bronchial epithelial cell senescence in chronic obstructive pulmonary disease.Oncoimmunology 2012; 1:630-41; PMID:22934255; http://dx.doi.org/10.4161/onci.20297 41.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Autophagy 2013; 9:808-12; PMID:23422284; http://dx.doi.org/10.4161/auto.23922 42.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Immunol 2014; 192:958-68; PMID:24367027; http://dx.doi.org/ 10.4049/jimmunol.1302341 43.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cardiovasc Res 1998; 39:8-33; PMID:9764187;http://dx.doi.org/10.1016/S0008-6363(98)00108-4 44.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circulation 2000; 102:2861-6; PMID:11104745; http://dx.doi.org/ 10.1161/01.CIR.102.23.2861 www.tandfonline.com 2031 Autophagy,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cardiovasc Res 2007; 74:223-34; PMID:17349984; http://dx.doi.org/10.1016/j.cardiores.2007.02.012 48.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Cardiovasc Res 1999; 41:376- 84; PMID:10341837; http://dx.doi.org/10.1016/ S0008-6363(98)00321-6 49.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Mol Biol Cell1996; 7:1335-42; PMID:8885230; http://dx.doi.org/ 10.1091/mbc.7.9.1335 50.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Free Radic Biol Med 2008; 44:1817-32; PMID:18329388; http://dx.doi.org/10.1016/j.freeradbiomed.2008.02.001 51.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circulation 2003; 108:2491-7; PMID:14581398; http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2006; 99:156-64; PMID:16794190; http://dx.doi.org/10.1161/01.RES.0000233315.38086.bc 54.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Arterioscler Thromb Vasc Biol 2011; 31:2787-91; PMID:22096098; http://dx.doi.org/ 10.1161/ATVBAHA.111.224899 57.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2015; 116:468-79; PMID:25634970; http://dx.doi.org/10.1161/CIRCRESAHA.116.303804 58.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Clin Invest 2015; 125:55-64; PMID:25654551; http://dx.doi.org/ 10.1172/JCI73943 59.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
MechAgeing Dev 2002; 123:1121-31; PMID:12044962; http://dx.doi.org/10.1016/S0047-6374(02)00008-8 60.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circulation 2013; 127:386-96; PMID:23224247; http://dx.doi.org/10.1161/CIRCULATIONAHA.112.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Atherosclerosis 2014; 233:601-7;PMID:24534455; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
J Cell Biol 1986; 102:343-52; PMID:3944187; http://dx.doi.org/ 10.1083/jcb.102.2.343 63.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 1988; 62:749-56; PMID:3280155; http://dx.doi.org/10.1161/01.RES.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Arterioscler Thromb Vasc Biol 2005; 25:1256-61;PMID:15831805; http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Anal Biochem 1993; 213:426-33; PMID:7694524; http://dx.doi.org/ 10.1006/abio.1993.1442 66.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Arterioscler Thromb Vasc Biol 2011; 31:1291-9; PMID:21372299; http://dx.doi.org/ 10.1161/ATVBAHA.110.218578 68.,Non-OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Methods Cell Biol 1994; 41:219-29; PMID:7532263; http://dx.doi.org/ 10.1016/S0091-679X(08)61720-3 69.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Circ Res 2001; 88:733-9; PMID:11304497; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bd/46/kaup-11-11-1096485.PMC4824610.pdf
Graphical abstract This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/06/01/nihms773625.PMC4824665.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online  at http://dx.doi.org/10.1016/j.celrep.2014.12.033 .,OADS,/arxiv_data1/oa_pdf/06/01/nihms773625.PMC4824665.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/92/main.PMC4824953.pdf
http://dx.doi.org/10.1016/j.scog.2016.02.001 2215-0013/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/64/92/main.PMC4824953.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/92/main.PMC4824953.pdf
Contents lists available at ScienceDirect Schizophrenia Research: Cognition journal homepage: http://www.schizrescognition.com/,Non-OADS,/arxiv_data1/oa_pdf/64/92/main.PMC4824953.pdf
"January, 2009. retrived from http://www.audiologyon- line.com 14  marciano E, laria C, malesci r, et al.",Non-OADS,/arxiv_data1/oa_pdf/8f/7d/0392-100X-36-64.PMC4825061.pdf
"April, 2015. retrived  from http://www.audiologyonline.com 18 English Km.",Non-OADS,/arxiv_data1/oa_pdf/8f/7d/0392-100X-36-64.PMC4825061.pdf
"April, 2015.  retrived from http://www.audiologyonline.com Address for correspondence: Eva orzan, SC Audiologia e otorino- laringoiatria, Dipartimento di Pediatria, irCCS materno-infantile “Burlo garofolo”, via dell’istria 65/1, 34137 Trieste, italy.",Non-OADS,/arxiv_data1/oa_pdf/8f/7d/0392-100X-36-64.PMC4825061.pdf
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/3.0/ >.,Non-OADS,/arxiv_data1/oa_pdf/5f/98/S1092852915000425a.PMC4825106.pdf
For further details and references see http://www.iuphar -db.org.,Non-OADS,/arxiv_data1/oa_pdf/5f/98/S1092852915000425a.PMC4825106.pdf
The study was approved by an institutional ethics review board ( http://www.clinicaltrials.gov identifier: NCT00330915).,Non-OADS,/arxiv_data1/oa_pdf/ff/49/cad-27-439.PMC4825111.pdf
Available at: http://ctep.cancer.,Non-OADS,/arxiv_data1/oa_pdf/ff/49/cad-27-439.PMC4825111.pdf
"Comorbidities were defined according to the Elix- hauser index (Agency for Healthcare Research and Quality classi- fications),8and body mass index (kg/m2) was coded according to the World Health Organization classification (see Supplemental Digital Content 1, available at http://links.lww.com/SLA/A827).9Cardio- vascular disease was defined by the presence of coronary artery disease, peripheral vascular disease, or congestive heart failure.",OADS,/arxiv_data1/oa_pdf/c2/f8/ansu-263-1010.PMC4825112.pdf
"Renal disease was defined by acute or chronic renal failure requiring dialysis, and liver disease included a documented history of cirrhosis, ascites, or varices.10,11 Patients were categorized by operative characteristics, accord- ing to the primary index operation as gastric, hepatobiliary, spleen, bowel, or gynecologic surgery (see Supplemental Digital Content 2, available at http://links.lww.com/SLA/A828).",Non-OADS,/arxiv_data1/oa_pdf/c2/f8/ansu-263-1010.PMC4825112.pdf
"Priorsurgical complications were recorded as well, including history of superficial wound infection, wound dehiscence, abscess, seroma, hematoma, postoperative wound bleeding, enterocutaneous fistula, and small bowel obstruction (see Supplemental Digital Content 3, available at http://links.lww.com/SLA/A829).",Non-OADS,/arxiv_data1/oa_pdf/c2/f8/ansu-263-1010.PMC4825112.pdf
"The benefit of this risk model can be appreciated by comparing 2 preoperative patient scenarios (see Supplemental Digital Content 4, available at http://links.lww.com/SLA/A830).",Non-OADS,/arxiv_data1/oa_pdf/c2/f8/ansu-263-1010.PMC4825112.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.188 Clinical and Molecular Hepatology 2016;22:188-191 Liver Pathology Corresponding author :  Regina C. Lo Department of Pathology and State Key Laboratory for Liver Research,  The University of Hong Kong, Room 216A, University Pathology Building,  Queen Mary Hospital, Pokfulam, Hong Kong, China Tel: +852-2255-4858, Fax: +852-2218-5243 E-mail: reginalo@pathology.hku.hkAbbreviations:   AFP , alpha-fetoprotein; FDG, Fluorodeoxyglucose;  HCC, hepatocellular  carcinoma; HPC, hemangiopericytoma; SFT, solitary fibrous tumorINTRODUCTION  Solitary fibrous tumor (SFT), previously known as hemangio - pericytoma (HPC), is a mesenchymal tumor primarily involving  the soft tissue and head and neck region.",Non-OADS,/arxiv_data1/oa_pdf/17/24/cmh-22-1-188.PMC4825158.pdf
"(Clin Mol Hepatol 2016;22:188-191) Keywords:  Hemangiopericytoma; Liver; Metastasis Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/17/24/cmh-22-1-188.PMC4825158.pdf
"Liver metastasis of HPC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.188Tomsich Pathology & Laboratory Medicine Institute and De - partment of Cancer Biology, Cleveland Clinic and Lerner Re - search Institute, USA.",Non-OADS,/arxiv_data1/oa_pdf/17/24/cmh-22-1-188.PMC4825158.pdf
190 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.188Clin Mol Hepatol Volume _22  Number _1  March 2016HPC) is incomplete or unavailable.,Non-OADS,/arxiv_data1/oa_pdf/17/24/cmh-22-1-188.PMC4825158.pdf
Liver metastasis of HPC http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.188Piepgras DG.,Non-OADS,/arxiv_data1/oa_pdf/17/24/cmh-22-1-188.PMC4825158.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.183 Clinical and Molecular Hepatology 2016;22:183-187 Case Report Corresponding author :  Byung-Cheol Song Department of Internal Medicine, Jeju National University School of  Medicine, 15 Aran 13-gil, Jeju 63241, Korea Tel: +82-64-754-7177, Fax: + 82-64-717-1131.",Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
"(Clin Mol Hepatol 2016;22:183-187) Keywords:  Hepatitis B virus; Entecavir; Esophageal varices; Liver cirrhosis Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
"184 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.183creatinine of 1.2 mg/dL (0.9-1.3), aspartate aminotransferase level  of 442 IU/L (N:8-38), alanine aminotransferase (ALT) level of 414  IU/L (N:4-44), total bilirubin of 1.7 mg/dL (N:0.2-1.2), albumin of  3.3 g/dL (N:3.8-5.3), and prothrombin time of 1.1 international  normalization ratio (INR) (N:0.88-1.2).",Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
"Regression of varices and entecavir http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.183a rate of 5-8% per year.15-17 Variceal bleeding, the mortality rate is  approximate 15-30%,18-21occurs at a yearly rate of 5-15%.17,22  Histological changes in liver cirrhosis have been believed to be  irreversible for a long time.23 However, recent studies conducted  by Marcellin et al.",Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
"186 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.183ter 3 years of sustained virological response following interferon  plus ribavirin combination thrapy.27 To the best of our knowledge,  this is a first report about regression of esophageal varices during  entecavir therapy in patients with HBV-related liver cirrhosis.",Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
KASL  Web site < http://www.kasl.org/bbs/?code=guide >.,Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
Regression of varices and entecavir http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.183thepatitic cirrhosis and haemochromatosis with cirrhosis.,Non-OADS,/arxiv_data1/oa_pdf/89/99/cmh-22-1-183.PMC4825159.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.146 Clinical and Molecular Hepatology 2016;22:146-151 Original Article Corresponding author :  Goh Eun Chung Department of Internal Medicine, Healthcare Research Institute,   Gangnam Healthcare Center, Seoul National University Hospital, 152  Teheran-ro, Gangnam-gu, Seoul 06236, Korea Tel: +82-2-2112-5741, Fax: +82-2-2112-5635 E-mail: gohwom@hanmail.netAbbreviations:   ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,  body mass index; GGT, gamma-glutamyltransferase; HDL, high-density  lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty  liver disease * Both are equally contributed to the study.",Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
"(Clin Mol Hepatol 2016;22:146-151) Keywords:  Fatty liver; Vitamin D; Metabolic factor Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
Vitamin D and NAFLD http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.146the skin or obtained from the diet.,Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
148 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.146Statistical analysis Categorical variables were compared using a chi-square test or  Fisher’s exact test and continuous variables between the two  groups were performed using the Student’s t-test.,Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
"Vitamin D and NAFLD http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.146DISCUSSION In the present study, we found that serum concentrations of vi - tamin D, even within the normal range, were inversely associated  with NAFLD in a dose-dependent manner.",Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
"150 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.146on ideal cut-off levels for vitamin D deficiency, and various factors  such as geography, sex and season may need to be considered.",Non-OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
"Vitamin D and NAFLD http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.146A, et al.",OADS,/arxiv_data1/oa_pdf/d0/d2/cmh-22-1-146.PMC4825160.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.76 Clinical and Molecular Hepatology 2016;22:76-139 Review Corresponding author :  KASL ( Committee Chair: Sook-Hyang Jeong) Room A1210 MapoTrapalace, 53 Mapo-daero, Mapo-gu, Seoul 04158, Korea Tel: +82-2-703-0051, Fax: +82-2-703-0071 E-mail: kasl@kams.or.kr *  Clinical Practice Guidelines Committee of KASL for the  Management of Hepatitis C Sook-Hyang Jeong (Committee Chair, Seoul National University College of  Medicine), Jung Il Lee (Yonsei University College of Medicine), Young Seok  Kim (SoonChunHyang University Bucheon Hospital), Kyung-Ah Kim (Inje  Unversity Ilsan Paik Hospital), Sang Hoon Park (Hallym University Kangnam  Sacred Heart Hospital), Byung Seok Lee (Chungnam National University  College of Medicine), Jun Yong Park (Yonsei University College of Medicine),  Ki Tae Yoon (Pusan National University School of Medicine), Young Kul Jung  (Korea University College of Medicine), Chang Wook Kim (Catholic University  College of Medicine), Eun Young Cho (Wonkwang University School of  Medicine), Geum-Youn Gwak (Sungkyunkwan University School of Medicine),  Woo Jin Chung (Keimyung University School of Medicine), Jeong Han Kim  (Konkuk University School of Medicine)Abbreviations:   3TC, lamivudine; AAR, AST/ALT ratio; ABC, abacavir; AGREE, Appraisal of guidelines  for research and evaluation; ALT, alanine transaminase; anti-HCV, antibody to  hepatitis C; APRI, aminotransferase-platelet ration index; ARFI, acoustic radiation  force; AST, aspartate aminotransferase; ATV, atazanavir; /r, /ritonavir; /c, /cobicistat;  Cat, catalyzed by human cathepsin; CEA, carboxylesterase; cEVR, complete EVR;  CLIA, chemiluminescent immunoassay; CrCl, creatinine clearance; CTP , Child-Pugh  Turcotte; DAA, direct-acting antivirals; DDI, drug-drug interactions; DRV, darunavir;  DTG, dolutegravir; DVR, delayed virologic response; ECLIA, electrochemiluminescence;  EFV, efavirenz; EIA, enzyme immunoassay; ESRD, end-stage renal disease; ETR, end-of  treatment response; ETR, etravirine; EVG, elvitegravir; EVR, early virologic response; FIB- 4, fibrosis-4 score; FPV, fosamprenavir; FTC, emtricitabine; G-CSF, granulocyte colony  stimulating factor; GFR, glomerular filtration rate; GRADE, grading of recommendations,  assessment, development and evaluation; HAV, hepatitis A virus; HBV, hepatitis B virus;  HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HINT, histidine triad nucleotide- binding protein; HIRA, Health Insurance Review and Assessment Service; HIV, human  immunodeficiency virus; IL 28B, interleukin 28B; IVDU, intravenous drug user; KASL,  Korean Association for the Study of the Liver; KCDC, Korea Centers for Disease Control  and Prevention; KHF, Korea Hemophilia Foundation; LC, liver cirrhosis; LPV, lopinavir;  MELD, Model for End-Stage Liver Disease; MR, magnetic resonance; MVC, maraviroc;  ddi, didanosine; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NS, non- structural; NVP , nevirapine; OATP , organic anion-transporting polypeptide; Opr+D,  ombitasvir/paritaprevir/ritonavir and dasabuvir; PCR, polymerase chain reaction;  PegIFN, peginterferon; pEVR, partial EVR; PI, protease inhibitor; PR, pegylated interferon- α+ribavirin therapy; PWID, people who inject drugs; R*, ribavirin started from 600 mg/ d; R, weight-based ribavirin; RAL, raltegravir; RAV, resistance-associated variants; RFMP ,  restriction fragment mass polymorphism; RIBA, recombinant immunoblot assays;  RPV, rilpivirine; RVR, rapid virologic response; SNP , single nucleotide polymorphism;  SQV, saquinavir; SVR, sustained virologic response; TDF, tenofovirdisoproxil fumarate;  TMA, transcription-mediated amplification; TPV, tipranavir; TSH, Thyroid-stimulating  hormone; UTR, untranslated region; ZDV, zidovudine Received :  Feb. 15, 2016 /  Accepted :  Feb. 22, 2016PREAMBLE Aims The Korean Association for the Study of the Liver (KASL) Prac - tice Guidelines for Management of Hepatitis C were first estab - lished in 2004, and revised in 2013, when direct-acting antivirals  (DAA) were not approved in Korea.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"These recommendations are not absolute standards of KASL clinical practice guidelines: management of   hepatitis C The Korean Association for the Study of the Liver (KASL)* Keywords:  Hepatitis C; Management; Guidelines; KASL Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"77 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76care, and adoption of the guidelines in clinical practice may differ  among individual patients.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"78 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76the level of evidence, the cost or preferences of the patients or  medical practitioners.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
Release of the guidelines and plan for updates The Korean version of the KASL Clinical Practice Guidelines for  the Management of Hepatitis C was released in November 2015  at a KASL meeting and published in January 2016 on the KASL  website ( http://www.kasl.org ).,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
79 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76been under surveillance since 2000.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"80 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76third-generation EIA was 42.3% in 2002, and the risk of infection  was correlated with age and severity of hemophilia.33 In their  2012 annual report, the Korea Hemophilia Foundation (KHF) re - ported that 430 of 2,148 (20.0%) hemophilia patients were anti- HCV-positive and 118 of 2,148 (5.5%) were HCV RNA-positive.34  Leprosy patients can be considered at high risk of HCV infection  due to their skin lesions and long-term cohabitation in limited ar - eas.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"81 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76of perinatal transmission increased in female infants, HIV-positive  mothers, and mothers with high blood HCV RNA levels.67 Cesare - an section reportedly does not prevent HCV transmission,67,68 and  the frequency of transmission via nursing was very low.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"82 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76load, and genotype 3.77-79 A Korean study reported that among 18  acute hepatitis C patients (17 patients showed symptoms), 12 pa - tients spontaneously recovered and 6 patients progressed to  chronic hepatitis.80 Another study including 47 acute hepatitis C  patients with a mean age of 45.8 years in seven Korean institu - tions reported that 21 of 47 (44.7%) patients recovered sponta - neously, and 16 patients received antiviral therapy.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
83 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.762.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"84 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76treated under coverage of Health Insurance Review and Assess - ment Service (HIRA) due to liver disease associated with HCV in - fection was 64,501 in 2009.113 These data suggest the possibility  that only about 20% of the patients were diagnosed and treated.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"85 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76upper limit of 7-8 log IU/mL and 98-99% diagnostic specificity ir - respective of HCV genotype.115,131-135 Therefore, quantitative HCV  RNA tests are now widely used for both diagnosis and evaluation  of the treatment response.127,136  In 1997, the World Health Organization established an interna - tional standard for HCV RNA quantification unit, IU, rather than  HCV copy number.137,138 However, since viral quantification results  can differ among laboratories,139 it is recommended to use the  same laboratory test before, during, and after-treatment for moni - toring, if possible.107,127  Blood HCV RNA is detectable as early as 2 weeks after infec - tion,76 rapidly increases to reach a plateau, and decreases along  with ALT after ALT has peaked.140 HCV RNA levels remain steady  in patients with chronic hepatitis C.140,141 HCV RNA levels are not  significantly correlated with the severity of hepatic inflammation  or fibrosis, and change little during chronic infection without anti - viral treatment.142,143 2.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
86 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76than that in those without NS5A RAVs.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"87 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76Noninvasive tests for evaluation of liver fibrosis Although liver biopsy is accepted as the gold standard test for  evaluation of liver fibrosis,197,198 it is associated with serious com - plications,199,200 sampling errors,201 high costs, and interobserver  variations.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"88 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76extrahepatic manifestations of HCV infection, such as mixed cryo - globulinemia and glomerulonephritis.242,243 [Recommendations] 1.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"89 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76ment after a virological response, and relapse is defined as the re - appearance of HCV RNA after treatment has been completed.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"90 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76pared to those with a viral load of >800,000 IU/mL.250,263,266 SVR  rates are lower in older patients (>40 years),254 African-Ameri - cans,267 body weight >70 kg,254,261 and insulin resistance.268,269  SVR rates vary depending on SNP of IL28B, in other words, a C or  T allele at the rs12979869 locus.270 The SVR rates of HCV geno - type 1 Caucasian patients are 69%, 33%, and 27% in CC homo - zygotes, CT heterozygotes, and TT homozygotes, respectively.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
91 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76suppressants tacrolimus and sirolimus.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
92 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76activation pathway involves sequential hydrolysis of the carboxyl  ester moiety catalyzed by human cathepsin A (CatA) or carboxy - lesterase 1 (CES1) and phosphoramidate cleavage by histidine tri - ad nucleotide-binding protein 1 (HINT1) followed by phosphoryla - tion by the pyrimidine nucleotide biosynthesis pathway.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
93 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76once daily (in the morning) and one dasabuvir 250 mg tablet  twice daily (morning and evening) are taken orally with a meal.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"94 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76received a combination of ledipasvir/sofosbuvir plus ribavirin or  ledipasvir/sofosbuvir, the SVR rates were 95% in those who re - ceived the therapy for 12 weeks and 98% in those who received  it for 24 weeks, showing no additional benefit in previously un - treated patients with liver cirrhosis of ribavirin addition or exten - sion of treatment duration to 24 weeks.279 In treatment-naïve patients without cirrhosis treated with ombi - tasvir/paritaprevir/ritonavir and dasabuvir (Opr+D) together with  ribavirin for 12 weeks, the SVR rates were 95% (307/322) in gen - otype 1a and 98% (148/151) in genotype 1b patients.280 To evalu - ate the importance of ribavirin administration with Opr+D, phase  3 trials were conducted in treatment-naïve, non-cirrhotic patients  with genotype 1a and 1b.281 Patients with HCV genotype 1b were  randomly assigned to receive Opr+D alone (n=209) or with ribavi - rin (n=210) for 12 weeks.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"95 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76is related to the higher frequency of favorable IL28B genotypes in  Koreans than in Caucasians or African-Americans.83 Patients with  genotype 1 who achieve a RVR and had a low baseline viral load  (<400,000 IU/mL) may have their duration of therapy shortened  to 24 weeks if there are no negative predictors of response, such  as advanced liver fibrosis, cirrhosis, obesity, or insulin resis - tance.249 Treatment should be stopped in patients who do not  achieve an EVR, as the SVR rate in these patients using the stan - dard treatment duration is <3%, and in patients with pEVR and  detectable HCV RNA at week 24, as the SVR rate is 2-4%.254,299 Retreatment of treatment-experienced patients  Few Korean HCV patients have experience of PI, except for  those who participated in clinical trials.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"96 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76patients who had not responded to treatment previously.306 There  were no differences in SVR rates based on sex, age, race, IL28B  genotype, or presence of cirrhosis.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
97 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76rhosis should be treated with daily daclatasvir (60 mg) and  asunaprevir (200 mg) for 24 weeks.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
98 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76tending treatment to 24 weeks is recommended for pa - tients with cirrhosis in whom use of ribavirin is contraindi - cated (B1).,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
99 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76of the efficacy of extended treatment up to 48 weeks in patients  with negative predictors of a response have been performed.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"100 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76mg in patients ≥ 75 kg, 1,000 mg in patients < 75 kg) and  sofosbuvir (400 mg) for 12 weeks (A1).",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"101 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76that a weight-based dose of ribavirin is more effective in achiev - ing SVR in HCV genotype 3 patients is lacking.262,314 Although the  SVR rate of HCV genotype 3 Korean patients has rarely been re - ported, HCV genotype 3 patients of other ethnicities showed a  10-20% lower SVR rate than genotype 2 patients.319,320,325 Retreatment of treatment-experienced patients In a phase III study, sofosbuvir plus ribavirin treatment for 12  weeks was compared with that for 16 weeks in treatment-experi - enced HCV genotype 3 patients.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"102 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76should be treated with daily sofosbuvir (400 mg) and  weight-based ribavirin (1,200 mg in patients ≥ 75 kg, 1,000  mg in patients < 75 kg) plus weekly PegIFN- α for 12 weeks  (A1).",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"103 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76(1,200 mg in patients ≥ 75 kg, 1,000 mg in patients < 75 kg)  for 12 weeks (B1).",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
104 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76(B1).,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
105 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76patients experienced drug discontinuation or dose reduction.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"106 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76liver function may lead to delisting of some of patients awaiting  transplantation.363 However, the duration of antiviral therapy can - not be predicted in a patient on the waiting list.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"107 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76complications.369 Anemia is the most common cause of treatment  discontinuation and recombinant erythropoietin is recommended  in this case.367,368 Allograft rejection related to interferon alpha use  can occur, and liver biopsy is required to differentiate the cause of  liver function deterioration during antiviral treatment.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
108 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76for 12 weeks can be used for post-liver transplantation  patients infected with HCV genotype 3 (C1).,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"109 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76MONITORING AND MANAGEMENT OF AD - VERSE EFFECTS DURING ANTIVIRAL TREAT - MENT FOR HCV INFECTION Monitoring during and after antiviral treatment Poor adherence to therapies increases the rate of treatment fail - ure due to virologic breakthrough, relapse after treatment, occur - rence of RAV, etc.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
110 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.765.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
111 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76continuous monitoring of these cell counts.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"112 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76virin combination therapy, the following are recommended: 1) Pretreatment evaluation of depression, cardiac and pul - monary diseases, hypertension, diabetes mellitus, thy - roid diseases, or anemia is required to monitor adverse  effects of treatment (B1).",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"113 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76from 3% to 80%,435 anti-HCV positivity rates from the late 1990s  to early 2000s in Korea were 5.9-14.7%.27,28,436 In contrast, the  Dialysis Registry, ESRD Registry Committee of Korean Society of  Nephrology reported a rate of 2.2% in 2014.29  The HCV infection rate is high in chronic kidney disease pa - tients.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
114 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76Table 14 .,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
115 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.766.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"116 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76used with antiretroviral drugs with which they do not have drug- drug interactions; i.e., raltegravir, enfuvirtide, tenofovir, emtric - itabine, lamivudine, atazanavir, dolutegravir.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"117 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76es in HBV/HCV-coinfected patients compared to those with HBV  monoinfection.487-489  In patients with HBV/HCV coinfection, blood HCV RNA and HBV  DNA levels, which are indicators of the replicative status of each  virus, should be evaluated, and if HCV infection is the dominant  cause of the liver disease, the same antiviral therapy as for HCV  monoinfection is recommended.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"118 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76the upper limit of normal,502 there is no universal consensus on  definition of HCV reactivation; blood ALT and HCV RNA levels are  commonly used as the criteria.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
119 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76following the same rules as in adults (B1).,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
120 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7612.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
121 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76ence.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
122 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7674.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"123 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76K, et al.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
124 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76fication in patients with complete virologic response according to  polymerase chain reaction-based assays.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
125 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76with simeprevir in phase 2b/3 studies.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
126 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76anti-D. Clin Gastroenterol Hepatol 2006;4:1271-1277.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
127 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.762004;3:8.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"128 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76Z, et al.",OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
129 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76with interferon alfa-2b plus ribavirin for initial treatment of chronic  hepatitis C: a randomised trial.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
130 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.761 in non-responders to pegylated interferon and ribavirin and  treatment-naive patients: the COSMOS randomised study.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
131 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76French observational cohort ANRS CO22 HEPATHER [Abstract].,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
132 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76of interferon-ribavirin nonresponder patients.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
133 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76Viral Hepat 2010;17:691-697.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
134 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.762004;39:1721-1731.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
135 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76ward a new classification.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"136 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.",Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
137 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76chronic hepatitis C virus infection in HIV-infected patients.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
138 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.76HIV and/or HBV co-infected patients.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
139 The Korean Association for the Study of the Liver (KASL)  KASL clinical practice guidelines: Management of Hepatitis C http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.76510.,Non-OADS,/arxiv_data1/oa_pdf/68/46/cmh-22-1-76.PMC4825161.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.172 Clinical and Molecular Hepatology 2016;22:172-176 Case Report Corresponding author :  So Young Kwon Digestive Disease Center, Department of Internal Medicine, Konkuk  University Hospital, Konkuk University School of Medicine, 120-1,  Neungdong-ro, Gwangjin-gu, Seoul 05030, Korea Tel: +82-2-2030-5027, Fax: +82-2-2030-5029 E-mail: sykwonmd@hotmail.comAbbreviations:   CBD, common bile duct; CT, computer tomography; ERBD, endoscopic  retrograde biliary drainage; ERCP , endoscopic retrograde cholangio - pancreatography; MRCP , magnetic resonance cholangiopancreatogra - phy; TIPS, transjugular intrahepatic portosystemic shunt *  Sung Jin Jeon and Jae Ki Min contributed equally to this work  as the first authors.",Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
"(Clin Mol Hepatol 2016;22:172-176) Keywords:  Bile duct obstruction; Portal hypertension; Endoscopic retrograde cholangiopancreatography; Biliary stent Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
"Portal Biliopathy http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.172CASE REPORT A 56-year-old man visited the emergency room with fever, chill,  and abdominal pain.",Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
174 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.172pericholecystic infiltration of the gallbladder (Fig.,Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
"Portal Biliopathy http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.172nous collateral vessels, due to the obstruction of extra- and intra- hepatic ducts, causing impediment to portal venous drainage.1,2  The underlying pathogenesis of the disease starts with the com - pression of venous collaterals on the bile duct and prolonged por - tal vein thrombosis.",Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
176 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.172biliary obstruction.,Non-OADS,/arxiv_data1/oa_pdf/04/a9/cmh-22-1-172.PMC4825162.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.140 Clinical and Molecular Hepatology 2016;22:140-145 Original Article Corresponding author :  Mi-Suk Park Department of Radiology, Severance Hospital, Yonsei University College  of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-7400, Fax: +82-2-393-3035 E-mail: radpms@yuhs.acAbbreviations:   APRI, AST to platelet ratio index; AST, aspartate aminotransferase;  MaxDisp, local maximum displacement; MaxP1, local maximum P1  strain; MinP2, local minimum P2 strain Received :  Jun.",Non-OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
"(Clin Mol Hepatol 2016;22:140-145) Keywords:  Liver cirrhosis; Fibrosis; Magnetic resonance imaging Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
"Magnetization-tagged MRI to assess liver fibrosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.140hand, non-invasive methods are being investigated for the diag - nosis of liver fibrosis including ultrasound-based transient elas - tography and magnetic resonance imaging (MRI)-based studies  using MR elastography.6-9 Ultrasound-based transient elastogra - phy is simple, but involves measurement limitations in regards to  depth and in patients with obesity.10 Although MR elastography is  known to be accurate, it requires special-purpose hardware in or - der to generate an externally induced vibration wave.11 Alterna - tively, recent studies on magnetization-tagged MRI have shown  that cardiac-induced liver motion can be measured to noninva - sively assess liver stiffness.12 Therewith, pulsations of the heart as  an intrinsic motion source are transmitted to the adjacent portion  of the liver during the cardiac cycle, resulting in relatively localized  motion and deformation of the liver.",Non-OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
"142 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.140Works Inc., MA, USA).12 Briefly, two families of orthogonally ori - ented phase images were generated from the filtered grid-tagged  images, and the associated displacement results were calculated  from the two sets of phase images.",OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
Magnetization-tagged MRI to assess liver fibrosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.140based on APRI.,OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
"144 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.140mean values of maximum displacement, maximum P1 (the  amount of greatest elongation or stretch of the tissue) and mini - mum P2 (the amount of greatest compression or shortening of the  tissue) were significantly different among the patients with no fi - brosis, moderate fibrosis, and significant fibrosis.",Non-OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
Magnetization-tagged MRI to assess liver fibrosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.140REFERENCES   1.,Non-OADS,/arxiv_data1/oa_pdf/5d/42/cmh-22-1-140.PMC4825163.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.7 Clinical and Molecular Hepatology 2016;22:7-17 Review Corresponding author :  Su Jong Yu Department of Internal Medicine, Seoul National University Hospital, 101  Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-7216, Fax: +82-2-743-6701 Email: ydoctor2@hanmail.netAbbreviations:   AASLD, american association for the study of liver disease; ACG, american college  of gastroenterology; AFP , α-fetoprotein; AJCC, american joint committee on cancer;  APASL, asian pacific association for the study of the liver; BCLC, barcelona-clinic liver  cancer; CEUS, contrast-enhanced ultrasonography; CT, computed tomography;  EASL, european association for the study of the liver; EBRT, external-beam radiation  therapy; EORTC, european organization for research and treatment of cancer; ESDO,  european society of digestive oncology; ESMO, european society for medical  oncology; HCC, hepatocellular carcinoma; JSH, japan society of hepatology; KLCSG,  korean liver cancer study group; LT, liver transplantation; RFA, radiofrequency ablation;  MDCT, multidetector computed tomography; MRI, magnetic resonance imaging;  NCC, national cancer center; NCCN, national comprehensive cancer network; PEIT,  percutaneous ethanol injection therapy; TACE, transarterial chemoembolization;  UICC, international union for cancer control; US, ultrasonography Received :  Feb. 25, 2016 /  Accepted :  Feb. 26, 2016INTRODUCTION  Hepatocellular carcinoma (HCC) is the fifth most common ma - lignancy and the second leading reason of cancer-associated deaths around the world, and more than 600,000 deaths are re - ported internationally each year.1,2 Many global studies have ex - amined the management of HCC.3-5 However, the general progno - sis is still poor with overall survival rates of 3-5%.6 Following a A concise review of updated guidelines regarding the  management of hepatocellular carcinoma around the  world: 2010-2016 Su Jong Yu Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea Many guidelines for hepatocellular carcinoma (HCC) have been published and updated globally.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"(Clin Mol Hepatol 2016;22:7-17) Keywords:  Hepatocellular carcinoma; Guideline  Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"8 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7management model, guidelines were defined as ‘systematically  derived statements to assist medical practitioner and patient deci - sions about proper healthcare for specific medical conditions’.7  The full application of guidelines could attain the following goals:  (i) serving as a guide for proper medical decision-making by prac - titioners; (ii) improving the quality of healthcare and outcomes for  patients and (iii) supporting and influencing local or nationwide  authorities that allocate resources.8 Many guidelines for HCC have  been published globally since the European Association for the  Study of the Liver (EASL) published their guidelines for HCC in  2001.9 In this article, we performed an English language literature  search on the subject of the guidelines or consensus for HCC pub - lished and/or updated in PubMed database during the period  2010-2016.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
9 Su Jong Yu  Comparison of HCC guidelines http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.7Table 2.,Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"10 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7their guidelines for the management of HCC, the AASLD recom - mends HCC screening and surveillance for the following high-risk  groups: Asian male hepatitis B carriers over age 40, Asian female  hepatitis B carriers over age 50, hepatitis B carriers with a family  history of HCC, Africans and African Americans with hepatitis B,  cirrhotic hepatitis B carriers, individuals with hepatitis C cirrhosis,  individuals with stage 4 primary biliary cirrhosis, individuals with  genetic hemochromatosis and cirrhosis, individuals with alpha  1-antitypsin deficiency and cirrhosis, individuals with cirrhosis  from other etiologies.15 Tests Ultrasonography (US) has long been the radiographic methodol - ogy of choice for HCC surveillance, and a meta-analysis reported  a pooled sensitivity of 94% in detecting lesions18 and a reported  specificity of >90%.19 Serum α-fetoprotein (AFP) has been tradi - tionally and commonly used as a tumor marker of HCC.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"11 Su Jong Yu  Comparison of HCC guidelines http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.7lines: (i) Size-based diagnostic algorithms was recommended by 5  (KLCSG-NCC, JSH, EASL-EORTC, AASLD, and NCCN) of the 8  guidelines.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"12 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7appeared as the most popular to guide treatment decision and  has been endorsed by many guidelines including AASLD, EASL- EORTC, and ESMO-ESDO [with two modifications: (i) Portal hy - pertension is omitted from the algorithm and gives more freedom  in the clinical decision for resection.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
13 Su Jong Yu  Comparison of HCC guidelines http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.7staging system.,Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"14 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7Treatment Although BCLC has long been dominant system for treatment- guiding staging of HCC, many Asia-pacific experts do not fully  agree with its principle.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"15 Su Jong Yu  Comparison of HCC guidelines http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.7group.58 Therefore, in case of portal vein invasion, Asian guide - lines state that TACE can be considered for patients with localized  tumors and well-preserved liver function.10-12 Systemic or selective  intra-arterial chemotherapy is not recommended in most western  guidelines, but NCCN guideline and Asian guidelines permit cyto - toxic chemotherapy especially in patients with advanced tumors  who have well-preserved hepatic function and good performance  status in whom sorafenib therapy has failed.10-12 ,16 Radiotherapy Most western guidelines and even Asian guidelines do not rec - ommend external-beam radiation therapy (EBRT) for the treat - ment of intrahepatic HCC.",Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
16 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.7et al.,Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
17 Su Jong Yu  Comparison of HCC guidelines http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.7lines for the management of hepatocellular carcinoma: HCC diag - nostic algorithm.,Non-OADS,/arxiv_data1/oa_pdf/60/bc/cmh-22-1-7.PMC4825164.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.160 Clinical and Molecular Hepatology 2016;22:160-167 Original Article Corresponding author :  Byoung Kuk Jang Department of Internal Medicine, Keimyung University Dongsan Hospital,  56 Dalsung-ro, Jung-gu, Daegu 41931, Korea Tel: +82-53-250-7088,  Fax: +82-53-250-7422 E-mail: jangha106@dsmc.or.krAbbreviations:   AFP , alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate  aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CT, computed  tomography; CTP , Child-Turcotte-Pugh; HBV, hepatitis B virus; HCC,  hepatocellular carcinoma; HCV, hepatitis C virus; HR, hepatic resection;  MELD, model for end-stage liver disease; PIVKA-II, protein induced  by vitamin K absence or antagonist-II; PT, prothrombin time; PVTT,  portal vein tumor thrombosis; RFA, radiofrequency ablation; TACE,  transarterial chemoembolization Received :  Sep. 18, 2015 /  Revised :  Feb. 11, 2016 /  Accepted :  Feb. 12, 2016Survival outcomes of hepatic resection compared with  transarterial chemoembolization or sorafenib for   hepatocellular carcinoma with portal vein tumor   thrombosis Jung Min Lee1, Byoung Kuk Jang1, Yoo Jin Lee1, Wang Yong Choi1, Sei Myong Choi1, Woo Jin Chung1, Jae Seok Hwang1,  Koo Jeong Kang2, Young Hwan Kim3, Anil Kumar Chauhan4, Soo Young Park5, Won Young Tak5, Young Oh Kweon5,  Byung Seok Kim6, and Chang Hyeong Lee6 Departments of 1Internal Medicine, 2Surgery, 3Radiology, and 4Immunology, Keimyung University School of Medicine; 5Department of  Internal Medicine, Kyungpook National University School of Medicine; 6Department of Internal Medicine, Catholic University of Daegu  School of Medicine, Daegu, Korea Background/Aims:  Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains  controversial.",Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
"(Clin Mol Hepatol 2016;22:160-167) Keywords:  Hepatocellular carcinoma; Portal vein tumor thrombosis; Transarterial chemoembolization; Hepatic  resection; Sorafenib Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
Survival outcomes of HR compared with TACE or sorafenib for HCC with PVTT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.160INTRODUCTION  Hepatocellular carcinoma (HCC) has one of the highest inci - dence rates of all malignancies worldwide.,Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
162 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.160counts and liver function tests.,Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
Survival outcomes of HR compared with TACE or sorafenib for HCC with PVTT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.160analysis.,Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
"164 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.160Survival analyses The median survival times in the HR, TACE, and sorafenib groups  were 19.9, 6.6, and 6.2 months, respectively ( P<0.001, Fig.",Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
Survival outcomes of HR compared with TACE or sorafenib for HCC with PVTT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.160Univariate and multivariate analyses of overall  survival for all patients Between overall survival and 20 variables with known values  for all patients were evaluated by univariate analysis.,OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
"166 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.160DISCUSSION According to the BCLC staging system, chemotherapy with a  molecular-targeted agent is the only treatment option for patients  with advanced HCC.",Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
"Survival outcomes of HR compared with TACE or sorafenib for HCC with PVTT http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.160stage HCC, the selection of treatment method should be considered  according to CTP class, the extent of PVTT, and location of lesion.",Non-OADS,/arxiv_data1/oa_pdf/58/e6/cmh-22-1-160.PMC4825165.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.18 Clinical and Molecular Hepatology 2016;22:18-75 Review Corresponding author :  KASL (Committee chair: Kwan Sik Lee) Room A1210 MapoTrapalace, 53 Mapo-daero, Mapo-gu, Seoul 04158, Korea Tel: +82-2-703-0051, Fax: +82-2-703-0071 E-mail: kasl@kams.or.kr *  Clinical Practice Guidelines Committee of KASL for the  Management of Chronic Hepatitis B Kwan Sik Lee (Committee Chair, Yonsei University College of Medicine), Si Hyun  Bae (Catholic University of Korea), Won Hyeok Choe (Konkuk University College  of Medicine), Moon Seok Choi (Sungkyunkwan University School of Medicine),  Woo Jin Chung (Keimyung University School of Medicine), Chang Wook Kim  (Catholic University of Korea), Hyung Joon Kim (Chung-Ang University College  of Medicine), Ja Kyung Kim (Yonsei University College of Medicine), Ji Hoon Kim  (Korea University College of Medicine), Suk Bae Kim (Dankook University Medical  College), Yoon Jun Kim (Seoul National University College of Medicine), Jae Sung  Ko (Seoul National University College of Medicine), Byung Seok Lee (Chungnam  National University College of Medicine), Jung Il Lee (Yonsei University College  of Medicine), Young-Suk Lim (University of Ulsan College of Medicine), Won  Young Tak (Kyungpook National University School of Medicine), Jong Eun Yeon  (Korea University College of Medicine), Ki Tae Yoon (Pusan National University  School of Medicine).",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"KASL clinical practice guidelines: management of  chronic hepatitis B The Korean Association for the Study of the Liver (KASL)* Keywords:  Chronic hepatitis B; Mangement; KASL guidelines Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Abbreviations:   AAR, AST/ALT ratio; AASLD, American Association for the Study of Liver Diseases;  ALP, alkaline phosphatase; ALT, alanine aminotransferase; anti-HAV, hepatitis A virus  antibody; anti-HBc, hepatitis B core antibody; anti-HBe, hepatitis B e antibody; anti- HBs, hepatitis B surface antibody; APASL, Asian Pacific Association for the Study of  the Liver; APR, Antiretroviral Pregnancy Registry; APRI, aspartate aminotransferase- platelet ratio index; ASPRI, age-spleen-platelet ratio index; AST, aspartate  aminotransferase; BCP, basal core promoter; CBC, complete blood count; CHB,  chronic hepatitis B; CK, creatine kinase; CPGRC, Clinical Practice Guideline Revision  Committee; cpm, copies/mL; CTP , Child-Turcotte-Pugh; DAA, direct-acting agent;  DMARD, disease-modifying antirheumatic drug; EASL, European Association for  the Study of the Liver; GGT, gamma-glutamyl transpeptidase; GRADE, Grading of  Recommendations, Assessment, Development and Evaluation; HAART, anti-retroviral  therapy; HBcAg, hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBIG, hepatitis  B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, Hepatitis B virus; HCC,  hepatocellular carcinoma; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human  immunodeficiency virus; IU, international unit; peginterferon, pegylated interferon;  KASL, Korean Association for the Study of the Liver; NA, nucleos(t)ide analog; PC,  precore; PT, prothrombin time; qHBsAg, quantity of HBsAg; R-CHOP ,  rituximab plus  cyclophosphamide, doxorubicin, vincristine, and prednisone; SR, success rate; IQR,  interquartile range; TACE, transcatheter arterial chemoembolization",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
19 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18Target population The main targets of this guideline are patients both newly diag - nosed with CHB and those being followed up or treated for CHB.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
20 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18  6.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"Release of the guidelines The revised CHB guidelines of KASL were released on Novem - ber 26, 2015 ( http://www.kasl.org ).",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"21 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18therapy.14,15 HBV DNA positivity indicates an acute or chronic HBV  infection, and negativity indicates resolution of infection.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"22 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18will reactivate to the HBeAg-negative or HBeAg-positive immune- active phase, and might experience recurring periods of reactiva - tion and inactivation throughout their lives, which can lead to cir - rhosis or HCC.34,35 This is why the ALT levels of patients in the  immune-control phase must be measured at least every 6 months  for life because currently there are no predictors of which patients  will remain in the inactive phase and which will revert to HBeAg- negative active hepatitis.15 4.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"23 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18three- to fourfold higher for males than for females, and the risk  of HCC and cirrhosis is low among those younger than 40 years,  then increases exponentially with increasing age after the fourth  decade of life.33,57-59 Those with a family history of HCC also have  a higher risk of contracting HCC.60,61 Environmental and social risk  factors for progression to cirrhosis or HCC are alcohol consump - tion, exposure to aflatoxin,62 and smoking.63 It is suggested that  obesity, metabolic syndrome, and fatty changes in histologic tests  increase the risk of CHB patients progressing to hepatic fibrosis or  HCC.64-67 Many epidemiological research studies have found that  coffee exerts protective effects against the development of hepat - ic fibrosis and HCC.68-72  Viral factors that may influence the progression of CHB patients  to cirrhosis or HCC include high levels of serum HBV DNA  (≥20,000 IU/mL), genotype C, BCP variants, and coinfection with  other viruses.57,59,73-75 According to the Taiwanese Risk Evaluation  of Viral Load Elevation and Association Liver Disease/Cancer-Hep - atitis B Virus (REVEAL-HBV) study, the risk of developing HCC  during the study period among subjects aged at least 40 years  was significantly higher in those with an HBV DNA level of ≥104  copies/mL (cpm) at the start of observation and 105 cpm 11 years  later than among those with an entry HBV DNA level of  <104 cpm.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"24 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18HBV infection.89 According to a long-term prospective study of  patients with chronic HBV infection, smoking also increases the  risks of liver cirrhosis and HCC, and so non-smoking is recom - mended in patients with chronic HBV infection.57,59,90 Vertical infection is the most important route of HBV trans - mission.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
25 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18Antigen/antibody test HBsAg immunoassay is a necessary and accurate test for di - agnosis of CHB.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"26 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18tion of genotyping is recommended selectively to help identify  patients who might be at greater risk of disease progression,  and routinely to determine the most appropriate candidates for  peginterferon therapy.117 However, genotyping is recommended  as being unnecessary in Korea because Korean patients are al - most exclusively infected with genotype C. Biochemical test Assessments of the severity of liver disease should include  biochemical markers such as AST, ALT, gamma-glutamyl trans - peptidase (GGT), alkaline phosphatase (ALP), prothrombin time  (PT), and serum albumin.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
27 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18DNA levels have essential roles in treatment decisions.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
28 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18flammation and fibrosis.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"29 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18risk of liver cirrhosis.145 Immune tolerance phase Antiviral therapy is not indicated for patients in the immune-tol - erant phase despite HBeAg positivity and a high level of HBV  DNA, because of the benign natural course of the disease and  such treatment results in minimal histologic changes.159  [Recommendations] Patients in the immune-tolerant phase (HBeAg positive and  persistently normal ALT level as recommended by this guide - line rather than local laboratory ULNs) are not indicated for  antiviral therapy.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
30 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18in treatment-naïve patients.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"31 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18CHB patients with peginterferon- α-2b alone or in combination  with lamivudine for 52 weeks, the virologic response rate (as indi - cated by HBeAg seroconversion and an HBV DNA level of  <10,000 copies/mL) was superior in those with cirrhosis than in  those without cirrhosis (35% vs. 14%, respectively).183 However,  acute exacerbation of hepatitis (33% vs. 12%, respectively) and  requirement for dose reduction (63% vs. 30%) were more com - mon in cirrhotic patients than in noncirrhotic patients.183 There - fore, interferon- α can be used with caution in cirrhotic patients  with preserved liver function.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
32 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18antiviral treatment.192 Pre- and post-transplantation antiviral ther - apy has been reported to reduce the risk of reactivation of hepati - tis after liver transplantation.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"33 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18Peginterferon therapy resulted in a more significant reduction in  qHBsAg levels than NA therapy.211,212 However, a low pretreat - ment qHBsAg level and greater qHBsAg decline were reported to  be positive predictors of a sustained virologic response.213,214  In  CHB patients receiving 10 years of NA therapy, low baseline qHB - sAg levels (<1,000 IU/mL) and a greater rate of HBsAg reduction  (>0.166 log10 IU/mL/year) were predictive of qHBsAg seroclear -ance, strengthening the prognostic role of HBsAg measurements  during NA therapy.203 Compliance and antiviral-resistance muta - tions should be monitored in patients who develop virologic  breakthrough while receiving NA, and an appropriate rescue ther - apy should be initiated if necessary.215-219 Most NAs are excreted through the kidney, and hence dose ad - justment is required in patients with renal insufficiency (Table 4),35 Table 4.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
34 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18and regular monitoring of renal function should be performed in  patients receiving adefovir or tenofovir.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
35 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18[Recommendations] 1.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
36 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18to the type of therapy.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"37 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18predictor of the outcome of treatment with lamivudine, adefovir,  or telbivudine.118 During treatment with lamivudine, adefovir, or  telbivudine, a virologic response at 24 or 48 weeks (undetectable  serum HBV DNA by a real-time PCR assay) is associated with lower  incidences of antiviral resistance (i.e., higher probability of a sus - tained virologic response) and HBeAg seroconversion in HBeAg- positive patients.156,225,248 HBV genotype does not influence the re - sponse to any NA.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
38 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18into two groups: NAs and nucleotide analogues.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
39 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.182.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"40 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18involving 91 lamivudine-resistant CHB patients consisted of ade - fovir monotherapy (n=29), adefovir and lamivudine combination  therapy (n=30), adefovir and entecavir 1 mg combination therapy  (n=32) found that the HBV DNA undetectable rate (<60 IU/mL)  was not significantly different (48.2% vs. 76.7% vs. 87.5%, re - spectively) but the adefovir resistance rate differed significantly  (27.6% vs. 13.3% vs. 0%, respectively) after 24 months.292 In a  small prospective study that compared an adefovir-plus-telbivu - dine combination-therapy group (n=21) with an adefovir-mono - therapy group (n=21), the HBV undetectable rate (<300 copies/ mL) was 38.5% and 0%, respectively, and adefovir resistant virus  was detected in 9.6% of patients in the adefovir-monotherapy  group after 96 weeks.294 Two small prospective studies revealed  that the reduction in HBV load was greater in the adefovir-plus- telbivudine combination-therapy group than the adefovir-plus-la - mivudine combination-therapy group.295,296  3.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"41 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18The rate of adefovir-resistance is 20% and 29% after 5 years of  adefovir treatment in HBeAg-positive and HBeAg-negative treat - ment naïve patients, respectively.157,308 The risk of genotypic resis - tance to adefovir increases in patients resistant to lamivudine  compared to treatment-naïve patients.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"42 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18sponse rate was 24-51% at 1 or 2 years of treatment with the  combination of adefovir and entecavir or lamivudine.326-328 ,332 2.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"43 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18classified as complete response, partial response and primary  non-response.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"44 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18in HBV DNA level, could be recommended as the incidence of resis - tance during long-term treatment is low.345 However, switching to  another high genetic barrier antiviral is another option.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"45 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18HBIG, the hepatitis B recurrence rate after 4 years of liver trans - plantation was ~40%.391,392 In contrast, a study of lamivudine and  adefovir combination therapy reported no recurrence in CHB pa - tients during the 22-month observation period.393 In patients who  received entecavir monotherapy without HBIG,394,395 the rate of  HBsAg loss was 88-91% and negative viremia was maintained in  more than 98% during a 26-53-month follow up; moreover, the  rate of HBV recurrence was lower than that with lamivudine  monotherapy.395 In a meta-analysis of 19 studies, lamivudine or adefovir with  HBIG significantly reduced HBV recurrence compared to mono - therapy with either lamivudine or adefovir.396 However, in a meta- analysis of 17 studies with 519 patients, those treated with lami - vudine and HBIG (6.1%) combination therapy showed a rate of  HBV recurrence comparable to that of those treated with either  entecavir or tenofovir monotherapy (3.9%, P=0.52), and signifi - cantly higher than that of those treated with the combination of  HBIG and either entecavir or tenofovir therapy (1%, P<0.001).397  To date, few studies regarding entecavir or tenofovir monotherapy  for the prevention of HBV recurrence after liver transplantation  have been reported.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
46 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18mivudine therapy alone.415-417 The protective effect against HBV  recurrence was similar between lamivudine and entecavir or teno - fovir.418 Lamivudine was more cost-effective than entecavir or te - nofovir according to a Markov model.419  [Recommendation]  1.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
47 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18tivation to a greater degree than lamivudine (6.3% vs. 39.3%;  P<0.05).,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"48 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18in cases with prolonged treatment (e.g., >1 year).433 A retrospec - tive study reported that the risks of hepatitis and chemotherapy  disruption due to HBV reactivation in lymphoma patients were  lower for entecavir than for lamivudine.469 However, data on the  relative efficacy and cost-effectiveness of antiviral agents are  scarce.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"49 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18tion due to pharmacodynamic changes.485,486 Several small studies  have reported the effectiveness of lamivudine.487-489 Resistance to  lamivudine was 39% at 16.5 months of treatment, which was  similar to the rate in patients with normal renal function.490 Ente - cavir or tenofovir may be preferentially used, given their potency  and resistance profile in patients with normal renal function.35  Careful dose adjustment is required for adefovir and tenofovir due  to their potential nephrotoxicity in patients with residual renal  function.491-494 Tenofovir is less nephrotoxic than adefovir.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
50 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18[Recommendation] 1.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
Safety data of antiviral agents during  pregnancy can be found at the Antiretroviral Pregnancy Registry  (APR; http://www.apregistry.com ).,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
51 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18and it contains a considerable amount of data on lamivudine and  tenofovir.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
52 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18[Recommendations] 1.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
53 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18without lamivudine-resistant virus.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
54 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18Jae Sung Ko: Nothing to disclose.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
55 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18term outcome after spontaneous HBeAg seroconversion in patients  with chronic hepatitis B. Hepatology 2002;35:1522-1527.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
56 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18history of chronic hepatitis type B throughout long-term follow-up.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
57 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.1885.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
58 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18Ba and Bj in Taiwan.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
National Cancer Screening Guideline  Revision web site < http://www.cancer.go.kr > National Cancer  Center-National Cancer Screening Guideline Revision Accessed  2015.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
59 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18advanced disease.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"60 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18sis, Update.",Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
61 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18201.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
62 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18with chronic hepatitis B. Gastroenterology 2009;136:486-495.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
63 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18sustained virologic response in hepatitis B and C. J Hepatol  2008;49:634-651.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
64 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.182005;10:727-734.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
65 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18303.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
66 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18adefovir-based combination therapy for patients with Lamivudine-  and entecavir-resistant chronic hepatitis B virus infection.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
67 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18antiviral treatment failure to adefovir in the absence of adefovir- resistant mutations J Hepatol 2008;48:391-398.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
68 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18et al.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
69 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18discontinuation.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
70 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18C.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
71 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18454.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
72 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18hemodialysis patient population.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
73 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18506.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
74 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.18Scand J Infect Dis 2003;35:814-819.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
75 The Korean Association for the Study of the Liver (KASL) Treatment guideline for hepatitis B http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.18al.,Non-OADS,/arxiv_data1/oa_pdf/8c/cc/cmh-22-1-18.PMC4825166.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.1 Clinical and Molecular Hepatology 2016;22:1-6 Review Corresponding author :  Richard Moreau Inserm, U1149, Centre de Recherche sur l’Inflammation (CRI), Faculté de  Médecine Bichat, 16 rue Henri Huchard, 75018 Paris, France Tel: +33-157277510, Fax: +33-157277471 E-mail: Richard.moreau@inserm.frAbbreviations:   ACLF, acute-on-chronic liver failure; AD, acute decompensation; CLIF,  chronic liver failure; CANONIC, EASL-CLIF Acute-oN-ChrONic liver  failure in cirrhosis; SOFA, Sequential Organ Failure Assessment; MELD,  Model for End-Stage Liver Disease; INR, International Normalized  Ratio; PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired  oxygen; SpO2, pulse oximetry saturation; HCV, hepatitis C virus; HBV,  hepatitis B virus; WCC, white-cell count; CRP , C-reactive protein; PRR,  pattern-recognition receptor; PAMP , pathogen-associated molecular  patterns; NOD, nucleotide-binding oligomerization domain; TLR, Toll- like receptor; DAMP , danger-associated molecular pattern Received :  Feb. 8, 2016 /  Accepted :  Feb. 15, 2016INTRODUCTION Patients with cirrhosis can rapidly develop an acute decompen - sation (AD), i.e., new onset ascites, hepatic encephalopathy, gas - trointestinal hemorrhage, bacterial infection, or any combination  of these.1 The development of AD usually leads patients to the  hospital.",Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
"(Clin Mol Hepatol 2016;22:1-6) Keywords:  Cirrhosis; Inflammation; Organ failures Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
"2 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.1observational study of patients with cirrhosis admitted for an AD.1  The results of this study allowed to establish an evidence-based  definition of ACLF and doing this clearly showed that ACLF is dis - tinct from mere AD, and is a new syndrome which is the final  common pathway driving patients with cirrhosis to death.1,10,11 The  aim of this review article is to comment on the novelty of the  ACLF syndrome described by the EASL-CLIF Consortium.",Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
"ACLF in cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.1pital for AD can be categorized into four different groups: no ACLF  (i.e., “mere” AD), ACLF grade 1, grade 2 and grade 3 (Table 2).1 The  diagnosis of absence or presence of ACLF is simple when the  number of organ failures is 0, 2, or 3 or more.",Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
4 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.1CONTEXTUAL FEATURES THAT DISTINGUISH  PATIENTS WITH ACLF Patients with ACLF are younger.,Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
"ACLF in cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.1some PRRs and trigger inflammation.19,20,25 An example of DAMP  released by necrotic cells is the non-histone protein high-mobility  group box 1 protein (HMGB1).",Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
6 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.116.,Non-OADS,/arxiv_data1/oa_pdf/fd/14/cmh-22-1-1.PMC4825167.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.192 Clinical and Molecular Hepatology 2016;22:192-197 Liver Imaging Corresponding author :  Woo Kyoung Jeong Department of Radiology and Center for Imaging Science, Samsung  Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon- ro, Gangnam-gu, Seoul 06351, Korea Tel: +82-2-3410-1923, Fax: +82-2-3410-0049 E-mail: jeongwk@gmail.comAbbreviations:   ADC, apparent diffusion coefficient; AFP , α-fetoprotein; ALT, alanine  aminotransferase; AST, aspartate aminotransferase; CA, carbohydrate antigen;  CEA, carcino-embryonic antigen; CK, cytokeratin; CT, computed tomography;  DWI, diffusion-weighted images; HCC, hepatocellular carcinoma; IPNB,  intraductal papillary neoplasm of the bile duct; MRCP , magnetic resonance  cholangiopancreaticography; MRI, magnetic resonance imaging; SI, signal  intensity; T1WI, T1-weighted images; T2WI, T2-weighted imagesINTRODUCTION  The spectrum of bile duct lesions ranges from benign tumors,  such as adenomas, papillomas, villous tumors and leiomyomas, to  malignant lesions, such as invasive intraductal papillary neoplasm  of the bile duct (IPNB) and intraductal cholangiocarcinomas.",Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
"However, two  years later, segmental intrahepatic bile duct dilatation in liver seg - ment 2 (S2) was depicted on the postoperative follow up abdomi - nal computed tomography (CT) scan and there was 4 cm low den - sity mass lesion around the dilated bile duct at the S2 periphery Intraductal malignant tumors in the liver mimicking  cholangiocarcinoma: Imaging features for differential  diagnosis Ah Yeong Kim and Woo Kyoung Jeong Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine,  Seoul, Korea Keywords:    Bile duct tumor; Intrabiliary metastasis; Intraductal growing hepatocellular carcinoma; Gadoxetic acid- enhanced MRI Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
Intraductal malignant tumors http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.192(Fig.,Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
"194 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.192Clin Mol Hepatol Volume _22  Number _1  March 2016bilirubin level was 17.2 mL/dL, and direct bilirubin was 12.9 mL/ dL.",Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
Intraductal malignant tumors http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.192Figure 3 .,Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
"196 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.192Clin Mol Hepatol Volume _22  Number _1  March 2016tion.1,2 Primary tumors that metastasize to the bile ducts include  cancers of the lung, breast, gallbladder, colon, testicle, prostate,  or pancreas; melanoma; and lymphoma.",Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
Intraductal malignant tumors http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.192from colon carcinoma in the bile duct: report of a case.,Non-OADS,/arxiv_data1/oa_pdf/1b/cc/cmh-22-1-192.PMC4825168.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.168 Clinical and Molecular Hepatology 2016;22:168-171 Case Report Corresponding author :  June Sung Lee Division of Gastroenterology, Department of Internal Medicine, Inje  University Ilsan Paik Hospital, 170 Juhwa-ro, Ilsanseo-gu, Goyang 10380,  Korea Tel: +82-31-910-7211, Fax: +82-31-910-7219 E-mail: jsleemd@paik.ac.krAbbreviations:   ALP , alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate  aminotransferase; CRP , C-reactive protein; CT, computed tomography;  HCV, hepatitis C virus; PEG-IFN-α, pegylated interferon alpha;   RBV, ribavirin; r-GT, gamma-glutamyl transpeptidase Received :  Aug. 11, 2014 /  Revised :  Sep. 17, 2014 /  Accepted :  Oct. 21, 2014INTRODUCTION  Hepatitis C virus (HCV) infection is a major cause of chronic liver  disease worldwide, and about 3% of the global population is esti - mated to have chronic HCV infection.1 Chronic HCV infection can  progress to liver cirrhosis in about 15-56% over periods of 20-25  years.",Non-OADS,/arxiv_data1/oa_pdf/ab/d8/cmh-22-1-168.PMC4825169.pdf
"(Clin Mol Hepatol 2016;22:168-171) Keywords:  Pegylated interferon alpha-2a; Pancreatitis; Hepatitis C virus Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ab/d8/cmh-22-1-168.PMC4825169.pdf
"Acute Pancreatitis After Pegylated Interferon-alpha-2a therapy http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.168that PEG-IFN- α-2b caused acute pancreatitis in a few cases.6,7  However, this is the first case of acute pancreatitis induced by  PEG-IFN-α-2a for chronic hepatitis C treatment in Korea.",Non-OADS,/arxiv_data1/oa_pdf/ab/d8/cmh-22-1-168.PMC4825169.pdf
"170 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.168creatitis was the first event after HCV treatment, aggravated after  readministration of PEG-IFN- α and RBV, and there was no recur - rence after stopping HCV treatment—she was highly likely to  have pancreatitis by PEG-IFN-α and RBV.",Non-OADS,/arxiv_data1/oa_pdf/ab/d8/cmh-22-1-168.PMC4825169.pdf
"Acute Pancreatitis After Pegylated Interferon-alpha-2a therapy http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.168Currently, the treatment of HCV is stopped in 10-20% of pa - tients due to serious side effects from a combined therapy of PEG- IFN-α and RBV; the dose is reduced in additional 20% to 30% of  patients.4,13,14 When adverse events such as leukopenia, thrombo - cytopenia, neuropsychiatric abnormality, and autoimmune diseas - es occur, drug administration should be modified or suspended.",Non-OADS,/arxiv_data1/oa_pdf/ab/d8/cmh-22-1-168.PMC4825169.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.152 Clinical and Molecular Hepatology 2016;22:152-159 Original Article Corresponding author :  Neung Hwa Park Department of Internal Medicine, Ulsan University Hospital, 877  Bangeojinsunhwando-ro, Dong-gu, Ulsan 44033, Korea Tel: +82-52-250-8845, Fax: +82-52-250-7048 E-mail: nhpark@uuh.ulsan.krAbbreviations:   ADV, adefovir; AE, adverse event; CHB, chronic hepatitis B; HBsAg,  hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular  carcinoma; LAM, lamivudine; PCR-RFLP , polymerase chain reaction- restriction fragment length polymorphism; PVR, partial virologic  response; RFMP , restriction fragment mass polymorphism; TDF,  tenofovir disoproxil fumarate; VBT, virologic breakthrough; VR, virologic  response Received :  Sep. 17, 2015 /  Revised :  Jan. 21, 2016 /  Accepted :  Feb. 11, 2016INTRODUCTION  Hepatitis B virus (HBV) infection is a serious public health prob - lem worldwide, with an estimated 2 billion infections, and a ma - jor cause of chronic hepatitis, cirrhosis, and hepatocellular carci - noma (HCC).1 Higher levels of HBV DNA are associated with an increased risk for hepatocellular carcinoma (HCC) and cirrhosis.2,3  Thus, lowering of HBV DNA levels from the highest levels has  been linked with a reduction in risk of both cirrhosis and HCC.4-7  Therefore, the goal of therapy in patients with chronic hepatitis B  (CHB) is rapid and sustained viral suppression.",Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
"(Clin Mol Hepatol 2016;22:152-159) Keywords:  Tenofovir; Lamivudine; Resistance; Chronic hepatitis B Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
TDF-based therapy in LAM-resistant CHB http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.152drugs have changed the treatment paradigm and prognosis of CHB.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
154 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.152and the absence of serum HBV DNA during treatment.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
TDF-based therapy in LAM-resistant CHB http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.152only one patient without a change in serum creatinine.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
156 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.152one in the TDF monotherapy group) during the treatment period.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
"TDF-based therapy in LAM-resistant CHB http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.152combination and monotherapy groups, and the TDF response was  not influenced by the presence of any resistance mutation.",Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
158 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.152Conflicts of Interest The authors have no conflicts to disclose.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
TDF-based therapy in LAM-resistant CHB http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.15227.,Non-OADS,/arxiv_data1/oa_pdf/55/0f/cmh-22-1-152.PMC4825170.pdf
"pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2016.22.1.177 Clinical and Molecular Hepatology 2016;22:177-182 Case Report Corresponding author :  Byung Ik Kim Department of Internal Medicine, Kangbuk Samsung Hospital,  Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno- gu, Seoul 03181, Korea Tel: +82-2-2001-8553, Fax: +82-2-2001-2610 E-mail: bik.kim@samsung.comAbbreviations:   CT, computed tomography; ENT, ear, nose and throat; SCC, squamous  cell carcinoma Received :  Jan. 13, 2015 /  Revised :  Apr.",Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
"(Clin Mol Hepatol 2016;22:177-182) Keywords:  Primary squamous cell carcinoma; Distant metastasis; Radiotherapy Copyright © 2016 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
"178 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.177have palpable lymph nodes on the head, neck, and inguinal area.",Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
Primary squamous cell carcinoma of the liver: a case report http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.177vein and bile duct.,Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
180 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.177Non-enhanced Chest CT from other hospital showed metas - tasis to the right ninth rib and surrounding paravertebral soft tis - sue with osteolytic change (Fig.,Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
Primary squamous cell carcinoma of the liver: a case report http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2016.22.1.177mous cell carcinoma (Fig.,Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
"182 http://www.e-cmh.orgClin Mol Hepatol Volume _22  Number _1  March 2016 http://dx.doi.org/10.3350/cmh.2016.22.1.177modality based on patient’s clinical status, and various therapy  including surgery, chemotherapy and radiotherapy for remis - sion and better prognosis.",Non-OADS,/arxiv_data1/oa_pdf/ca/ef/cmh-22-1-177.PMC4825171.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 4 http://e-eht.org/ Introduction Perfluorooctanesulfonic acid (PFOS), a perfluorinated com - pound, is a synthetic compound.",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"In South Korea (hereafter Ko - rea), the enforcement ordinance for the Persistent Organic Pol - lutants Control Act was revised on April 11, 2011, listing PFOS  and PFOS salts as persistent organic pollutants and strictly lim - iting their production, export, and use.Study on the biodegradation of  perfluorooctanesulfonate (PFOS) and PFOS  alternatives Bongin Choi1, Suk-Hyun Na1, Jun-Hyo Son1, Dong-Soo Shin2, Byung-T aek Ryu3,   Kyun-Suk Byeon2, Seon-Y ong Chung1 1Department of Environment and Energy Engineering, Chonnam National University College of Engineering, Gwangju;  2Department of Chemistry, Changwon National University, Changwon; 3Environmental Safety Center, Korea Environmental  Corporation, Incheon, Korea • Brief Report Open Access Environmental Health and Toxicology Volume: 31, Article ID: e2016002, 4 pages http://dx.doi.org/10.5620/eht.e2016002 eISSN: 2233-6567  Objectives  In this study, we investigated the biodegradation features of 4 perfluorooc - tanesulfonate (PFOS) alternatives developed at Changwon National University com - pared to those of PFOS.",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"Keywords  Perfluorooctanesulfonate, Alternatives, Persistent organic pollutantsCorrespondence:  Seon-Yong Chung  77 Yongbong-ro, Buk-gu, Gwangju 61186,  Korea  Tel: +82-62-530-1858 Fax: +82-62-530-0742 E-mail: sychung@jnu.ac.kr Received:  October 16, 2015 Accepted:  January 29, 2016 Published:  January 29, 2016 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"http://e-eht.org/ Page 2 of 4Environmental Health and Toxicology    2016;31:e2016002 Although 3M volutariliy suspended its PFOS production in  2002 and developed alternatives including perfluorobutanesul - fonate with a reduced number of carbon chains, a fully replaca - ble material for PFOS has not been developed.",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"http://e-eht.org/ Page 3 of 4Bong-In Choi, et al.",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"http://e-eht.org/ Page 4 of 4Environmental Health and Toxicology    2016;31:e2016002 Discussion  C8F17SO 3Na, the PFOS sodium salt, was not degraded by mi - croorganisms over the 28-day experimental period.",Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
ORCID Bongin Choi  http://orcid.org/0000-0002-4563-8337 Suk-Hyun Na  http://orcid.org/0000-0001-6148-7308 Jun-Hyo Son  http://orcid.org/0000-0002-3611-7193 Dong-Soo Shin  http://orcid.org/0000-0002-7948-0419 Byung-T aek Ryu  http://orcid.org/0000-0003-2931-6060 Kyun-Suk Byeon  http://orcid.org/0000-0002-2097-3825  Seon-Y ong Chung  http://orcid.org/0000-0001-8664-9625 References 1.,Non-OADS,/arxiv_data1/oa_pdf/34/fc/eht-31-e2016002.PMC4825188.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11 http://e-eht.org/ Introduction Malaria is a representative infectious disease that manifests as  a health effect of climate change in the tropical regions [1,2].",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"However, in some tropical ar - eas, incidence of malaria is expected to decrease in accordance Time trend of malaria in relation to climate  variability in Papua New Guinea Jae-Won Park1, Hae-Kwan Cheong2, Yasushi Honda3, Mina Ha4, Ho Kim5, Joel Kolam6,   Kasis Inape7, Ivo Mueller8 1Department of Microbiology, Graduate School of Medicine, Gachon University of Medicine and Science, Incheon; 2Department  of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, Suwon, Korea; 3Graduate School of  Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; 4Department of Preventive Medicine, Dankook  University College of Medicine, Cheonan; 5Department of Biostatistics and Epidemiology, Graduate School of Public Health,  and Institute of Public Health and Environment, Seoul National University, Seoul, Korea; 6National Department of Health,  Port Moresby; 7National Weather Service, Port Moresby; 8Papua New Guinea Institute of Medical Research, Goroka, Papua  New Guinea• Original ArticleOpen Access Environmental Health and Toxicology Volume: 31, Article ID: e2016003, 11 pages http://dx.doi.org/10.5620/eht.e2016003 eISSN: 2233-6567  Objectives  This study was conducted to describe the regional malaria incidence in rela - tion to the geographic and climatic conditions and describe the effect of altitude on the  expansion of malaria over the last decade in Papua New Guinea.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"Keywords  Climate change, Malaria, Asia-Pacific, Tropical area, Highland, Descriptive epi - demiology, Vector-borne diseases, Time trend Correspondence:  Hae-Kwan Cheong 2066 Seobu-ro, Jangan-gu, Suwon 16419,  Korea Tel: +82-31-299-6300 Fax:+82-31-299-6299 E-mail: hkcheong@skku.edu  Received:  October 15, 2015 Accepted:  February 17, 2016 Published:  February 25, 2016 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 2 of 11Environmental Health and Toxicology    2016;31:e2016003 with decreased rainfall, which represents reverse direction of fa - vorable health effects of climate change, according to the Inter - governmental Panel on Climate Change [6].",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 3 of 11Jae-Won Park, et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
http://e-eht.org/ Page 4 of 11Environmental Health and Toxicology    2016;31:e2016003 mate trend in PNG.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 5 of 11Jae-Won Park, et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
http://e-eht.org/ Page 6 of 11Environmental Health and Toxicology    2016;31:e2016003 Province.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 7 of 11Jae-Won Park, et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 8 of 11Environmental Health and Toxicology    2016;31:e2016003 ready high enough to support malaria transmission [4,21].",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
ORCID Jae-Won Park  http://orcid.org/ 0000-0002-5959-7628 Hae-Kwan Cheong  http://orcid.org/0000-0003-2758-9399 Yasushi Honda  http://orcid.org/0000-0003-2248-1629 Mina Ha  http://orcid.org/000-0003-1011-9446 Ho Kim  http://orcid.org/0000-0001-7472-3752 Ivo Mueller  http://orcid.org/0000-0001-6554-6889 References 1.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
Available from: http://www.who.int/malaria/publi - cations/world_malaria_report_2012/en/.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
Available from: http://www.ipcc.ch/ipccreports/sres/region -,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 9 of 11Jae-Won Park, et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
Available from: http://www.who.int/malaria/publi - cations/world-malaria-report-2015/en/.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
http://e-eht.org/ Page 10 of 11Environmental Health and Toxicology    2016;31:e2016003 Figure S1.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"http://e-eht.org/ Page 11 of 11Jae-Won Park, et al.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/eht-31-e2016003.PMC4825189.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 2 http://e-eht.org/ Humidifier disinfectant was added to the humidifier water  tank to keep the water sterile.",Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
"This is especially true for the effects on Humidifier disinfectants, unfinished stories Y eyong Choi1, Domyung Paek2 1Asian Citizen’s Center for Environment and Health, Seoul; 2Graduate School of Public Health, Seoul National University,  Seoul, Korea• Editorial Open Access Environmental Health and Toxicology Volume: 31, Article ID: e2016004, 2 pages http://dx.doi.org/10.5620/eht.e2016004 eISSN: 2233-6567  Once released into the air, humidifier disinfectants became tiny nano-size particles, and  resulted in chemical bronchoalveolitis.",Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
"Keywords   Humidifier disinfectant, Upper airway disease, Systemic toxicityCorrespondence:  Domyung Paek 1 Gwanak-ro, Gwanak-gu, Seoul 08826,  Korea Tel: +82-2-880-2733 Fax: +82-2-743-8240 Email: paekdm@snu.ac.kr  Received:  January 17, 2016 Accepted:  January 26, 2016 Published:  February 28, 2016 This article is available from: http://e-eht.org/",Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
"http://e-eht.org/ Page 2 of 2Environmental Health and Toxicology    2016;31:e2016004 the upper airways, such as asthma and sinusitis, as these macro - molecules were shown to exert their biocidal effects by irritating  microbial cell membranes [7].",Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
ORCID Domyung Paek http://orcid.org/0000-0003-4510-6362References  1.,Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
Available from: http://eco-health.org/bbs/board.php?bo_table  =sub02_04&wr_id=160 (Korean).,Non-OADS,/arxiv_data1/oa_pdf/67/5f/eht-31-e2016004.PMC4825190.pdf
"Copyright © 2016 The Korean Society of Environmental Health and Toxicology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 4 http://e-eht.org/ Are we being exposed to radiation in the hospital?",Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
"Y eonghee Kim Sunflower-Korean Association of Lawyers Against Nuclear Power Plants Representative • News and VoicesOpen Access Environmental Health and Toxicology Volume: 31, Article ID: e2016005, 4 pages http://dx.doi.org/10.5620/eht.e2016005 eISSN: 2233-6567  Unconsented Harms of Medical Radiation  Need to Be Explained X-rays or computed tomography (CT) scans are performed  frequently in the hospital for health examination or treatment  purposes.",Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
"UNSCEAR 2008 report to the General Assembly, with scientific  annexes (http://www.unscear.org/unscear/en/publications/2008_1.html).",Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
http://e-eht.org/ Page 2 of 4Environmental Health and Toxicology    2016;31:e2016005 Table 2.,Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
National implementation of patient dose monitoring system for CT scan; 2014 Jan 22 (http://www.mfds.go.kr/index.,Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
http://e-eht.org/ Page 3 of 4Yeonghee Kim  | Are we being exposed to radiation in the hospital?,Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
"http://e-eht.org/ Page 4 of 4Environmental Health and Toxicology    2016;31:e2016005 Nonetheless, until as of the present (the end of December,  2015) the system has not been enacted into law.",Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
"ORCID Y eonghee Kim http://orcid.org/0000-0002-8411-9134 The article is the English version of an article that was pub - lished in Catholic News, Here and Now .",Non-OADS,/arxiv_data1/oa_pdf/20/ce/eht-31-e2016005.PMC4825191.pdf
"148  Ultrasonography 35(2), April 2016 e-ultrasonography.orgComparison of needle aspiration and  vacuum-assisted biopsy in the ultrasound-guided drainage of lactational breast abscesses Yun-Dan Kang1, You Me Kim2 Departments of 1Obstetrics and Gynecology and 2Diagnostic Radiology, Dankook University  College of Medicine, Cheonan, Koreahttp://dx.doi.org/10.14366/usg.15041 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:148-152 Purpose: The purpose of this study was to compare needle aspiration and vacuum-assisted  biopsy in the ultrasound-guided treatment of lactational breast abscesses.",Non-OADS,/arxiv_data1/oa_pdf/f9/02/usg-15041.PMC4825204.pdf
"+82-41-552-9674 E-mail: sirenos@hanmail.netORIGINAL ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/f9/02/usg-15041.PMC4825204.pdf
ORCID: Yun-Dan Kang: http://orcid.org/0000-0003-1411-5485; You Me Kim:  http://orcid.org/0000-0001-5807-9012 Conflict of Interest No potential conflict of interest relevant to this article was reported.,Non-OADS,/arxiv_data1/oa_pdf/f9/02/usg-15041.PMC4825204.pdf
"104  Ultrasonography 35(2), April 2016 e-ultrasonography.orgUsefulness of strain elastography of the  musculoskeletal system Su Ji Kim, Hee Jin Park, So Yeon Lee Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of  Medicine, Seoul, Korea http://dx.doi.org/10.14366/usg.15072 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:104-109 Received: November 5, 2015 Revised: December 21, 2015Accepted: December 23, 2015 Correspondence to: Hee Jin Park, MD, Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/a2/b1/usg-15072.PMC4825205.pdf
"+82-2-2001-1030  E-mail: parkhiji@gmail.comREVIEW ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/a2/b1/usg-15072.PMC4825205.pdf
ORCID: Su Ji Kim: http://orcid.org/0000-0002-1721-3489; Hee Jin Park: http://orcid.,Non-OADS,/arxiv_data1/oa_pdf/a2/b1/usg-15072.PMC4825205.pdf
org/0000-0002-3135-0586; So Yeon Lee: http://orcid.org/0000-0002-0109-0998 Conflict of Interest No potential conflict of interest relevant to this article was reported.,Non-OADS,/arxiv_data1/oa_pdf/a2/b1/usg-15072.PMC4825205.pdf
" Ultrasonography 35(2), April 2016 e-ultrasonography.org164Signet-ring cell carcinoma of the  appendix: a case report with an emphasis on sonographic findings Young Jong Cho1, Hyuk Jung Kim1, Suk Ki Jang1, Jae Woo Yeon1, Ki Ho Kim2, So Ya Paik3 Departments of 1Radiology, 2Surgery, and 3Diagnostic Pathology, Daejin Medical Center,  Bundang Jesaeng General Hospital, Seongnam, Koreahttp://dx.doi.org/10.14366/usg.15063 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:164-167 In this report, we present a rare case of primary signet-ring cell carcinoma of the appendix  in a 51-year-old woman with right lower quadrant pain.",Non-OADS,/arxiv_data1/oa_pdf/fe/9a/usg-15063.PMC4825206.pdf
"+82-31-779-0062E-mail: hyukjungk@naver.comCASE REPORT This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/fe/9a/usg-15063.PMC4825206.pdf
ORCID: Young Jong Cho: http://orcid.org/0000-0003-2881-9221; Hyuk Jung Kim:  http://orcid.org/0000-0002-4629-4142; Suk Ki Jang: http://orcid.org/0000-0002- 8625-7573; Jae Woo Yeon: http://orcid.org/0000-0002-1612-6279; Ki Ho Kim: http:// orcid.org/0000-0003-0100-7936; So Ya Paik: http://orcid.org/0000-0003-4707-574X Conflict of Interest No potential conflict of interest relevant to this article was reported.References  1.,Non-OADS,/arxiv_data1/oa_pdf/fe/9a/usg-15063.PMC4825206.pdf
"124  Ultrasonography 35(2), April 2016 e-ultrasonography.orgUltrasonographic findings of low-grade  endometrial stromal sarcoma of the uterus with a focus on cystic degeneration Ga Eun Park1, Sung Eun Rha1, Soon Nam Oh1, Ahwon Lee2, Keun Ho Lee3, Mee-Ran Kim3 Departments of 1Radiology, 2Hospital Pathology, and 3Obstetrics and Gynecology, Seoul St.  Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Koreahttp://dx.doi.org/10.14366/usg.15045 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:124-130 Purpose: The goal of this study was to perform a retrospective analysis of the ultrasonographic  findings associated with low-grade endometrial stromal sarcoma.",Non-OADS,/arxiv_data1/oa_pdf/06/c3/usg-15045.PMC4825207.pdf
"+82-2-599-6771 E-mail: serha@catholic.ac.kr ORIGINAL ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/06/c3/usg-15045.PMC4825207.pdf
"Ga Eun Park, et al.130  Ultrasonography 35(2), April 2016 e-ultrasonography.orgORCID: Ga Eun Park: http://orcid.org/0000-0002-2479-6950; Sung Eun Rha:  http://orcid.org/0000-0003-1514-929X; Soon Nam Oh: http://orcid.org/0000-0003-2373-7024; Ahwon Lee: http://orcid.org/0000-0002-2523-9531; Keun Ho Lee: http://orcid.org/0000-0001-9005-7796; Mee-Ran Kim: http://orcid.org/0000-0003-4492-0768 Conflict of Interest  No potential conflict of interest relevant to this article was reported.",Non-OADS,/arxiv_data1/oa_pdf/06/c3/usg-15045.PMC4825207.pdf
"e-ultrasonography.org Ultrasonography 35(2), April 2016153Thyroid nodules with minimal cystic  changes have a low risk of malignancy Dong Gyu Na1, Ji-hoon Kim2, Dae Sik Kim1,3, Soo Jin Kim1,4 1Department of Radiology, Human Medical Imaging and Intervention Center, Seoul;  2Department of Radiology, Seoul National University Hospital, Seoul National University  College of Medicine, Seoul; 3Department of Radiology, Incheon Medical Center, Incheon;  4Department of Radiology, New Korea Hospital, Gimpo, Korea http://dx.doi.org/10.14366/usg.15070 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:153-158 Purpose: The goal of this study was to determine the risk of malignancy of thyroid nodules with  minimal cystic changes.",Non-OADS,/arxiv_data1/oa_pdf/21/32/usg-15070.PMC4825208.pdf
"+82-2-512-6646 E-mail: nndgna@gmail.comORIGINAL ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/21/32/usg-15070.PMC4825208.pdf
ORCID: Dong Gyu Na: http://orcid.org/0000-0001-6422-1652; Ji-hoon Kim: http:// orcid.org/0000-0002-6349-6950; Dae Sik Kim: http://orcid.org/0000-0001-8424- 8561; Soo Jin Kim: http://orcid.org/0000-0001-8233-1388 Conflict of Interest No potential conflict of interest relevant to this article was reported.,Non-OADS,/arxiv_data1/oa_pdf/21/32/usg-15070.PMC4825208.pdf
http://dx.doi.org/10.1089/thy.2015.0020.,Non-OADS,/arxiv_data1/oa_pdf/21/32/usg-15070.PMC4825208.pdf
Available from: http://www.nccn.org/.,Non-OADS,/arxiv_data1/oa_pdf/21/32/usg-15070.PMC4825208.pdf
"e-ultrasonography.org Ultrasonography 35(2), April 2016159Non-puerperal mastitis masking  pre-existing breast malignancy: importance of follow-up imaging Jin Kyung An1, Jeong Joo Woo1, Seung A Lee2 Departments of 1Radiology and 2Surgery, Eulji General Hospital, Eulji University School of  Medicine, Seoul, Koreahttp://dx.doi.org/10.14366/usg.15024 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:159-163 Mastitis is an inflammatory condition of the breast with common symptoms of pain, swelling,  erythema, warmth, and fever.",Non-OADS,/arxiv_data1/oa_pdf/4e/fa/usg-15024.PMC4825209.pdf
"+82-2-970-8346 E-mail: jkan0831@eulji.ac.krCASE REPORT This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/4e/fa/usg-15024.PMC4825209.pdf
ORCID: Jin Kyung An: http://orcid.org/0000-0003-1086-426X; Jeong Joo Woo:  http://orcid.org/0000-0002-4669-6176; Seung A Lee: http://orcid.org/0000-0003-2435-1254 Conflict of Interest No potential conflict of interest relevant to this article was reported.,Non-OADS,/arxiv_data1/oa_pdf/4e/fa/usg-15024.PMC4825209.pdf
"e-ultrasonography.org Ultrasonography 35(2), April 201689International guidelines for  contrast-enhanced ultrasonography: ultrasound imaging in the new millennium Christian Pállson Nolsøe, Torben Lorentzen Ultrasound Section, Department of Gastric Surgery, Herlev Hospital, University of  Copenhagen, Herlev, Denmarkhttp://dx.doi.org/10.14366/usg.15057 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:89-103 The intent of this review is to discuss and comment on common clinical scenarios in which  contrast-enhanced ultrasonography (CEUS) may play a decisive role and to illustrate important points with typical cases.",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"+45-38144189 E-mail: cnolsoe@dadlnet.dkREVIEW ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"ORCID: Christian Pállson Nolsøe: http://orcid.org/0000-0003-0168-6131 Abbreviations:  AFSUMB, Asian Federation of Societies for  Ultrasound in Medicine and Biology; AIUM, American Institute of Ultrasound in Medicine; ASUM, Australasian Society for Ultrasound in Medicine; CEUS, contrast-enhanced ultrasonography; CT, computed tomography; EFSUMB, European Federation of Societies for Ultrasound in Medicine and Biology; FLAUS, Latin American Federation of Societies for Ultrasound in Medicine and Biology; FLL, focal liver lesion; HCC, hepatocellular carcinoma; ICUS, International Contrast Ultrasound Society; MRI, magnetic resonance imaging; Fig.",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"In the arterial phase, the hyperechoic lesion shows  globular filling-in contrast enhancement, whereas the hypoechoic  lesion demonstrated arterial hyperenhancement (http://dx.doi.org/10.14366/usg.15057.v001).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"During the portal phase, the hyperechoic lesion  continues the same pattern of contrast filling-in enhancement, whereas the hypoechoic lesion shows a contrast wash-out pattern, thus confirming the B-mode diagnosis of hemangioma and metastasis (http://dx.doi.org/10.14366/usg.15057.v002).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"During the late phase, the same contrast enhancement  pattern as in Video clip 2C continues (http://dx.doi.org/10.14366/usg.15057.v003).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"Contrast-enhanced ultrasonography sequence  illustrates arterial contrast uptake with very early (before normal liver tissue) enhancement of the central lesion with a centrifugal pattern, a feeding artery consistent with the focal nodular hyperplasia arterial pattern, and the slower centripetal globular filling-in enhancement pattern of the larger lesion consistent with the arterial pattern of hemangioma (http://dx.doi.org/10.14366/usg.15057.v004).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"Contrast-enhanced ultrasonography sequence  captured immediately after Video clip 4, illustrates arterial contrast uptake with slow centripetal globular filling-in enhancement pattern of another more peripherally located lesion consistent with the arterial pattern of hemangioma (http://dx.doi.org/10.14366/usg.15057.v005).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"Contrast-enhanced ultrasonography from the portal  phase shows the typical slow filling-in of a large hemangioma in which the central areas do not display enhancement, likely due to necrosis and scarring, as well as the sustained hyperenhancement of focal nodular hyperplasia (http://dx.doi.org/10.14366/usg.15057.v006).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"A contrast-enhanced ultrasonography sequence  in the parenchymal phase shows the typical slow filling-in of a large hemangioma in which the central areas do not display enhancement, as well as the sustained hyperenhancement of focal nodular hyperplasia, with both features extending long into the parenchymal phase (http://dx.doi.org/10.14366/usg.15057.v007).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"In a patient of minor spleen trauma, contrast- enhanced ultrasonography of the left flank clearly shows a small hematoma in the lower pole of the spleen (http://dx.doi.org/10.14366/usg.15057.v008).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"In addition, a minor laceration is present in the spleen parenchyma near the medial-cranial pole, which is not as clearly visualized in the sonogram as in the corresponding fused CT (http://dx.doi.org/10.14366/usg.15057.v009).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"A fused contrast-enhanced ultrasonography and  computed tomography image clearly demonstrates the small laceration, and also confirms that no extravasation of the ultrasound contrast agent was present, thus demonstrating that bleeding from the spleen had ceased (http://dx.doi.org/10.14366/usg.15057.v010).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"A contrast-enhanced sonogram in the arterial  phase performed in our unit demonstrates arterial enhancement, which is slightly delayed and slightly hypoenhancing compared to the surrounding normal spleen tissue (http://dx.doi.org/10.14366/usg.15057.v011).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"By a contrast-enhanced ultrasonography-guided  biopsy, the final diagnosis was splenoma, a benign hamartoma-like tumor of the spleen (http://dx.doi.org/10.14366/usg.15057.v012).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
A Sonazoid contrast-enhanced ultrasonography  shows arterial hyperenhancement with earlier onset than the surrounding liver tissue (please note that there is in addition a simple cyst in the patients right upper corner of the Video clip which appears typically totally non-enhancing and echopoor) (http://dx.doi.org/10.14366/usg.15057.v013).,Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
A Sonazoid contrast-enhanced ultrasonongraphy- guided 1.2-mm TruCut biopsy of an isoenhancing lesion in the postvascular phase at 13 minutes post-contrast revealed well-differentiated hepatocellular carcinoma (http://dx.doi.org/10.14366/usg.15057.v014).,Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
A Sonazoid contrast-enhancing ultrasonography  shows sustained isoenhancement in the postvascular phase at 31  minutes post-contrast (http://dx.doi.org/10.14366/usg.15057.v015).,Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"SonoVue contrast-enhanced ultrasonography shows  a well-demarcated ablation cavity without any enhancement, indicating successful ablation with no suspicion of skipped areas and no viable tissue (http://dx.doi.org/10.14366/usg.15057.v016).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"After the reinjection of SonoVue, a contrast- enhanced ultrasonography-guided cytology biopsy was directed towards the suspected recurrence area, and microscopy confirmed the diagnosis of local recurrence (http://dx.doi.org/10.14366/usg.15057.v017).",Non-OADS,/arxiv_data1/oa_pdf/23/bb/usg-15057.PMC4825210.pdf
"140  Ultrasonography 35(2), April 2016 e-ultrasonography.orgDiabetic mastopathy: imaging features  and the role of image-guided biopsy in its diagnosis Jonghyeon Kim, Eun-Kyung Kim, Min Jung Kim, Hee Jung Moon, Jung Hyun Yoon Department of Radiology, Research Institute of Radiological Science, Yonsei University  College of Medicine, Seoul, Korea http://dx.doi.org/10.14366/usg.15052 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:140-147 Purpose: The goal of this study was to evaluate the imaging features of diabetic mastopathy (DMP)  and the role of image-guided biopsy in its diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/3a/c6/usg-15052.PMC4825211.pdf
"+82-2-393-3035 E-mail: ekkim@yuhs.ac ORIGINAL ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/3a/c6/usg-15052.PMC4825211.pdf
"DMP: imaging features and the role of core biopsy e-ultrasonography.org Ultrasonography 35(2), April 2016147ORCID: Jonghyeon Kim: http://orcid.org/0000-0001-6155-198X; Eun-Kyung Kim:  http://orcid.org/0000-0002-3368-5013; Min Jung Kim: http://orcid.org/0000-0003-4949-1237; Hee Jung Moon: http://orcid.org/0000-0002-5643-5885; Jung Hyun Yoon: http://orcid.org/0000-0002-2100-3513 Conflict of Interest No potential conflict of interest relevant to this article was reported.",Non-OADS,/arxiv_data1/oa_pdf/3a/c6/usg-15052.PMC4825211.pdf
"110  Ultrasonography 35(2), April 2016 e-ultrasonography.orgCurrent status of ultrasonography of   the finger Seun Ah Lee1, Baek Hyun Kim1, Seon-Jeong Kim2, Ji Na Kim3, Sun-Young Park4,  Kyunghee Choi5  1Department of Radiology, Korea University Ansan Hospital, Korea University College of  Medicine, Ansan; 2Department of Radiology, Myongji Hospital, Seonam University College  of Medicine, Goyang; 3Department of Radiology, Chungnam National University Hospital,  Chungnam National University School of Medicine, Daejeon; 4Department of Radiology,  Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang;  5Department of Radiology, Incheon Baek Hospital, Incheon, Koreahttp://dx.doi.org/10.14366/usg.15051 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:110-123 The recent development of advanced high-resolution transducers has enabled the fast, easy, and  dynamic ultrasonographic evaluation of small, superficial structures such as the finger.",Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
"+82-31-412-5226 E-mail: kimbaekh@hanmail.netREVIEW ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
"US of the finger e-ultrasonography.org Ultrasonography 35(2), April 2016123ORCID: Seun Ah Lee: http://orcid.org/0000-0002-6190-5503; Baek Hyun Kim:  http://orcid.org/0000-0002-3284-1803; Seon-Jeong Kim: http://orcid.org/0000-0001-9064-7155; Ji Na Kim: http://orcid.org/0000-0002-1877-9273; Sun-Young Park: http://orcid.org/0000-0001-6500-3411; Kyunghee Choi: http://orcid.org/0000-0003-1287-6379 Conflict of Interest  No potential conflict of interest relevant to this article was reported.",Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
"Since the sagittal band prevents  deviation of the extnesor tendon during metacarpophalangeal joint  flexion and bowstring during hyperextension, sagittal band injury causes extensor tendon dislocation during flexion (http://dx.doi.org/10.14366/usg.15051.v001).",Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
"If the examiner  moves the distal phalanx only, while locking the middle phalanx, the flexor digitorum profundus tendon can be seen to glide under a stationary flexor digitorum superficialis tendon (http://dx.doi.org/10.14366/usg.15051.v002).",Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
Dynamic ultrasonography can  visualize the locking and snapping of the flexor tendon at the metacarpophalangeal joint level (http://dx.doi.org/10.14366/usg.15051.v003).,Non-OADS,/arxiv_data1/oa_pdf/45/33/usg-15051.PMC4825212.pdf
"e-ultrasonography.org Ultrasonography 35(2), April 2016131Hyalinizing trabecular tumor of the  thyroid: diagnosis of a rare tumor using ultrasonography, cytology, and intraoperative frozen sections  Hyunsik Jang1, Cheol Keun Park2, Eun Ju Son3, Eun-Kyung Kim1, Jin Young Kwak1,   Hee Jung Moon1, Jung Hyun Yoon1  1Department of Radiology, Research Institute of Radiological Science, Severance Hospital,  Seoul; 2Department of Pathology, 3Department of Radiology, Gangnam Severance Hospital,  Yonsei University College of Medicine, Seoul, Koreahttp://dx.doi.org/10.14366/usg.15054 pISSN: 2288-5919 • eISSN: 2288-5943 Ultrasonography 2016;35:131-139 Purpose: The goal of this study was to evaluate the clinicopathological and imaging features of  thyroid nodules surgically diagnosed as hyaline trabecular tumor (HTT), and to assess the role of  cytology and frozen sections (FS) in the diagnosis of HTT.Methods: This study included 21 thyroid nodules in 21 patients treated from August 2005 to  March 2015 (mean age, 53.3 years) who were either diagnosed as HTT or had HTT suggested as a possible diagnosis based on cytology, FS, or the final pathology report.",Non-OADS,/arxiv_data1/oa_pdf/79/ab/usg-15054.PMC4825213.pdf
"+82-2-393-3035 E-mail: lvjenny@yuhs.acORIGINAL ARTICLE This is an Open Access article distributed under the  terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/79/ab/usg-15054.PMC4825213.pdf
ORCID: Hyunsik Jang: http://orcid.org/0000-0002-2495-2140; Cheol Keun Park:  http://orcid.org/0000-0001-7689-0386; Eun Ju Son: http://orcid.org/0000-0002-7895-0335; Eun-Kyung Kim: http://orcid.org/0000-0002-3368-5013; Jin Young Kwak: http://orcid.org/0000-0002-6212-1495; Hee Jung Moon: http://orcid.org/0000-0002-5643-5885; Jung Hyun Yoon: http://orcid.org/0000-0002-2100-3513 Conflict of Interest No potential conflict of interest relevant to this article was reported.,Non-OADS,/arxiv_data1/oa_pdf/79/ab/usg-15054.PMC4825213.pdf
Childhood im- munisation –Immunise4life (http://www.immunise4life.,Non-OADS,/arxiv_data1/oa_pdf/b6/09/S0950268815002393a.PMC4825214.pdf
Vaccination (http://www.cdc.gov.tw/page.aspx?treeid=D78DE698C2E70A89&nowtreeid=9D2E1B3A862F06FB).,Non-OADS,/arxiv_data1/oa_pdf/b6/09/S0950268815002393a.PMC4825214.pdf
Schedule regular childhood vaccines (http://www.pidst.net/A385.html).,Non-OADS,/arxiv_data1/oa_pdf/b6/09/S0950268815002393a.PMC4825214.pdf
"This was admixed with severe, violent, arrhythmic, and large amplitude movements of the proximal limb withFreely available online Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/d7/1b/tre-06-359-7522-1.PMC4825330.pdf
A Rare Case of Ipsilateral Hemichorea-hemiballism Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services2,Non-OADS,/arxiv_data1/oa_pdf/d7/1b/tre-06-359-7522-1.PMC4825330.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/d7/1b/tre-06-359-7522-1.PMC4825330.pdf
A Rare Case of Ipsilateral Hemichorea-hemiballism Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/d7/1b/tre-06-359-7522-1.PMC4825330.pdf
Tremor and Other Hyperkinetic Movements http://www.tremor journal.or gThe Center for Digital Research and ScholarshipColumbia Universit y Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/d7/1b/tre-06-359-7522-1.PMC4825330.pdf
"http://surgicalneurologyint.com/Using-intrinsic-and-extrinsic-motivation-in- continuing-professional-education/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/c4/dc/SNI-7-197.PMC4825346.pdf
"Access this article online Quick Response Code: Website:    www.surgicalneurologyint.com DOI:    10.4103/2152-7806.179231  Editor: Mona Stecker,   Winthrop University Hospital,   Mineola, NY 11501, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.com",Non-OADS,/arxiv_data1/oa_pdf/c4/dc/SNI-7-197.PMC4825346.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: Mona Stecker,   Winthrop University Hospital,   Mineola, NY 11501, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: Neuroscience Nursing, a supplement to Surgical Neurology InternationalS196Nursing is a profession.",Non-OADS,/arxiv_data1/oa_pdf/30/22/SNI-7-196.PMC4825347.pdf
"http://surgicalneurologyint.com/Exhibiting-pride-in-the-profession:-Making-the-case- for-continued-professional-development/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/30/22/SNI-7-196.PMC4825347.pdf
"Editor: Mona Stecker,  Winthrop University Hospital,   Mineola, NY 11501, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: Neuroscience Nursing, a supplement to Surgical Neurology International © 2016 Surgical Neurology International | Published by Wolters Kluwer - Medknow S185S185Abstract Background: Brain tumor patients often present with neurological changes in  the presence of cerebral edema.",Non-OADS,/arxiv_data1/oa_pdf/19/93/SNI-7-185.PMC4825348.pdf
"http://surgicalneurologyint.com/Collaboration-in-the-presence-of-cerebral-edema:-The-complications-of-steroids/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and  build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/19/93/SNI-7-185.PMC4825348.pdf
Available  from: http://www.aann.org/pubs/content/guidelines.html.,Non-OADS,/arxiv_data1/oa_pdf/19/93/SNI-7-185.PMC4825348.pdf
Available from: http://www.researchgate.net/profile/Robin_Newhouse/ publication/8083076_Evidence‑based_practice_a_practical_approach_to_ implementation/links/00b49519e00eb63b6d000000.pdf.,Non-OADS,/arxiv_data1/oa_pdf/19/93/SNI-7-185.PMC4825348.pdf
"© 2016 Surgical Neurology International | Published by Wolters Kluwer - MedknowEditor: Mona Stecker,   Winthrop University Hospital,   Mineola, NY 11501, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comSNI: Neuroscience Nursing, a supplement to Surgical Neurology InternationalS190INTRODUCTION Intracranial tumors are one of the common causes  of mortality and morbidity worldwide.",Non-OADS,/arxiv_data1/oa_pdf/ef/bc/SNI-7-190.PMC4825349.pdf
"http://surgicalneurologyint.com/Trends-in-cognitive-dysfunction-following-surgery- for-intracranial-tumors/This is an open access article distributed under the terms of the Creative Commons  Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix,  tweak, and build upon the work non-commercially, as long as the author is credited and  the new creations are licensed under the identical terms.",Non-OADS,/arxiv_data1/oa_pdf/ef/bc/SNI-7-190.PMC4825349.pdf
Available from: http://www.seer.cancer.gov/ csr/1975_2011/.,Non-OADS,/arxiv_data1/oa_pdf/ef/bc/SNI-7-190.PMC4825349.pdf
targetscan.org/vert_61/) or MicroCosm Targets version 5 (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) was used to identify transcripts bioinformatically predicted to be targets of miRNAs of interest based on complementarity to the seed region asdescribed in Supplementary methods.,OADS,/arxiv_data1/oa_pdf/ef/7d/ACER-40-826.PMC4825401.pdf
"Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1256_allegato.pdf (accessed July 28, 2015).",Non-OADS,/arxiv_data1/oa_pdf/b7/4a/APA-105-e200.PMC4825404.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/14/2b/evw008.PMC4825418.pdf
Supplementary Material Supplementary ﬁgures S1–S3 andtable S1 are available at Genome Biology and Evolution online ( http://www.gbe.,OADS,/arxiv_data1/oa_pdf/14/2b/evw008.PMC4825418.pdf
"Available from: http://www.phe-culturecollections.org.uk/products/bacteria/detail.jsp?refId=NCTC+8164&collection=nctc Pupo GM, Karaolis DK, Lan R, Reeves PR.",Non-OADS,/arxiv_data1/oa_pdf/14/2b/evw008.PMC4825418.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a6/ca/evw010.PMC4825419.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/a0/evw013.PMC4825420.pdf
"Accepted: January 28, 2016 Data deposition: This project has been deposited at at Dryad under the accession address http://dx.doi.org/10.5061/dryad.hq669 .",Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
The population genetic data and methods can be found in the digital repository http://dx.doi.org/10.5061/dryad.,OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
"R package version 3.1- 119, http://CRAN.R-project.org/package=nlme , last accessed February 18, 2016).",Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
Supplementary Material Supplementary tables S1 and S2 a r ea v a i l a b l ea t Genome Biology and Evolution online (http://www.gbe.oxfordjour nals.org/ ).,Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
Available from: https://www.R-project.org/ R Core Team 2015.,Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
"Availablefrom: https://www.R-project.org/ Raikhel AS, Dhadialla TS.",Non-OADS,/arxiv_data1/oa_pdf/0c/ad/evw014.PMC4825421.pdf
"Cell Cycle 2015; 14(14); PMID: 26131730; http:/dx.doi.org/1 0.1080/15384101.2015.1049782 Imre Gombos and L /C19aszl/C19oV/C19ıgh*; Institute of Biochemistry; Biological Research Centre; Hungarian Academy of Sciences; Szeged, Hungary; *Correspondence to L/C19aszl/C19oV/C19ıgh; Email: vigh@brc.hu; http://dx.doi.org/10.1080/15384101.2015.1069506; /C211Imre Gombos and L /C19aszl/C19oV/C19ıgh; This is an Open Access article distrib- uted under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which per mits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Semin Immunol 2000 12:23-34; PMID:10723795; http://dx.doi.org/10.1006/smim.,Non-OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Semin Immunol 2005 17:23-33; PMID:15582486; http://dx.doi.org/10.1016/j.smim.,Non-OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
J Immunol 2002 168:2233-9; PMID:11859110; http://dx.doi.org/10.4049/jimmunol.,Non-OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Immunity 2002 17:303-15; PMID:12354383; http://dx.doi.org/10.1016/S1074- 7613(02)00396-5.,OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Biochim Biophys Acta 2014 1838: 546-56; PMID:23680625; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Biochim Biophys Acta 2014 1838:1594- 618; PMID:24374314; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
Trends Biochem Sci 2007 32:357-63; PMID:17629486; http://dx.doi.org/10.1016/j.tibs.,OADS,/arxiv_data1/oa_pdf/45/59/kccy-14-19-1069506.PMC4825518.pdf
"Cell Cycle 2015; 14(15):2473-84; PMID:26083678; http://dx.doi.org/10.1080/15384101.2015.1060381 Hanspeter Naegeli; Institute of Pharmacology and Toxicology; University of Zurich-Vetsuisse; Zurich, Switzerland; Email: naegelih@vetpharm.uzh.ch; http://dx.doi.org/10.1080/15384101.2015.1071140 Exonuclease 1 (EXO1) is one of several nucleic acid-trimming enzymes required for the repair of double strand breaks that con-stitute the most toxic form of DNA damage.By resecting DNA ends, this processive 5 0to 30exonuclease helps to produce recombi- nogenic 30overhangs, which are than cap- tured by the homologous recombinationmachinery to repair double strand breaks, i.e., to reestablish an intact DNA double helix.",Non-OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
"Upon substrate engagement andresection, EXO1 is ubiquitinated and delivered to proteasomal destruction.© Hanspeter Naegeli This is an Open Access article distributed under theterms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
DNA Rep 2009; 8:983-95; PMID:19473888; http://dx.doi.org/10.1016/j.dnarep.2009.04.017 2.,OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
Cell Cycle 2015; 14(15):2473-84; http://dx.doi.org/10.1080/15384101.2015.1060381 3.,OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
Sci Signal 2011; 4:rs4; PMID: 21693764; http://dx.doi.org/10.1126/scisignal.2001484 4.,OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
Nat Struct Mol Biol 2014; 21:927-36; PMID:25218447; http://dx.doi.org/ 10.1038/nsmb.2890 5.,OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
Nature 2009; 462:935-39; PMID:20016603; http://dx.doi.org/10.1038/ nature08657 6.,Non-OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
Trends Biochem Sci 2015; 40:233-42; PMID:25778614; http://dx.doi.org/ 10.1016/j.tibs.2015.02.006 2874 Volume 14 Issue 18 Cell Cycle,OADS,/arxiv_data1/oa_pdf/97/e0/kccy-14-18-1071140.PMC4825536.pdf
"© Ian J Restall, Doris A E Parolin, Manijeh Daneshmand, Jennifer E L Hanson, Manon A Simard, Megan E Fitzpatrick, Ritesh Kumar, Sylvie J Lavictoire, and Ian A J Lorimer*Correspondence to: Ian AJ Lorimer; Email: ilorimer@ohri.caSubmitted: 04/08/2015; Revised: 07/03/2015; Accepted: 07/07/2015 http://dx.doi.org/10.1080/15384101.2015.1071744 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Materials and Methods AntibodiesKi-67 rabbit polyclonal antibody (ab15580) used for immu- noﬂuorescence was from Abcam (http://www.abcam.com/ki67-antibody-ab15580.html).,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cyclin E mouse monoclonal antibody (sc-247) was from Santa Cruz Bio-technology (http://www.scbt.com/datasheet-247-cyclin-e-he12-antibody.html).,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
g-tubulin mouse monoclonal antibody (T6557) was from Sigma-Aldrich (http://www.sigmaaldrich.com/catalog/product/sigma/t6557?lang Denandregion DCA).,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
PML mouse monoclonal antibody was from Santa Cruz Biotechnology(http://www.scbt.com/datash eet-966-pml-pg-m3-antibody.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cytokine arrays Normal cells or senescent cells were grown in serum-free media for 24 h. Conditioned media was analyzed on a RayBio-tech Human Cytokine Antibody Array 5 according to the man- ufacturer’s instructions (http://www.raybiotech.com/c-series- human-cytokine-array-5-2.html ).,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Exp Cell Res 1961; 25:585-621; PMID:13905658; http://dx.doi.org/10.1016/ 0014-4827(61)90192-6 2.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 1990; 345:458-60; PMID:2342578; http://dx.doi.org/ 10.1038/345458a0 3.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell 2011; 144:646-74;PMID:21376230; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell 1997; 88:593-02; PMID:9054499; http://dx.doi.org/10.1016/S0092- 8674(00)81902-9 5.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Genes Dev 2007; 21:379-84; PMID:17299132; http://dx.doi.org/10.1101/ gad.1516407 6.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2005; 436:642; PMID:16079833; http://dx.doi.org/10.1038/436642a 7.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Cell 2009; 15:294-303; PMID:19345328; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Cell 2006; 10: 459-72; PMID:17157787; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2005; 436:720-4; PMID:16079850; http://dx.doi.org/10.1038/nature03890 10.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2007; 445:661-5;PMID:17251932; http://dx.doi.org/10.1038/ nature05541 11.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2007;445:656-60; PMID:17251933; http://dx.doi.org/ 10.1038/nature0552912.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Oncogene 2012; 31:3584-96;PMID:22120720; http://dx.doi.org/10.1038/ onc.2011.524 13.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Biochem Pharmacol 2008; 76:947-57; PMID:18657518; http://dx.doi.org/ 10.1016/j.bcp.2008.06.024 14.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Res 2005; 65:2795-803; PMID:15805280; http://dx.doi.org/10.1158/0008- 5472.CAN-04-1270 18.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nat Rev Mol Cell Biol 2013; 14:25-37;PMID:23258294; http://dx.doi.org/10.1038/nrm3494 19.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Curr Biol 2006; 16:1194-200; PMID:16782009; http://dx.doi.org/10.1016/j.cub.2006.04.043 20.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell Cycle 2010; 9:1792-801; PMID:20436289; http://dx.doi.org/10.4161/ cc.9.9.11519 21.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Dev Cell 2004; 7:637-51; PMID:15525526; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
J Biol Chem 2007; 282:29273- 83; PMID:17675670; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Expert Opin Ther Tar-gets 2009; 13:701-18; PMID:19409033; http://dx.doi.org/10.1517/1472822090294234824.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330 25.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2008; 455:1061-8; PMID:18772890; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Curr Biol 1998; 8:1069-77; PMID:9768361; http://dx.doi.org/10.1016/S0960-9822(98)70444-0 27.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Science 1998; 281:2042-5; PMID:9748166; http://dx.doi.org/10.1126/science.281.5385.2042 28.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Res 2005; 65:8905-11; PMID:16204062; http://dx.doi.org/10.1158/0008-5472.CAN-05-2372 29.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
J Cell Physiol 2011; 226:879-87; PMID:20945390; http://dx.doi.org/10.1002/ jcp.22463 30.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Oncogene 2008; 27:3587-95; PMID:18212741;http://dx.doi.org/10.1038/sj.onc.1211027 31.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Oncogene 2006; 25:2909-19; PMID:16331246; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
EMBO J 2002; 21:6771-80; PMID:12485998; http://dx.doi.org/10.1093/emboj/cdf684 34.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Annu Rev Pathol 2010;5:99-118; PMID:20078217; http://dx.doi.org/ 10.1146/annurev-pathol-121808-102144 36.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
2010; 141:81-93; PMID:20371347; http://dx.doi.org/ 10.1016/j.cell.2010.01.031 37.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Res 2005; 65:7832-9; PMID:16140952; http://dx.doi.org/ 10.1158/0008-5472.CAN-04-4313 38.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Curr Pharm Des 2010; 16:734-40; PMID:20388083; http://dx.doi.org/10.2174/ 138161210790883714 39.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
J Cell Sci 2008; 121:1-84; PMID:18089652; http://dx.doi.org/10.1242/ jcs.025742 40.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Int J Cancer 2006; 119:2717-23; PMID:17016823; http://dx.doi.org/ 10.1002/ijc.22245 41.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
J Cell Biol 2006;174:625-30; PMID:16943179; http://dx.doi.org/ 10.1083/jcb.200606051 42.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Oncogene 2010; 29:6184-92; PMID:20729911; http://dx.doi.org/10.1038/onc.2010.354 43.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell Death Dis 2010; 1:e35; PMID:21364642; http://dx.doi.org/10.1038/cddis.2010.12 44.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Exp Gerontol 2001; 36:1327-47; PMID:11602208; http://dx.doi.org/10.1016/S0531-5565(01)00105-X 47.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Ann N Y Acad Sci 2010; 1197:108-17; PMID:20536839; http://dx.doi.org/10.1111/j.1749- 6632.2009.05396.x 48.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Mol Biol Cell 2014; 25:3105-18; PMID:25143403; http://dx.doi.org/10.1091/mbc.E14-03-0844 49.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Mol Cell 2007; 27:462-73; PMID:17679094; http://dx.doi.org/10.1016/j.molcel.2007.06.013 50.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cytometry A 2008; 73:808-15; PMID:18618767; http://dx.doi.org/ 10.1002/cyto.a.20604 51.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell Cycle 2013; 12:1424-32; PMID:23574719; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cell Cycle 2010; 9:4469-73; PMID:21088502; http://dx.doi.org/ 10.4161/cc.9.22.13684 54.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nat Genet 2004; 36:744-9; PMID:15208629; http://dx.doi.org/ 10.1038/ng1382 55.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Br J Cancer 2009; 101:1900-8; PMID:19935801; http://dx.doi.org/10.1038/sj.bjc.6605419 56.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2001; 409:355-9; PMID:11201745; http://dx.doi.org/10.1038/ 35053094 57.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Res 2004; 64:440-5; PMID:14744753; http://dx.doi.org/ 10.1158/0008-5472.CAN-03-3119 58.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nature 2010; 464:374-9; PMID:20237562; http://dx.doi.org/10.1038/nature08815 59.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Cancer Res 2007; 67:2373-81; PMID:17332370; http://dx.doi.org/ 10.1158/0008-5472.CAN-06-3796 60.,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
J Biol Chem 2006; 281:3800-9;PMID:16316983; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
Nat Protoc 2009; 4:1798-806; PMID:20010931; http://dx.doi.org/ 10.1038/nprot.2009.191 2948 Volume 14 Issue 18 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/72/a8/kccy-14-18-1071744.PMC4825548.pdf
"6,24-30Analysis of mice haploinsufﬁcient for © Gonzalo I Cancino, Michael P Fatt, Freda D Miller, and David R Kaplan *Correspondence to: David R Kaplan; Email: dkaplan@sickkids.ca; Freda D Miller; Email: fredam@sickkids.caSubmitted: 05/11/2015; Revised: 08/19/2015; Accepted: 08/22/2015 http://dx.doi.org/10.1080/15384101.2015.1087618 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/10.1038/356215a0 2.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Curr Biol 1994; 4:1-7; PMID:7922305; http://dx.doi.org/10.1016/S0960-9822(00)00002-6 3.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nat Genet 1995; 10:175-80; PMID:7663512; http://dx.doi.org/10.1038/ng0695-175 4.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nature 1999; 398:708-13; PMID:10227293; http://dx.doi.org/10.1038/ 19531 5.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nature 1999; 398:714-8; PMID:10227294; http://dx.doi.org/ 10.1038/19539 6.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nature 2000; 404:99-103; PMID:10716451; http://dx.doi.org/10.1038/ 35003607 7.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Cell Stem Cell 2009; 5:64-75;PMID:19570515; http://dx.doi.org/10.1016/j.stem.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Neuron 2011;72:748-59; PMID:22153372; http://dx.doi.org/ 10.1016/j.neuron.2011.09.009 9.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Biol Chem 2011; 286:38757- 67; PMID:21880709; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Stem Cells 2011; 29:1672-83; PMID:21898690; http://dx.doi.org/10.1002/stem.723 11.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
EMBO Mol Med 2012;4:192-205; PMID:22247000; http://dx.doi.org/ 10.1002/emmm.20110019912.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Dev Cell 2014; 28:147-60; PMID:24412575; http://dx.doi.org/10.1016/j.devcel.2013.11.019 14.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nature 2014; 511:358-61; PMID:25030175; http://dx.doi.org/10.1038/nature13465 17.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Nat Rev Mol Cell Biol 2000; 1:199-207;PMID:11252895; http://dx.doi.org/10.1038/35043127 19.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Genes Dev 2010; 24:549-60; PMID:20194434; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2004; 24:9174-84; PMID:15483136; http://dx.doi.org/10.1523/ JNEUROSCI.1588-04.2004 22.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2004; 24:9638-47; PMID:15509751; http://dx.doi.org/ 10.1523/JNEUROSCI.1299-04.2004 23.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Genes Dev 2008; 22:2677-91; PMID:18805989; http://dx.doi.org/10.1101/gad.1695308 25.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Curr Biol 2010; 20:2058-65;PMID:21074438; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
2010; 1: e109;PMID:21368881; http://dx.doi.org/10.1038/cddis.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Cell Death Differ 2010; 17:1816-29; PMID:21076477; http://dx.doi.org/10.1038/cdd.2010.131 29.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
2011; 108:21093-8; PMID:22160687; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Cell Death Differ 2014;21:1546-59; PMID:24809925; http://dx.doi.org/ 10.1038/cdd.2014.61 32.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Brain 2008; 131:2425-42; PMID:18559370; http://dx.doi.org/10.1093/brain/awn125 3280 Volume 14 Issue 20 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Neuron 2008; 59:708-21; PMID:18786355; http://dx.doi.org/10.1016/j.neuron.2008.07.021 34.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Neurobiol Aging 2013; 34:387- 99; PMID:22592019; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Neuron 2005; 48:743-56; PMID:16337913; http://dx.doi.org/10.1016/j.neuron.2005.10.027 36.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2013; 33:12569-85;PMID:23904595; http://dx.doi.org/10.1523/ JNEUROSCI.1251-13.2013 37.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2009;29:6710-21; PMID:19458240; http://dx.doi.org/ 10.1523/JNEUROSCI.5878-08.2009 38.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Cell Cycle 2011; 10:680-9;PMID:21293190; http://dx.doi.org/10.4161/ cc.10.4.14859 39.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
2008; 11:1153-61; PMID:18758458; http://dx.doi.org/10.1038/ nn.2185 40.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2014; 34:5164-75; PMID:24719096; http://dx.doi.org/10.1523/ JNEUROSCI.0370-14.2014 41.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neurosci 2013; 33:244-58; PMID:23283338; http://dx.doi.org/10.1523/ JNEUROSCI.1665-12.2013 42.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Cereb Cortex 2004; 14:484- 95; PMID:15054064; http://dx.doi.org/10.1093/cercor/bhh010 44.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Genesis 2002; 32:138- 41; PMID:11857801; http://dx.doi.org/10.1002/ gene.10067 4 7 .,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
J Neuro- sci 2007; 27:12623-9; PMID:18003841; http://dx.doi.org/ 10.1523/JNEUROSCI.3812-07.2007 48.,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Dev Cell 2015; 32:31-42;PMID:25556659; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Neuron 2014; 84:723-39; PMID:25456498; http://dx.doi.org/ 10.1016/j.neuron.2014.10.022 50.,OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
Stem Cells 2008; 26:2938-44; PMID:18757294; http://dx.doi.org/10.1634/ stemcells.2008-0558 www.tandfonline.com 3281 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/80/3b/kccy-14-20-1087618.PMC4825551.pdf
"Cell Cycle 2015; 14(18):2980-95; PMID:26102294;http://dx.doi.org/10.1080/15384101.2015.1056948 David Murray* and Razmik Mirzayans; Department of Oncology; University of Alberta; Cross Cancer Institute; Edmonton, AB Canada; *Correspondence t o: David Murray; Email: david.murray5@albertahealthservices.ca; http://dx.doi.org/10.1080/15384101.2015.1069507 OCT4A is best known as a “master ”tran- scription factor involved in stem cell pluripo-tency and self renewal in concert with SOX2and NANOG.",Non-OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
"Note the reported roles of p53 in both promoting and blocking senescence4and of AMPK in activating the p53 axis in response to DNA damage.5 www.tandfonline.com 2871 Cell Cycle© David Murray and Razmik Mirzayans This is an Open Access article distributed under theterms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
Cell Cycle 2015; 14(18):2980-95; PMID:26102294; http://dx.doi.org/10.1080/15384101.2015.1056948 3.,Non-OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
Proc Natl Acad Sci USA 2010; 107:9660-9664; PMID:20457898; http://dx.doi.org/ 10.1073/pnas.1002298107.,OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
FEBS Lett 2011; 585:952-957; PMID:21396365; http://dx.doi.org/10.1016/j.febslet.,OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
"Int J Mol Sci 2015, 16:11609- 11628; PMID:26006237; http://dx.doi.org/10.3390/ijms160511609.",OADS,/arxiv_data1/oa_pdf/cf/2f/kccy-14-18-1069507.PMC4825567.pdf
"The accumulation of DSBs is lethal for cells lacking © Idun Dale Rein, Kirsti Solberg Landsverk, Francesca Micci, Sebastian Patzke, and Trond Stokke *Correspondence to: Trond Stokke; Email: tstokke@rr-research.noSubmitted: 05/20/2015; Accepted: 08/14/2015 http://dx.doi.org/10.1080/15384101.2015.1085137 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nature 2005; 434:913-17; PMID:15829966; http://dx.doi.org/10.1038/nature03443 3.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Blood 2010; 116:953- 61; PMID:20421449; http://dx.doi.org/10.1182/ blood-2010-01-263806 4.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Proc Natl Acad Sci U S A 2006; 103:2352-7; PMID:16461462; http://dx.doi.org/10.1073/ pnas.0510441103 5.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Proc Natl Acad Sci U S A 2000;97:2773-8; PMID:10706620; http://dx.doi.org/ 10.1073/pnas.050400997 6.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Lancet 1999; 353:26-9; PMID:10023947; http://dx.doi.org/10.1016/S0140- 6736(98)10117-4 7.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nature 2008; 455:1069-75; PMID:18948947; http://dx.doi.org/ 10.1038/nature07423 10.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Genome Integr 2010; 1:9; PMID:20678261; http://dx.doi.org/10.1186/2041- 9414-1-9 11.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Oncogene 2008; 27:2501-6; PMID:17982490; http://dx.doi.org/10.1038/sj.onc.1210885 12.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Res 2006; 66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140 14.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
BMC Mol Biol 2007; 8:29; PMID:17459151; http://dx.doi.org/10.1186/1471-2199-8-29 15.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Blood 2010; 116:4578-87;PMID:20739657; http://dx.doi.org/10.1182/blood- 2010-01-265769 16.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Mol Cancer Ther 2010; 9:347-57; PMID:20124459; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Hematol Oncol 2011; 30:175–179; PMID:22170260; http://dx.doi.org/10.1002/ hon.1020 18.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
NatRev Mol Cell Biol 2006; 7:517-28; PMID:16829982; http://dx.doi.org/10.1038/nrm1963 20.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Eur J Biochem 1987; 169:365-72; PMID:3121314; http://dx.doi.org/ 10.1111/j.1432-1033.1987.tb13621.x 22.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
J Biol Chem 2001; 276:36425-30; PMID:11477085; http://dx.doi.org/ 10.1074/jbc.M105215200 23.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Biochem J 1999; 342 (Pt 2):249-68;PMID:10455009; http://dx.doi.org/10.1042/ bj3420249 24.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Res 2012; 72:5588-99; PMID:23118055; http://dx.doi.org/10.1158/0008- 5472.CAN-12-2753 26.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nucleic Acids Res 2011; 39:3166-75;PMID:21183466; http://dx.doi.org/10.1093/nar/ gkq124127.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Res 2010; 70:5389-98; PMID:20551068;http://dx.doi.org/10.1158/0008-5472.CAN-09-4716 28.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
DNA Repair (Amst) 2008; 7:2010-9;PMID:18832051; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
EMBO J 2008; 27:1368-77; PMID:18388863; http://dx.doi.org/10.1038/ emboj.2008.61 30.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Breast Cancer Res Treat 2012; 135:505-517; PMID:22875744; http://dx.doi.org/10.1007/s10549-012-2188-0 31.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Res 2011; 71:2632-42; PMID:21300766; http://dx.doi.org/ 10.1158/0008-5472.CAN-10-1120 33.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
J Cell Biol 2005; 170:341-7; PMID:16061690;http://dx.doi.org/10.1083/jcb.200411083 34.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
NatStruct Mol Biol 2009; 16:814-8; PMID:19633669; http://dx.doi.org/10.1038/nsmb.1640 35.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
J Exp Med 2009; 206:669-79; PMID:19221393; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nat Struct Mol Biol 2009; 16:819-24; PMID:19633668; http://dx.doi.org/ 10.1038/nsmb.1641 37.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Lancet 2010; 376:245-51; PMID:20609468; http://dx.doi.org/10.1016/S0140- 6736(10)60893-8 38.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
J Clin Oncol 2010; 28:2512-9; PMID:20406929;http://dx.doi.org/10.1200/JCO.2009.26.9589 39.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
PMID:20609467; http://dx.doi.org/10.1016/S0140- 6736(10)60892-6 40.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cell Cycle 2011; 10:481-91; PMID:21263216; http://dx.doi.org/10.4161/ cc.10.3.14713 41.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Adv Exp Med Biol 2010; 676:123-35;PMID:20687473; http://dx.doi.org/10.1007/978-1- 4419-6199-0_8 45.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Leukemia Research 2006; 30:449- 57; PMID:16183118; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Investigational New Drugs 2012; 30:417-22; PMID:20953816; http://dx.doi.org/10.1007/s10637-010-9564-6 48.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cell Cycle 2010; 9:662-9; PMID:20139725; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Proc Natl Acad Sci U S A 2003; 100:5057-62; PMID:12679524; http://dx.doi.org/ 10.1073/pnas.0830918100 51.,OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
European Journal of Cancer (1965) 2004;13:377-9; http://dx.doi.org/10.1016/0014-2964(77) 90085-8 55.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Int J Cancer 2005; 115:935- 42; PMID:15723354; http://dx.doi.org/10.1002/ ijc.20962 57.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Br J Haematol 2004; 125:330-6;PMID:15086413; http://dx.doi.org/10.1111/j.1365- 2141.2004.04913.x 59.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Leukemia 1997; 11:64-72; PMID:9001420;http://dx.doi.org/10.1038/sj.leu.2400555 60.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Genet Cytogenet 2004; 153:144-50; PMID:15350304; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Nat Genet 1997; 17:96-9; PMID:9288106; http://dx.doi.org/10.1038/ng0997-96 62.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
J Med Chem 2008; 51:6581-91; PMID:18800822; http://dx.doi.org/10.1021/ jm8001263 63.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cancer Res 2004; 64:9152-9;PMID:15604286; http://dx.doi.org/10.1158/0008- 5472.CAN-04-2727 64.,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
Cytometry 1999; 38:53-60; PMID:10323217; http://dx.doi.org/10.1002/(SICI) 1097-0320(19990415)38:2%3c53::AID-CYTO2%3e3.0.CO;2-0 3260 Volume 14 Issue 20 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/ea/7e/kccy-14-20-1085137.PMC4825575.pdf
"Since © Ken Dornfeld, Michael Madden, Andrew Skildum, and Kendall B Wallace *Correspondence to: Ken Dornfeld; Email: Kenneth.dornfeld@essentiahealth.orgSubmitted: 05/11/2015; Revised: 08/15/2015; Accepted: 08/22/2015 http://dx.doi.org/10.1080/15384101.2015.1087619 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Drug treatment Doxorubicin was obtained fr om Sigma (http://www.sig- maaldrich.com/catalog/p roduct/sigma/44583?lang Denandregio nDUS).,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
"using BioVision NAD/NADH colorimetric determination kit (K337–100, http://www.biovision.com/nad- nadh-quantitation-colorimetric-kit-2853.html).",Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
"Contaminating enzyme activity was removed by pass- ing the extraction supernatant through BioVision columns (catalog # 1997–25, http://www.biovision.com/10k-spin-col-umn-5277.html).",Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Pharmacol Toxicol 2003 Sep; 93(3): 105-15; http://dx.doi.org/10.1034/j.1600-0773.2003.930301.x.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Oncogene 2005 Jul 14; 24(30):4765-77; http://dx.doi.org/10.1038/sj.onc.1208627.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Cancer Res 2007 Dec 1; 67(23):11411-8; http://dx.doi.org/10.1158/0008-5472.CAN-07-2399.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
PLoS One 2009 Jun 8; 4(6):e5830; http://dx.doi.org/10.1371/journal.pone.0005830.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
"Dornfeld K, Johnson M. AP endonuclease deﬁciency results in extreme sensitivity to thymidine deprivation.Nucleic Acids Res 2005 Nov 27; 33(20):6644-53; http://dx.doi.org/10.1093/nar/gki975.",Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Genetics 2012 Jan; 190(1):51-77; http://dx.doi.org/ 10.1534/genetics.111.128314.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
FEMS Yeast Res 2009 Jun; 9(4):535-51; http://dx.doi.org/10.1111/j.1567- 1364.2009.00505.x.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Genetics 2012 Mar; 190(3):885-929;http://dx.doi.org/10.1534/genetics.111.133306.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
J Biol Chem 2003 Mar 21; 278(12):10264-72; http://dx.doi.org/10.1074/jbc.M211692200.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
EMBO J 2001; 20:5060-9; PMID:11566871; http://dx.doi.org/10.1093/emboj/20.18.5060.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Separation of 2 glutamic-oxalacetic transaminases by paper electropho- resis Proc Soc Exp Biol Med 1960 Jan; 103:229-31; http://dx.doi.org/10.3181/00379727-103-25469.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Methods Cell Biol 2007; 80:199-222; PMID:17445696; http://dx.doi.org/10.1016/S0091- 679X(06)80010-5.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
J Clin Invest 2013 Mar; 123(3):1068-81; http://dx.doi.org/ 10.1172/JCI64264.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Am J Physiol Regul Integr Comp Physiol 2010Apr; 298(4):R1075-88; http://dx.doi.org/10.1152/ ajpregu.00360.2009.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Cardiovasc Res 2011 May 1; 90(2):210-9; http://dx.doi.org/10.1093/cvr/cvr055.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Am J Physiol Heart Circ Physiol 2008 Dec; 295(6):H2315-20; http://dx.doi.org/10.1152/ajpheart.00739.2008.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Curr Heart Fail Rep 2012 Sep; 9(3):211-8; http://dx.doi.org/10.1007/s11897-012-0098-4.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Breast Cancer Res Treat 2011 Oct; 129 (3):785-97; http://dx.doi.org/10.1007/s10549-010-1268-2.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Cardiovasc Toxicol 2007; 7:178-191; PMID:17901561; http://dx.doi.org/10.1007/s12012-007-0026-0.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Toxicology 2010; 270:92-98; PMID:20132857; http://dx.doi.org/10.1016/j.tox.,OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Cancer Res 2010 Feb 15; 70(4):1564-72; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-3228.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Genetics 2014 Jun; 197 (2):451-65; http://dx.doi.org/10.1534/genetics.114.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
Hum Mol Genet 2013 May 1; 22(9):1699-708; http://dx.doi.org/10.1093/hmg/ddt016.,Non-OADS,/arxiv_data1/oa_pdf/89/5f/kccy-14-20-1087619.PMC4825578.pdf
"In a similarfashion, Carmona and colleagues 3 described the epigenetic silencing of a © Miguel Vizoso and Manel Esteller *Correspondence to: Manel Esteller; Email: mesteller@idibell.cat Submitted: 07/08/2015; Accepted: 07/13/2015http://dx.doi.org/10.1080/15384101.2015.1076300 Comment on: Vizoso M, et al.",OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
"Nat Med 2015; 21( 7): 741-50; PMID: 26030178; http://dx.doi.org/10.1038/nm.3863 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Nat Rev Cancer 2013; 13:497- 510; PMID:23760024; http://dx.doi.org/10.1038/nrc3486 2.,Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Proc Natl Acad Sci U S A 2008; 105:13556-61; PMID:18768788; http://dx.doi.org/ 10.1073/pnas.08030551053.,OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
J Pathol 2012; 228:230-40; PMID:22374749; http://dx.doi.org/10.1002/path.4011 4.,Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Sci Transl Med 2011; 3:75ra25; PMID:21430268; http://dx.doi.org/10.1126/scitranslmed.3001875 5.,Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Nat Med 2015; 21(7):741-50; PMID:26030178; http://dx.doi.org/10.1038/nm.38636.,Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Oncogene 2012; 31:2062-74; PMID:21874049; http://dx.doi.org/10.1038/onc.,OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
Cancer Res 2014; 74:5608-19; PMID:25106427; http://dx.doi.org/10.1158/0008- 5472.CAN-13-3659 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/09/da/kccy-14-18-1076300.PMC4825588.pdf
"13Cellular senescence has traditionally been con- sidered a terminal cell fate.13,14However, more recently it has been shown to be reversible at early stages, at least in tumor cells.15-18Furthermore, a direct link between senescence and © Anda Huna, Kristine Salmina, Jekaterina Erenprei sa, Alejandro Vazquez-Martin, Jekabs Krigerts, Inna Inashkina, Bogdan I Gerashchenko, Paul A To wnsend, Mark S Cragg, and Thomas R Jackson*Correspondence to: Thomas Robert Jackson; Email: tom.jackson-2@manchester.ac.ukSubmitted: 04/17/2015; Revised: 05/22/2015; Accepted: 05/27/2015 http://dx.doi.org/10.1080/15384101.2015.1056948 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nat Genet 2008; 40(5):499-507; PMID:18443585; http://dx.doi.org/ 10.1038/ng.127 2.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nature 2001; 414 (6859): 105-111; PMID:11689955; http://dx.doi.org/ 10.1038/35102167 3.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Clin Cancer Res 2008; 14(13): 4085-4095;PMID:18593985; http://dx.doi.org/10.1158/1078- 0432.CCR-07-4404 4.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cancer Biol Ther 2010; 9(4): 295-302; PMID:20026903; http://dx.doi.org/10.4161/cbt.9.4.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
BmcCancer 2011; 11:42; PMID:21276239; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
World JGastroenterol 2012; 18(7): 712-719; PMID:22363145; http://dx.doi.org/10.3748/wjg.v18.i7.712 8.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
"Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.Med Oncol 2012; 29(2): 829-834; PMID:21533858; http://dx.doi.org/10.1007/s12032-011-9962-4 9.",Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Med Oncol 2012; 29(2): 878-885;PMID:21336986; http://dx.doi.org/10.1007/s12032- 011-9860-9 10.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Stem Cells 2012; 30(5): 833-844; PMID:22489015; http://dx.doi.org/10.1002/stem.1058 11.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Mol Cancer2013; 12; PMID:23537295; http://dx.doi.org/ 10.1186/1476-4598-12-24 12.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Drug Resistance Updates2001; 4(5): 303-313; PMID:11991684; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Aging Cell 2011; 10(6): 949-961; PMID:21824272; http://dx.doi.org/ 10.1111/j.1474-9726.2011.00736.x 16.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cancer Res 2005; 65(7): 2795-2803; PMID:15805280; http://dx.doi.org/10.1158/0008-5472.CAN-04-1270 18.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Genes Dev 2009; 23(18): 2134-2139; PMID:19696146;http://dx.doi.org/10.1101/gad.1811609 20.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell 2013; 155(5): 1119-1130; PMID:24238961; http://dx.doi.org/10.1016/j.cell.2013.10.041 22.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Transl Res 2015; 165(1): 241-249; PMID:24924348; http://dx.doi.org/10.1016/j.trsl.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
J Aging Res 2011; 2011: 103253; PMID:21629737; http://dx.doi.org/10.4061/ 2011/103253 24.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2013; 12(3): 430-441; PMID:23287532; http://dx.doi.org/ 10.4161/cc.23285 25.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell 2005; 122 (6): 947-956; PMID:16153702; http://dx.doi.org/10.1016/j.cell.2005.08.02026.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Stem Cell 2013; 12(1): 88-100; PMID:23260487;http://dx.doi.org/10.1016/j.stem.2012.12.001 27.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Mol Cell Biochem 2007; 306(1- 2): 239-245; PMID:17786544; http://dx.doi.org/ 10.1007/s11010-007-9575-6 28.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2009; 8(5): 788-791; PMID:19221486;http://dx.doi.org/10.4161/cc.8.5.7787 29.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nat Cell Biol 2011; 13(2): 132-U71; PMID:21258367; http://dx.doi.org/10.1038/ncb2152 30.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Int J Cancer 2012; 130(8): 1715-1725; http://dx.doi.org/10.1002/ ijc.27316 32.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nucleus-Aus- tin 2011; 2(1): 47-60; http://dx.doi.org/10.4161/nucl.13655 33.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
BiochemJ 2010; 426: 171-181; PMID:19968627; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Physica A- Statistical Mechanics Its Applications 2010; 389(16): 3193-3217: http://dx.doi.org/10.1016/j.physa.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Development 2009; 136 (23): 3853-3862; PMID:19906852; http://dx.doi.org/ 10.1242/dev.035139 38.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell 2001; 105(3): 297-306;PMID:11348589; http://dx.doi.org/10.1016/S0092- 8674(01)00334-8 39.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Plos Biol 2009; 7(7);PMID:19582141; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nat Cell Biol 2005; 7(2): 165-U80; PMID:15619621; http://dx.doi.org/10.1038/ncb1211 41.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cancer Biol Ther 2014; 15 (2): 156-169; PMID:24100703; http://dx.doi.org/ 10.4161/cbt.26726 42.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2011; 10(9):1499-1501; PMID:21566461; http://dx.doi.org/ 10.4161/cc.10.9.15423 43.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Sci- ence 2010; 329(5996): 1201-1205; PMID:20647423; http://dx.doi.org/10.1126/science.1191241 44.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.Mol Cell 2005; 18(3): 283-293; PMID:15866171; http://dx.doi.org/10.1016/j.molcel.2005.03.027 45.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2014; 13(9): 1424-1439; PMID:24626185; http://dx.doi.org/10.4161/cc.28402 47.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Int J Cancer 2013; 132(7): 1505-1515; http://dx.doi.org/10.1002/ijc.27810 49.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nat Rev Genet 2009; 10(5): 336-342; PMID:19337290; http://dx.doi.org/10.1038/nrg2556 50.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Science2012; 336(6087): 1440-1444; PMID:22700930; http://dx.doi.org/10.1126/science.1218351 51.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2012; 11(19): 3599-3610; PMID:22935696; http://dx.doi.org/10.4161/cc.21884 52.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
2013; 202(1): 129-143; PMID:23816621; http://dx.doi.org/ 10.1083/jcb.201212110 53.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nat Genet 2003; 35(3): 219-220; PMID:14578886; http://dx.doi.org/10.1038/ng1259 55.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Cell Cycle 2011; 10(17): 3016-3030; PMID:21862875; http://dx.doi.org/10.4161/cc.10.17.17543 57.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
J Cell Biol 2013; 202(1): 11-13; PMID:23816622; http://dx.doi.org/10.1083/ jcb.201305155 58.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Aging Cell 2013; 12(2): 247-256; PMID:23360310; http://dx.doi.org/10.1111/acel.12047 59.,OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Nature 2013; 501 (7467):421-5; PMID:23945590; http://dx.doi.org/ 10.1038/nature12437 61.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Int J Cancer 1980; 25(1): 19-32;http://dx.doi.org/10.1002/ijc.2910250104 62.,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
Histochemistry 1979; 60 (3): 321-325; PMID:89109; http://dx.doi.org/ 10.1007/BF00500660 2984 Volume 14 Issue 18 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/f8/3c/kccy-14-18-1056948.PMC4825594.pdf
"fahraeus@inserm.fr Submitted: 07/22/2015Revised: 08/26/2015 Accepted: 08/29/2015 http://dx.doi.org/10.1080/15384101.2015.1090066 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell Cycle 2007; 6:1006- 10; PMID:17457049; http://dx.doi.org/10.4161/cc.6.9.4211 2.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161;http://dx.doi.org/10.1038/nrm2147 3.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell 1992; 71:587-97; PMID:1423616; http://dx.doi.org/10.1016/0092-8674(92)90593-2 5.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell 1995; 80:293-9; PMID:7834749; http://dx.doi.org/ 10.1016/0092-8674(95)90513-8 6.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2011; 30:2901-11; PMID:21383691; http://dx.doi.org/10.1038/onc.2011.34 7.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2007; 26:1645-9; PMID:16964282; http://dx.doi.org/ 10.1038/sj.onc.1209972 8.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2000; 19:5338-47; PMID:11103935; http://dx.doi.org/10.1038/sj.onc.1203956 9.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Gen Dev 2013; 27:1857-67; PMID:23973961; http://dx.doi.org/ 10.1101/gad.227249.113 12.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Nat Cell Biol 2008; 10:1098-105; PMID:19160491; http://dx.doi.org/10.1038/ncb1770 13.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell Cycle 2009; 8:31-4; PMID:19106616; http://dx.doi.org/10.4161/cc.8.1.7326 14.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Mol Cell 2014; 54:500-11; PMID:24813712; http://dx.doi.org/10.1016/j.molcel.2014.02.035 15.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Curr Opin Cell Biol 2006; 18:444-52; PMID:16781856; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell Cycle 2009; 8:1643-4; PMID:19411860; http://dx.doi.org/10.4161/cc.8.11.8637 17.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Mol Cell 2010; 38:78-88; PMID:20385091; http://dx.doi.org/ 10.1016/j.molcel.2010.01.041 18.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Gen Dev 2001; 15:2083-93; PMID:11511540; http://dx.doi.org/ 10.1101/gad.889201 19.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Nat Commun 2014; 5:5067; PMID:25295585; http://dx.doi.org/10.1038/ncomms6067 20.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2006; 25:6936-47; PMID:16983332; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
GenDev 2004; 18:306-19; PMID:14871929; http://dx.doi.org/ 10.1101/gad.1162404 22.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Gen Dev 2010; 24:2408-19; PMID:21041409; http://dx.doi.org/10.1101/ gad.1987810 23.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2013; 32:3165-74; PMID:22824800; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell Death Differ 2003; 10:404-8; PMID:12719716; http://dx.doi.org/ 10.1038/sj.cdd.4401191 25.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
RNA 2007; 13:1825-33;PMID:17804642; http://dx.doi.org/10.1261/rna.673407 26.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2007; 26:5029-37; PMID:17310983; http://dx.doi.org/10.1038/sj.onc.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Oncogene 2008; 27:5774-84; PMID:18560357;http://dx.doi.org/10.1038/onc.2008.189 28.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Mol Cell 2003; 12:1151-64; PMID:14636574; http://dx.doi.org/ 10.1016/S1097-2765(03)00431-3 29.,OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
The EMBO J 2003; 22:2810-20; PMID:12773395; http://dx.doi.org/10.1093/emboj/ cdg265 30.,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
Cell Cycle 2008; 7:950-9; PMID:18414054; http://dx.doi.org/10.4161/cc.7.7.5626 3378 Volume 14 Issue 21 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/62/88/kccy-14-21-1090066.PMC4825612.pdf
"From this example, one can see that it is necessary to provide an outlier query language with  which a user can specify the candidate set ( e.g., Christos’ coauthors), the aspect ( e.g.,  publishing venues) by which the outliers will be judged, and sometimes the reference set  1http://www.informatik.uni-trier.de/~ley/dbKuck et al.",Non-OADS,/arxiv_data1/oa_pdf/2f/d8/nihms743073.PMC4825692.pdf
2http://docs.neo4j.org/chunked/stable/cypher-introduction.htmlKuck et al.,OADS,/arxiv_data1/oa_pdf/2f/d8/nihms743073.PMC4825692.pdf
3http://arnetminer.org/AMinerNetworkKuck et al.,OADS,/arxiv_data1/oa_pdf/2f/d8/nihms743073.PMC4825692.pdf
4https://sites.google.com/site/aseplim/Kuck et al.,OADS,/arxiv_data1/oa_pdf/2f/d8/nihms743073.PMC4825692.pdf
"We and othershave previously demonstrated that TAp73Keywords: angiogenesis, DNp73, HIF- 1a, hypoxia, Siah1, tumors, Vegf-A © Iqbal Dulloo, Phang Beng Hooi, and Kanaga Saba- pathy *Correspondence to: Kanaga Sabapathy; Email: cmrksb@nccs.com.sg Submitted: 07/08/2015Accepted: 07/26/2015 http://dx.doi.org/10.1080/15384101.2015.1078038 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop-erly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Oncogene 2007; 26:5169-83; PMID:17334395; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Cancer Sci 2005; 96:729-37; PMID:16271066; http://dx.doi.org/ 10.1111/j.1349-7006.2005.00116.x 4.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Cell Death Differ2002; 9:237-45; PMID:11859406; http://dx.doi.org/ 10.1038/sj.cdd.4400995 5.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
2008; 22:2677-91; PMID:18805989; http://dx.doi.org/10.1101/gad.1695308 6.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
J Biol Chem 2004; 279:44713-22; PMID:15302867; http://dx.doi.org/ 10.1074/jbc.M407672200 7.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
EMBO J 2005; 24:836-48; PMID:15678106; http://dx.doi.org/ 10.1038/sj.emboj.7600444 8.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Pharm Des 2011;17:578-90; PMID:21391908; http://dx.doi.org/ 10.2174/138161211795222667 9.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Cancer Res 2004; 64:2449-60; PMID:15059898; http://dx.doi.org/10.1158/0008-5472.CAN-03-1060 12.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Cancer Res 2009; 69:8563-71; PMID:19861536; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-0259 16.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Cell Signal 2001; 13: 727-33; PMID:11602183; http://dx.doi.org/ 10.1016/S0898-6568(01)00195-4 17.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/10.1038/nrc704 18.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Oncogene 2010; 29:625-34; PMID:19946328; http://dx.doi.org/ 10.1038/onc.2009.441 19.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Nat Rev Cancer 2008; 8:967-75; PMID:19946328; http://dx.doi.org/ 10.1038/nrc254020.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Nat Cell Biol 2015; 17:511-23; PMID:25774835; http://dx.doi.org/10.1038/ncb3130 21.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
"Chew EH, Poobalasingam T, Hawkey CJ, Hagen T. Characterization of cullin-based E3 ubiquitin ligases in intact mammalian cells–evidence for cullind i m e r i z a t i o n .C e l lS i g n a l2 0 0 7 ;1 9 : 1 0 7 1 - 8 0 ; PMID:17254749; http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Biochem Biophys Res Com- mun 2005; 331:707-12; PMID:15865926; http://dx.doi.org/10.1016/j.bbrc.2005.03.158 25.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Proc Nat Acad Sci 2010;107:4902-7; PMID:20185758; http://dx.doi.org/ 10.1073/pnas.0906782107 26.,OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Mol Cell Biol 2009; 29:1814-25;PMID:19158275; http://dx.doi.org/10.1128/MCB.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
Nucleic Acids Res 2008; 36:4498-509; PMID:18611950; http://dx.doi.org/10.1093/nar/ gkn414 29.,Non-OADS,/arxiv_data1/oa_pdf/84/53/kccy-14-22-1078038.PMC4825702.pdf
"1 Global gene expression analyses have allowed the delineation of 5 differentKeywords: Antibiotics, breast cancer, basal-like, Biolog, cancer stem cells, clau- din-low, drug repositioning, drug repur-posing, phenotype, ribosomes © Elisabet Cuy /C18as, Bego ~na Martin-Castillo, Bruna Corominas-Faja, Anna Massaguer, Joaquim Bosch- Barrera, and Javier A Menendez *Correspondence to: Javier A Menendez; Email:jmenendez@idibgi.org Submitted: 03/03/2015Accepted: 04/18/2015 http://dx.doi.org/10.1080/15384101.2015.1044173 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non- Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits unrestrictednon-commercial use, distribution, and reproductionin any medium, provided the original work is prop- erly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
J Clin Oncol 2008; 26:2813-20; PMID:18539959; http://dx.doi.org/10.1200/JCO.2008.16.3931 3.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
2012; 22:396-403; PMID:22554795; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Clin Chem 2013; 59:168-79; PMID:23220226; http://dx.doi.org/ 10.1373/clinchem.2012.184655.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Nature 2013; 501:328-37; PMID:24048065; http://dx.doi.org/10.1038/ nature12624.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Nat Rev Drug Discov 2014; 13:497-512; PMID:24981363; http://dx.doi.org/10.1038/nrd4253.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Cancer Discov 2015; 5:22-4; PMID:25583800; http://dx.doi.org/10.1158/2159- 8290.CD-14-0788.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Breast Cancer Res Treat 2013; 142:237-55; PMID:24162158; http://dx.doi.org/10.1007/s10549-013-2743-3.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Mol Oncol 2011; 5:5-23;PMID:21147047; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
2010; 12: R68; PMID:20813035; http://dx.doi.org/10.1186/ bcr2635.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
PLoS Genet 2012; 8: e1002723; PMID:22654675; http://dx.doi.org/ 10.1371/journal.pgen.1002723.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Proc Natl Acad Sci U S A 2009;106:13820-5; PMID:19666588; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
PLoS One 2009; 4:e6693; PMID:19690609; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
J Clin Invest 2014; 124:398-412; PMID:24316975; http://dx.doi.org/10.1172/JCI71180.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
EMBO Mol Med 2014; 6:1542-60; PMID:25330770; http://dx.doi.org/ 10.15252/emmm.201404402.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Cancer Res 2013; 73:5218-31; PMID:23774212; http://dx.doi.org/10.1158/0008- 5472.CAN-13-0429.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Genes Chromosomes Cancer 2007; 46:543-58; PMID:17334996; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Bio- chem Biophys Res Commun 2010; 397:27-33; PMID:20470755; http://dx.doi.org/10.1016/j.bbrc.2010.05.041.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Cell Cycle 2011 Nov 15;10:3871-85; http://dx.doi.org/10.4161/ cc.10.22.17976.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Cell Cycle 2013; 12:225-45; PMID:23255137; http://dx.doi.org/ 10.4161/cc.23274.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Elife 2014; 3; http://dx.doi.org/10.7554/eLife.03080.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Cancer Biol Ther 2011; 11:1008-16; PMID:21464611; http://dx.doi.org/ 10.4161/cbt.11.12.15540.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Nat Rev Cancer 2010; 10:254-66; PMID:20332778; http://dx.doi.org/10.1038/nrc2824.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Nat RevDrug Discov 2004; 3:673-83; PMID:15286734; http://dx.doi.org/10.1038/nrd1468.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Drug Resist Updat 2011;14:212-23; PMID:21600837; http://dx.doi.org/10.1016/j.drup.2011.04.003.,OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
Mol Cancer Ther 2011; 10:1818-1828; PMID:21859839; http://dx.doi.org/10.1158/ 1535-7163.MCT-11-0268.,Non-OADS,/arxiv_data1/oa_pdf/d7/22/kccy-14-22-1044173.PMC4825717.pdf
"Results ISL-1 binds directly to the CyclinD1 promoter in parallel with the changes in CyclinD1 expression during cell cycle progression ISL-1 had been demonstrated not only to play an important tissue speciﬁc role during the early pancreas development,19but © Zhe Yang, Qiao Zhang, Qin Lu, Zhuqing Jia, Ping Chen, Kangtao Ma, Weiping Wang, and Chunyan Zhou *Correspondence to: Chunyan Zhou; Email: chunyanzhou@bjmu.edu.cn; Weiping Wang; wwp@bjmu.edu.cnSubmitted: 03/23/2015; Revised: 07/01/2015; Accepted: 07/01/2015 http://dx.doi.org/10.1080/15384101.2015.1069926 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Nature 1990; 344:879-82; PMID:1691825; http://dx.doi.org/ 10.1038/344879a0 2.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Nature 2009; 460:113-7;PMID:19571884; http://dx.doi.org/10.1038/ nature08191 3.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
J Neurosci 2008; 28:8510-6;PMID:18716209; http://dx.doi.org/10.1523/ JNEUROSCI.1189-08.2008 4.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
PloS one 2011; 6:e22387; PMID:21829621; http://dx.doi.org/10.1371/journal.pone.0022387 6.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Nature 1997; 385:257-60; PMID:9000074; http://dx.doi.org/10.1038/385257a0 7.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Proc Natl Acad Sci U S A 2007; 104:9313-8; PMID:17519333; http://dx.doi.org/10.1073/ pnas.0700923104 8.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Science 1992; 256:1555-60; PMID:1350865; http://dx.doi.org/ 10.1126/science.1350865 9.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Neuroscience 1999; 88:917-25; PMID:10363827; http://dx.doi.org/10.1016/S0306-4522(98)00263-2 10.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Cell 1996; 84:309-20; PMID:8565076; http://dx.doi.org/ 10.1016/S0092-8674(00)80985-X 11.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Diabetologia 2008; 51:1169-80; PMID:18491072; http://dx.doi.org/10.1007/ s00125-008-1006-z 12.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Diabetes 2009; 58:2059-69; PMID:19502415; http://dx.doi.org/10.2337/db08-0987 13.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
J Biol Chem 1995; 270:12646-52; PMID:7759514; http://dx.doi.org/ 10.1074/jbc.270.21.12646 16.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Diabetes 2014; 63:4206-17; PMID:25028525; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Thromb Haemost 2010; 103:188-97; PMID:20062933; http://dx.doi.org/10.1160/TH09- 07-0433 19.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Expression of Isl1 during mouse development.Gene Expr Patterns 2013; 13:407-12; PMID:23906961; http://dx.doi.org/10.1016/j.gep.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
J Surg Res 2008; 144:8-16;PMID:17583748; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Proc Natl Acad Sci U S A 2008;105:5728-32; PMID:18391193; http://dx.doi.org/ 10.1073/pnas.0801788105 23.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Genes Dev 2008; 22:2980-93; PMID:18981476;http://dx.doi.org/10.1101/gad.1689708 24.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Epigenetics 2009; 4:383-7; PMID:19684477; http://dx.doi.org/10.4161/epi.4.6.9450 25.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Proc Natl Acad Sci U S A 2011; 108:1925-30; PMID:21245319; http://dx.doi.org/ 10.1073/pnas.1019619108 26.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Islets 2009; 1:269-72; PMID:21099283;http://dx.doi.org/10.4161/isl.1.3.9779 27.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Prog Mol Biol Transl Sci 2014; 121:321-49; PMID:24373242; http://dx.doi.org/10.1016/B978-0-12-800101-1.00010-7 28.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Baillieres Clin Endocrinol Metab1991; 5:689-98; PMID:1755812; http://dx.doi.org/ 10.1016/S0950-351X(10)80010-2 29.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Diabetes 2001; 50:S25-S9; PMID:11272193; http://dx.doi.org/10.2337/diabetes.50.2007.S25 30.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
J Diabetes Sci Technol 2014; 8:1221-6; PMID:25355714; http://dx.doi.org/10.1177/193229 6814540611 31.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Nature 2004; 429:41-6; PMID:15129273; http://dx.doi.org/10.1038/nature02520 32.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Mol Cell Endocrinol 2009; 297:18-27; PMID:18824066; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Ann Rev Cell Dev Biol 2006; 22:311-38; PMID:NOT_FOUND;http://dx.doi.org/ 10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Biochem Bio- phys Res Commun 2014; 449:295-300; PMID:24845569; http://dx.doi.org/10.1016/j.bbrc.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Mol Cancer 2014; 13:181; PMID:25070240; http://dx.doi.org/10.1186/1476- 4598-13-181 36.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Trends Genet 1998; 14:156-62; PMID:9594664; http://dx.doi.org/10.1016/S0168-9525(98)01424-3 37.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Cell 2009; 138:660-72; PMID:19703393; http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Endocr J 2008; 55:235-52; PMID:17938503; http://dx.doi.org/10.1507/endocrj.K07E-041 39.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Mol Cell Biol 2013; 33:4017- 29; PMID:23938296; http://dx.doi.org/10.1128/MCB.00469-13 40.,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
RNA Biol 2014; 11:339- 50; PMID:24646523; http://dx.doi.org/10.4161/rna.28300 41.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
EMBO J 2007; 26:2645-57; PMID:17476305; http://dx.doi.org/10.1038/sj.emboj.7601710 42.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
Biochim Biophys Acta 2009; 1793:300-11; PMID:18851995; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
J Mol Biol 2009;392:566-77; PMID:19619559; http://dx.doi.org/ 10.1016/j.jmb.2009.07.036 www.tandfonline.com 3829 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/87/37/kccy-14-24-1069926.PMC4825718.pdf
"7,8Both SIAH1 and SIAH2 were reported to increase proliferation of liver cancer cells9,10and SIAH2 © Bayer Pharma & DKFZ *Correspondence to: Carolyn Algire; Email: carolyn.algire@bayer.com; Thomas G Hofmann; Email: t.hofmann@dkfz.deSubmitted: 07/14/2015; Revised: 09/25/2015; Accepted: 09/29/2015 http://dx.doi.org/10.1080/15384101.2015.1104441 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.o rg/licenses/ by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A 1999; 96:8070-3; PMID:10393949; http://dx.doi.org/ 10.1073/pnas.96.14.8070 3.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Natl Cancer Inst 2008; 100:1606-29; PMID:19001609; http://dx.doi.org/10.1093/jnci/ djn365 4.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
BreastCancer Res Treat 2011; 129:717-24; PMID:21088888; http://dx.doi.org/10.1007/s10549- 010-1254-8 5.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Cell 2010; 18:23-38; PMID:20609350; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Brit J Cancer 2015; 112:514-22; http://dx.doi.org/10.1038/ bjc.2014.659 7.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Disc 2012; 2:401-4;PMID:22588877; http://dx.doi.org/10.1158/2159- 8290.CD-12-0095 8.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Sci Signaling 2013; 6:pl1; PMID:23550210; http://dx.doi.org/ 10.1126/scisignal.2004088 9.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Hepatol 2011; 55:1049-57; PMID:21356256; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Int J Cancer J Int du Cancer 2012; 131:2016-26; PMID:22323152; http://dx.doi.org/ 10.1002/ijc.27473 11.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell Metab 2014; 19:285-92;PMID:24506869; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Pig- ment Cell & Melanoma Res 2009; 22:799-808;PMID:19712206; http://dx.doi.org/10.1111/j.1755- 148X.2009.00628.x 13.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Res 2007; 67:11798-810; PMID:18089810; http://dx.doi.org/10.1158/0008-5472.CAN-06-4471 14.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Res 2009; 69:8835-8;PMID:19920190; http://dx.doi.org/10.1158/0008- 5472.CAN-09-1676 16.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nat Cell Biol 2009; 11:85-91; PMID:19043406; http://dx.doi.org/10.1038/ ncb1816 17.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell 2004; 117:941-52; PMID:15210114; http://dx.doi.org/10.1016/j.cell.2004.06.001 18.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A 2008; 105:16713-8; PMID:18946040; http://dx.doi.org/10.1073/ pnas.0804063105 19.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
PMID:20018442; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nat Cell Biol 2008; 10:812-24; PMID:18536714; http://dx.doi.org/ 10.1038/ncb1743 21.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A2001; 98:15067-72; PMID:11752454; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Biol Chem 2004; 279:5374-9; PMID:14645235; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Res 2013; 73:2400-6; PMID:23455005; http://dx.doi.org/10.1158/0008-5472.CAN-12-4348 24.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Oncogene 2009; 28:289-96; PMID:18850011; http://dx.doi.org/10.1038/ onc.2008.382 25.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nature 2015; 518:422-6; PMID:25470049; http://dx.doi.org/10.1038/nature13952 26.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Res 2012; 72:1694-704; PMID:22354750; http://dx.doi.org/10.1158/0008- 5472.CAN-11-3310 27.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
"Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.Nat Cell Biol 2015; 17:95-103; PMID:25438054; http://dx.doi.org/10.1038/ncb3073 2 8 .C h a nP ,M o l l e rA ,L i uM C ,S c e n e a yJ E ,W o n g CS, Waddell N, Huang KT, Dobrovic A, Millar EK, O’Toole SA, et al.",OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Oncotarget 2014; 5:12509-27;PMID:25587023; http://dx.doi.org/10.18632/ oncotarget.2997 30.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Oncogene 2009; 28:2959-68; PMID:19543318; http://dx.doi.org/10.1038/onc.2009.15632.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
BMC Cancer 2010; 10:403; PMID:20682032; http://dx.doi.org/10.1186/1471-2407-10-403 33.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A2002; 99:14976-81; PMID:12399545; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Sci2010; 101:73-9; PMID:19775288; http://dx.doi.org/ 10.1111/j.1349-7006.2009.01339.x 36.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cancer Res: MCR 2009; 7:1438-45; PMID:19723875; http://dx.doi.org/10.1158/1541- 7786.MCR-09-0234 38.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Breast Cancer Res Treat 2009; 116:263-71; PMID:18629630; http://dx.doi.org/10.1007/s10549- 008-0125-z 39.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Trafﬁc 2004; 5:470- 7; PMID:15180824; http://dx.doi.org/10.1111/j.1600-0854.2004.00196.x 40.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Int JBiochem Cell Biol 2003; 35:39-50; PMID:12467646; http://dx.doi.org/10.1016/S1357- 2725(02)00071-7 41.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Science 2010; 330:1834-8; PMID:21109632; http://dx.doi.org/10.1126/science.1198480 44.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell Cycle 2011; 10:2592- 602; PMID:21734459; http://dx.doi.org/10.4161/ cc.10.15.16912 45.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Res 2011; 71:2350-9; PMID:21248071; http://dx.doi.org/10.1158/0008-5472.CAN-10-3486 46.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Mol Cell Biol 2012; 4:316-30; PMID:22878263; http://dx.doi.org/ 10.1093/jmcb/mjs047 47.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cell Biol 2012; 32:320-32; PMID:22037769; http://dx.doi.org/10.1128/ MCB.05790-11 48.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
EMBO J 2002; 21:5756-65; PMID:12411493;http://dx.doi.org/10.1093/emboj/cdf576 49.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
PloS One 2014; 9: e106547; PMID:25202994; http://dx.doi.org/ 10.1371/journal.pone.0106547 50.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
The Oncologist 2005; 10:780-91; PMID:16314288; http://dx.doi.org/10.1634/theoncologist.10-10-780 52.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cancer 2011; 10:57; PMID:21586138; http://dx.doi.org/10.1186/ 1476-4598-10-57 53.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cell Biol 2002; 22:8155-64; PMID:12417719;http://dx.doi.org/10.1128/MCB.22.23.8155- 8164.2002 55.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Cell 2006; 10:515-27; PMID:17157791; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Endocrinol 1999; 13:2122-36; PMID:10598586; http://dx.doi.org/10.1210/ mend.13.12.0394 57.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
M Cell Biol2000; 20:2890-901; PMID:10733592; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A 2005; 102:13153-7; PMID:16141343; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nat Cell Biol 2005; 7:665-74;PMID:15951807; http://dx.doi.org/10.1038/ ncb1268 62.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Genes Dev 1998; 12:1775- 80; PMID:9637679; http://dx.doi.org/10.1101/gad.12.12.1775 63.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Cell Biol 2014; 204:291-302;PMID:24493586; http://dx.doi.org/10.1083/ jcb.201311112 65.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Trends Biochem Sci 1994; 19:279-83; PMID:8048167; http://dx.doi.org/10.1016/0968- 0004(94)90005-1 67.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell 1994; 78:67-74; PMID:8033213; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Dev Cell 2012; 23:729-44; PMID:23022035; http://dx.doi.org/ 10.1016/j.devcel.2012.08.006 70.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Cell 2005; 7:51-63; PMID:15652749; http://dx.doi.org/10.1016/j.ccr.2004.11.025 71.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Curr Opin Cell Biol 2002; 14:18-24; PMID:11792540; http://dx.doi.org/ 10.1016/S0955-0674(01)00289-7 72.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Trends Cell Biol 2005; 15:346-8; PMID:15951178; http://dx.doi.org/10.1016/j.tcb.2005.05.008 73.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Genes Dev2000; 14:2393-409; PMID:11018009; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cell Biol 1997; 17:5771-83; PMID:9315635; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Ann Surg Oncol 2013; 20:4041-54; PMID:22911364; http://dx.doi.org/10.1245/s10434-012-2519-8 76.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
E2F sites in the Op18 promoter are required for h i g hl e v e lo fe x p r e s s i o ni nt h eh u m a np r o s t a t ec a r - cinoma cell line PC-3-M. Gene 2004; 341:209-18; PMID:15474303; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Cell Biochem 2007; 100:151-60; PMID:16888801; http://dx.doi.org/10.1002/jcb.21040 78.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
"J Biol Chem 2005;280:18120-9; PMID:15746092; http://dx.doi.org/ 10.1074/jbc.M500758200 79. le Gouvello S, Manceau V, Sobel A. Serine 16 of stathmin as a cytosolic target for Ca2 C/calmodulin- dependent kinase II after CD2 triggering of human T lymphocytes.",OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Euro J Biochem/FEBS 1994; 225:53-60; PMID:7925472; http://dx.doi.org/ 10.1111/j.1432-1033.1994.00053.x 81.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
http://dx.doi.org/ 10.1158/1538-7445.AM2014-3154 86.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Science 1992; 257:201-6; PMID:1378648; http://dx.doi.org/10.1126/science.1378648 87.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell Signalling 2011;23:763-71; PMID:20940043; http://dx.doi.org/ 10.1016/j.cellsig.2010.10.014 88.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
JCell Biol 1987; 105:2167-77; PMID:3316248; http://dx.doi.org/10.1083/jcb.105.5.2167 89.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
ISRN Pharmacol 2013; 2013:279593; PMID:23819061; http://dx.doi.org/10.1155/2013/279593 90.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Int J Cancer J Int du Cancer 2003; 106:8-16; PMID:12794751;http://dx.doi.org/10.1002/ijc.11172 91.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
EMBO J 2003; 22:4082-90; PMID:12912907; http://dx.doi.org/10.1093/emboj/cdg392 92.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell 2004; 117:851-3; PMID:15210106; http://dx.doi.org/ 10.1016/j.cell.2004.06.010 93.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Biol Cell 2008; 19:2003-13; PMID:18305103; http://dx.doi.org/10.1091/mbc.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cytoskeleton 2012; 69:278-89;PMID:22407961; http://dx.doi.org/10.1002/ cm.21024 95.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Oncogene 2007;26:1003-12; PMID:16909102; http://dx.doi.org/ 10.1038/sj.onc.1209864 96.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nature 2002; 417:455-8; PMID:12024216; http://dx.doi.org/10.1038/417455a 97.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Cell Sci2013; 126:445-53; PMID:23230143; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cell Cycle 2005; 4:87-95; PMID:15611642; http://dx.doi.org/ 10.4161/cc.4.1.1360 99.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Cancer Sci 2014; 105:690-6; PMID:24708177; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Trans Med 2013; 11:212; PMID:24040910; http://dx.doi.org/10.1186/1479-5876-11-212 101.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Virol 2015; 89:35-47; PMID:25320307; http://dx.doi.org/ 10.1128/JVI.02317-14 102.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proc Natl Acad Sci U S A 2011; 108:12851-6;PMID:21768358; http://dx.doi.org/10.1073/ pnas.1017372108 103.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
BMC Cancer 2014; 14:28; PMID:24433541; http://dx.doi.org/10.1186/1471-2407-14-28 104.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Proteome Res 2012; 11:1433-45; PMID:22181002; http://dx.doi.org/10.1021/ pr2010956 1 0 5 .,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
"L i nX ,L i a oY ,X i eJ ,L i uS ,S uL ,Z o uH .O p 1 8 / stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.Cancer Biother Radiopharm 2014; 29:376-86; PMID:25379611; http://dx.doi.org/10.1089/ cbr.2014.1649 106.",Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Biochem Pharmacol 2012; 84:432-43; PMID:22634050; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Cell Biol 2006; 172:245-57; PMID:16401721; http://dx.doi.org/10.1083/jcb.200503021109.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
LabInvestigat; J Tech Methods Pathol 2004; 84:588-96; PMID:15064772; http://dx.doi.org/10.1038/ labinvest.3700078 111.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
FASEBJ: Off Pub Federat Am Soc Exp Biol 2001; 15:1877- 85; PMID:11532967; http://dx.doi.org/10.1096/ fj.01-0065com 112.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Circulation 2001; 103:2967-72;PMID:11413088; http://dx.doi.org/10.1161/01.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Skp2- RNAi suppresses proliferation and migration of gall- bladder carcinoma cells by enhancing p27 expression.World J Gastroenterol: WJG 2013; 19:4917-24; PMID:23946596; http://dx.doi.org/10.3748/wjg.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Cell Sci 2014; 127:2920-33;PMID:24727615; http://dx.doi.org/10.1242/ jcs.148130 115.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
J Biol Chem 1997; 272:13467-70;PMID:9153188; http://dx.doi.org/10.1074/ jbc.272.21.13467 118.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Proteomics 2007; 7:3207-18; PMID:17683050; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Exp Cell Res 2010; 316:68- 77; PMID:19744480; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Nat Struct Biol2002; 9:68-75; PMID:11742346; http://dx.doi.org/ 10.1038/nsb743 123.,OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Mol Cancer Therap 2012; 11:2265-73;PMID:22821149; http://dx.doi.org/10.1158/1535- 7163.MCT-12-0286 124.,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
Circ Res 2013; 113:1206-18; PMID:24025447; http://dx.doi.org/10.1161/ CIRCRESAHA.113.301686 www.tandfonline.com 3747 Cell Cycle,Non-OADS,/arxiv_data1/oa_pdf/30/88/kccy-14-23-1104441.PMC4825722.pdf
"Cell Cycle 2015; 14(18):2949-58; PMID: 26259964; http://dx.doi.org/10.1080/15384101.2015.1071745 Eric Dufour*; BioMediTech and Tampere University Hospital; University of Tampere; Tampere, Finland; *Correspondence to: Eric Dufour; Email: Eric .Dufour@uta.",OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
"ﬁ; Keywords: Adaptation to temperature, Aging, FOXO, Insulin signaling, TORC1; http://dx.doi.org/10.1080/15384101.2015.1105695; /C211Eric Dufour; This is an Open Access article distributed under the terms of the Creative Commons Attribution-on-ommercial License (http://creativecommons.org/license s/byc/3.0/), which permits unrestricted nonommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
Cell Cycle 2015; 14:2949 –2958; PMID:26259964; http://dx.doi.org/10.1080/15384101.2015.1071745 3.,Non-OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
Trends Cell Biol 2014; 24:400-406; PMID: 24698685; http://dx.doi.org/ 10.1016/j.tcb.2014.03.003 4.,OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
Trends Mol Med 2009; 15:217- 224; PMID:19380253; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
Cell Cycle 2010; 9:3151-3156; PMID:20724817; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
Cell 2012; 149:274-293; PMID: 22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017 3780 Volume 14 Issue 24 Cell Cycle,OADS,/arxiv_data1/oa_pdf/6c/94/kccy-14-24-1105695.PMC4825737.pdf
"1, 25 –40 http://dx.doi.org/10.1080/15384101.2015.1121324",Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"67LILRB5 is unique among LILRBs in that it is the only LILRB that is not highly expressed by M5 AML cells, and its expression level does not correlate with the overall survival of AML patients based on analysis of TCGA database of AMLpatients (https://tcga-data.nci.nih.gov/tcga/).",Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity 1995; 3:635-46;PMID:7584153; http://dx.doi.org/10.1016/1074-7613(95)90134-5 2.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cell Signal 2004; 16:435-56; PMID:14709333; http://dx.doi.org/10.1016/j.cellsig.2003.08.013 3.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biomed Biotechnol 2011; 2011:275302;PMID:20976309; http://dx.doi.org/10.1155/2011/275302 4.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
ImmunolRev 2008; 224:11-43; PMID:18759918; http://dx.doi.org/10.1111/j.1600-065X.2008.00666.x 5.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Adv Immunol 2006; 91:251-72; PMID:16938543; http://dx.doi.org/10.1016/S0065-2776(06)91007-4 6.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J BiolChem 2000; 275:37357-64; PMID:11016922; http://dx.doi.org/10.1074/jbc.M003518200 7.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity 1996; 5:629-38; PMID:8986721; http://dx.doi.org/ 10.1016/S1074-7613(00)80276-9 9.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Med 2002; 8:61-7; PMID:11786908; http://dx.doi.org/10.1038/nm0102-61 10.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Mol Cell Biol 2003;23:6291-9; PMID:12917349; http://dx.doi.org/10.1128/MCB.23.17.6291-6299.2003 11.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Immunol 2009; 10:340-7; PMID:19295630; http://dx.doi.org/10.1038/ni.1706 12.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 1997; 186:1809-18; PMID:9382880; http://dx.doi.org/10.1084/jem.186.11.1809 14.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
EurJ Immunol 1997; 27:660-5; PMID:9079806; http://dx.doi.org/10.1002/eji.1830270313 16.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Trend Immu-nol 2002; 23:81-8; PMID:11929131; http://dx.doi.org/10.1016/S1471-4906(01)02155-X 17.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Mam-malian Gen 1999; 10:154-60; PMID:9922396; http://dx.doi.org/ 10.1007/s003359900961 18.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
ProcNatl Acad Sci U S A 1997; 94:5261-6; PMID:9144225; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nature 2012; 485:656-60; PMID:22660330; http://dx.doi.org/10.1038/nature11095 22.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Science 2008; 322:967-70; PMID:18988857; http://dx.doi.org/10.1126/science.1161151 24.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Science 2013; 341:1399-404; PMID:24052308; http://dx.doi.org/10.1126/science.1242077 25.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cell 2015;161:205-14; PMID:25860605; http://dx.doi.org/10.1016/j.cell.2015.03.030 26.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Adv Immunol 2015; 127:33-144; PMID:26073983; http://dx.doi.org/10.1016/bs.ai.2015.04.001 27.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"Olde Nordkamp MJ, van Eijk M, Urbanus RT, Bont L, Haagsman HP, Meyaard L. Leukocyte-associated Ig-like receptor-1 is a novel inhibitory receptor for surfactant protein D. J Leukoc Biol 2014;96:105-11; PMID:24585933; http://dx.doi.org/10.1189/jlb.3AB0213-092RR 28.",OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity 1997; 7:283-90; PMID:9285412; http://dx.doi.org/10.1016/S1074-7613(00)80530-0 29.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 1995; 25:369-76; PMID:7875198; http://dx.doi.org/10.1002/eji.1830250210 30.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 2006; 203:1419-25; PMID:16754721; http://dx.doi.org/10.1084/jem.20052554 31.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Cell Biol 2015; 17:665-77; PMID:25915125; http://dx.doi.org/10.1038/ncb3158 32.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Leukemia 2012; 26:1889-92; PMID:22441169; http://dx.doi.org/10.1038/ leu.2012.62 36.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2011; 117:2864-73; PMID:21233315; http://dx.doi.org/10.1182/blood-2010-09-309781 37.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2004; 103:1796-8; PMID:14592815;http://dx.doi.org/10.1182/blood-2003-10-3372 38.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Clin Dev Immunol 2012; 2012:652130; PMID:22844324; http://dx.doi.org/10.1155/2012/652130 40.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cytometry B Clin Cytom 2007;72:354-62; PMID:17266150; http://dx.doi.org/10.1002/cyto.b.20164 41.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Diagn Pathol 2014; 9:85; PMID:24762057; http://dx.doi.org/10.1186/1746-1596-9-85 42.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Chest 2008;134:783-8; PMID:18625675; http://dx.doi.org/10.1378/chest.07-1100 43.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2009; 114:2323-32; PMID:19617579; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2007; 178:7432-41;PMID:17513794; http://dx.doi.org/10.4049/jimmunol.178.11.7432 45.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nature 2015; 521:357-61; PMID:25799995; http://dx.doi.org/10.1038/nature14231 47.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity2011; 34:385-95; PMID:21376641; http://dx.doi.org/10.1016/j.immuni.2011.02.004 48.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunol Rev 2008; 224:98-123; PMID:18759923; http://dx.doi.org/10.1111/j.1600-065X.2008.00653.x 50.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunol Rev 2015;267:117-36; PMID:26284474; http://dx.doi.org/10.1111/imr.12314 51.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Immunol 2003; 4:913-9; PMID:12897781; http://dx.doi.org/10.1038/ni961 52.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
PLoS One2015; 10:e0129063; PMID:26098415; http://dx.doi.org/10.1371/ journal.pone.0129063 55.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2009; 182:1033-40; PMID:19124746; http://dx.doi.org/10.4049/jimmunol.182.2.1033 57.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Retrovirology 2013; 10:122; PMID:24156302; http://dx.doi.org/10.1186/1742-4690-10-122 58.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2008; 181:4229-39; http://dx.doi.org/ 10.4049/jimmunol.181.6.4229 59.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunology 2005; 115:433-40; PMID:16011512; http://dx.doi.org/10.1111/j.1365-2567.2005.02177.x 60.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cytometry B Clin Cytom 2013; 84:21-9;PMID:23027709; http://dx.doi.org/10.1002/cyto.b.21050 62.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Mol Cell Biol 2000; 20:7178-82; PMID:10982834; http://dx.doi.org/10.1128/MCB.20.19.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2012; 120:3256-9; PMID:22948046; http://dx.doi.org/10.1182/blood-2012-03-419093 65.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2012; 188: 548-58; PMID:22156345; http://dx.doi.org/10.4049/jimmunol.1102044 66.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"Hunt JS, Petroff MG, Morales P, Sedlmayr P, Geraghty DE, Ober C. HLA-G in reproduction: studies on the maternal-fetal interface.Human immunology 2000; 61:1113-7; PMID:11137215; http://dx.doi.org/10.1016/S0198-8859(00)00195-6 67.",OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J LeukocBiol 2008; 83:334-43; PMID:17998301; http://dx.doi.org/10.1189/ jlb.0507314 68.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Hum Immunol 2010; 71:942-9; PMID:20600445; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2010; 115:3278-86; PMID:20194892; http://dx.doi.org/10.1182/blood-2009-09-243493 70.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2000; 30:3552-61;PMID:11169396; http://dx.doi.org/10.1002/1521-4141(200012) 30:12%3c3552::AID-IMMU3552%3e3.0.CO;2-L 71.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Methods 2002; 268:43-50; PMID:12213342; http://dx.doi.org/ 10.1016/S0022-1759(02)00199-0 72.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 2006; 281:10439-47; PMID:16455647; http://dx.doi.org/10.1074/jbc.M512305200 73.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity 1999; 11:603-13;PMID:10591185; http://dx.doi.org/10.1016/S1074-7613(00)80135-1 74.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunity 2000; 13:727-36;PMID:11114384; http://dx.doi.org/10.1016/S1074-7613(00)00071-6 75.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2001; 167:5543-7; http://dx.doi.org/10.4049/jimmunol.167.10.5543 76.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Inter Immunol 1999; 11:29-35; PMID:10050671; http://dx.doi.org/10.1093/intimm/11.1.29 77.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 1999; 29:277-83; PMID:9933109;http://dx.doi.org/10.1002/(SICI)1521-4141(199901)29:01%3c277:: AID-IMMU277%3e3.0.CO;2-4 78.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2008; 181:2368-81; PMID:18684926; http://dx.doi.org/10.4049/jimmunol.181.4.2368 79.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
FASEB J 2010; 24:689-99; PMID:19841038; http://dx.doi.org/10.1096/fj.09-135194 81.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Proc Natl Acad Sci U S A 1999; 96:5674-9; PMID:10318943; http://dx.doi.org/10.1073/ pnas.96.10.5674 82.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Reproduct Immunol 2002; 56:3-17; PMID:12106880; http://dx.doi.org/10.1016/S0165-0378(02)00024-4 83.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Clin Invest 2011;121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816 84.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2015; 45:1560-9; PMID:25726929; http://dx.doi.org/10.1002/eji.201445353 85.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immu-nol 2005; 175:5006-15; http://dx.doi.org/10.4049/ jimmunol.175.8.5006 86.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Biol Blood MarrowTrans 2010; 16:612-21; PMID:20139023; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
PloS one 2008; 3:e1975; PMID:18398485; http://dx.doi.org/10.1371/journal.pone.0001975 89.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 1998;28:3423-34; PMID:9842885; http://dx.doi.org/10.1002/(SICI) 1521-4141(199811)28:11%3c3423::AID-IMMU3423%3e3.0.CO;2-2 90.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2013; 191:3651-62;PMID:23997222; http://dx.doi.org/10.4049/jimmunol.1300567 91.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Pathol 2002; 196:266-74; PMID:11857488; http://dx.doi.org/10.1002/path.1039 92.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Gene 2004; 331:159-64;PMID:15094202; http://dx.doi.org/10.1016/j.gene.2004.02.018 93.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2008; 111:3090-6; PMID:18094328; http://dx.doi.org/10.1182/blood-2007-05-089771 94.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immu- nol Lett 2008; 120:49-56; PMID:18652845; http://dx.doi.org/10.1016/ j.imlet.2008.06.009 9 5 .,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2005; 174:6757-63; http://dx.doi.org/10.4049/jimmunol.174.11.6757 96.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2007; 37:1924-37; PMID:17549736; http://dx.doi.org/10.1002/eji.200737089 97.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Virol 2010;84:9463-71; PMID:20631139; http://dx.doi.org/10.1128/JVI.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2001; 166:3933-41; http://dx.doi.org/10.4049/jimmunol.166.6.3933 101.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunology 2004; 112:531- 42; PMID:15270723; http://dx.doi.org/10.1046/j.1365-2567.2004.01907.x 103.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"J Immunol (Baltimore, Md : 1950) 2002; 168:207-15; PMID:11751964; http://dx.doi.org/10.4049/jimmunol.168.1.207 104.",Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Infect Immun 2001; 69:6022-9; PMID:11553539; http://dx.doi.org/10.1128/IAI.69.10.6022-6029.2001 105.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2001; 166:2514-21; PMID:11160312;http://dx.doi.org/10.4049/jimmunol.166.4.2514 106.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Transplantation2008; 86:1125; PMID:18946352; http://dx.doi.org/10.1097/ TP.0b013e318186fccd 107.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cell Mol Life Sci 2011; 68:3385-99; PMID:21337044; http://dx.doi.org/10.1007/s00018-011-0632-7 109.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2004; 172:5629-37; http://dx.doi.org/10.4049/ jimmunol.172.9.5629 110.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immu- nol 2007; 178:3536-43; http://dx.doi.org/10.4049/jimmunol.178.6.3536 111.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2014; 192:1536-46; http://dx.doi.org/10.4049/ jimmunol.1300438 113.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Inter Immunol 2004; 16:1055-68; PMID:15226269; http://dx.doi.org/ 10.1093/intimm/dxh107 115.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Transpl Immunol 2003; 11:245-58; PMID:12967778; http://dx.doi.org/10.1016/S0966-3274 (03)00058-3 117.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
PLoS genetics 2014; 10:e1004196; PMID:24603468; http://dx.doi.org/10.1371/journal.pgen.1004196 118.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
BMC Immunol 2009; 10:56; PMID:19860908; http://dx.doi.org/10.1186/1471-2172- 10-56 119.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2004; 104:2832-9; PMID:15242876; http://dx.doi.org/10.1182/blood-2004-01-0268 120.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Am J Transplant 2006; 6:76-82; PMID:16433759; http://dx.doi.org/ 10.1111/j.1600-6143.2005.01162.x 123.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 2011; 286:18013-25;PMID:21454581; http://dx.doi.org/10.1074/jbc.M111.221028 125.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
PloS one 2014; 9:e115488; PMID:25551576; http://dx.doi.org/10.1371/journal.pone.0115488 126.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 2009; 284:34839-48; PMID:19833736; http://dx.doi.org/10.1074/jbc.M109.035683 127.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2006; 176:2790-8; PMID:16493035;http://dx.doi.org/10.4049/jimmunol.176.5.2790CELL CYCLE 37,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Diabetes 2008; 57:1878-86; PMID:18420485; http://dx.doi.org/10.2337/db08-0054 129.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2009; 182:5208-16; http://dx.doi.org/10.4049/jimmunol.0804048 131.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2010; 185:5714-22; http://dx.doi.org/ 10.4049/jimmunol.1001732 132.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"Nat Immunol 2015; 16:267-75; PMID:25599562; http://dx.doi.org/10.1038/ni.3083 133. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP.",OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Oncoimmunology 2015; 4:e1014242; PMID:26140237; http://dx.doi.org/10.1080/2162402X.2015.1014242 134.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.Trans Oncol 2012; 5:85-91; PMID:22496924; http://dx.doi.org/10.1593/tlo.11328 135.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
CirculCardiov Gen 2014; 7:880-6; PMID:25214527; http://dx.doi.org/ 10.1161/CIRCGENETICS.113.000395 136.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 1998; 187:1355-60; PMID:9547347; http://dx.doi.org/10.1084/jem.187.8.1355 137.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Acta Haematol 2010; 124:134-40; PMID:20881379; http://dx.doi.org/10.1159/000315553 138.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Immunol 2002; 3:542-8; PMID:12021780;http://dx.doi.org/10.1038/ni801 139.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Gastroenterol 2010; 139:530-41; PMID:20398663; http://dx.doi.org/10.1053/j.gastro.2010.04.006 140.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Am J Resp Cell Mol Biol 2013; 48:456-64; PMID:23258232; http://dx.doi.org/10.1165/rcmb.2012-0329OC 141.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Int Immunol 2009; 21:1151-61; PMID:19684158; http://dx.doi.org/10.1093/intimm/dxp081 142.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Sci Trans Med 2014; 6:258ra140; http://dx.doi.org/10.1126/scitranslmed.3010157 144.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Science 2006; 313:1795-800;PMID:16917027; http://dx.doi.org/10.1126/science.1128232 146.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Proc Natl Acad Sci U S A1983; 80:5916-8; PMID:6577460; http://dx.doi.org/10.1073/ pnas.80.19.5916 148.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
CellImmunol 1984; 83:242-54; PMID:6198098; http://dx.doi.org/ 10.1016/0008-8749(84)90303-4 149.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 2003; 198:1243-51; PMID:14557414; http://dx.doi.org/10.1084/jem.20030906 150.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2000; 164:5215-20; http://dx.doi.org/10.4049/jimmunol.164.10.5215 151.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2003; 170:4095-101; http://dx.doi.org/10.4049/jimmunol.170.8.4095 152.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 1998; 273:1070-4; PMID:9422771; http://dx.doi.org/10.1074/jbc.273.2.1070 153.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 1999; 274:5791-6; PMID:10026201; http://dx.doi.org/10.1074/jbc.274.9.5791 155.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2014; 193:635-44; http://dx.doi.org/10.4049/jimmunol.1302772 156.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 2001; 194:227-34; PMID:11457897; http://dx.doi.org/10.1084/jem.194.2.227 157.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2003; 33:2262-8; PMID:12884301; http://dx.doi.org/ 10.1002/eji.200323978 158.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2005; 35:1530-8; PMID:15827966;http://dx.doi.org/10.1002/eji.200425895 159.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Immunol 2010; 184:1003-13; http://dx.doi.org/10.4049/ jimmunol.0900877 160.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Blood 2004; 103:1398-407; PMID:14551136;http://dx.doi.org/10.1182/blood-2003-07-2617 162.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cell Signal 2008; 20:453-9; PMID:17993263;http://dx.doi.org/10.1016/j.cellsig.2007.10.002 163.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunol Lett 2010; 128:26-8; PMID:19836418; http://dx.doi.org/10.1016/j.imlet.2009.09.014 164.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Haematologica 2014; 99:881-7; PMID:24415628; http://dx.doi.org/10.3324/ haematol.2013.096362 165.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Leukemia 2008; 22:980-8; PMID:18288129; http://dx.doi.org/10.1038/leu.2008.21 166.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur J Immunol 2000; 30:2751-8; PMID:11069054; http://dx.doi.org/10.1002/1521-4141(200010) 30:10%3c2751::AID-IMMU2751%3e3.0.CO;2-L 167.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Eur JImmunol 2001; 31:3667-75; PMID:11745387; http://dx.doi.org/10.1002/1521-4141(200112)31:12%3c3667::AID- IMMU3667%3e3.0.CO;2-G 168.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nature 2006; 442:818-22; PMID:16862118; http://dx.doi.org/ 10.1038/nature04980 169.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cancer Cell 2006; 10:257-68; PMID:17045204; http://dx.doi.org/10.1016/j.ccr.2006.08.020 170.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Med 2006; 12:945-9; PMID:16892037; http://dx.doi.org/10.1038/nm1443 171.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nature 2013; 498:502-5; PMID:23739325; http://dx.doi.org/10.1038/nature12216 173.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
NatBiotech 2012; 30:997-1001; PMID:22983091; http://dx.doi.org/ 10.1038/nbt.2354 174.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 2000; 275:17440-6; PMID:10764762; http://dx.doi.org/10.1074/jbc.M001313200 175.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Biol Chem 2002; 277:36878-88; PMID:12145285; http://dx.doi.org/ 10.1074/jbc.M203917200 176.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Leukoc Biol 2006; 79:828-36;PMID:16461736; http://dx.doi.org/10.1189/jlb.0705370 177.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Leukemia 2011; 25:1768-81; PMID:21701493; http://dx.doi.org/10.1038/leu.2011.152 179.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Cell Biochem 2003; 90:1026-37; PMID:14624462; http://dx.doi.org/10.1002/jcb.10727 182.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Exp Med 1996; 184:1111-26; PMID:9064328; http://dx.doi.org/10.1084/jem.184.3.1111 183.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Nat Genet 1996; 13:309-15;PMID:8673130; http://dx.doi.org/10.1038/ng0796-309 184.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
J Korean Med Sci 2009; 24:493-7; PMID:19543515; http://dx.doi.org/ 10.3346/jkms.2009.24.3.493 186.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Pediat Hematol Oncol 2009; 26:48-56;PMID:19206008; http://dx.doi.org/10.1080/08880010802625530CELL CYCLE 39,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Cancer Cell 2011; 19:629-39; PMID:21575863; http://dx.doi.org/10.1016/j.ccr.2011.03.023 188.,Non-OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Annal New York Acad Sci 2014; 1321:41-54; PMID:25123209; http://dx.doi.org/10.1111/nyas.12499 189.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
Immunol Rev 2015; 263:68-89; PMID:25510272; http://dx.doi.org/10.1111/imr.1224340 X. KANG ET AL.,OADS,/arxiv_data1/oa_pdf/42/6d/kccy-15-01-1121324.PMC4825776.pdf
"1, 13 –21 http://dx.doi.org/10.1080/15384101.2015.1093709",Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cold Spring Harb Perspect Biol 2015; 7:a016634; http://dx.doi.org/10.1101/cshperspect.a016634 2.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
AnnuRev Genet 2014; 48:187-214; PMID:25421598; http://dx.doi.org/10.1146/annurev-genet-120213-092304 3.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genome Res 2012; 22:957-65; PMID:22367190;http://dx.doi.org/10.1101/gr.130583.111 4.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2011; 144:719-31; PMID:21376234; http://dx.doi.org/10.1016/j.cell.2011.02.009 5.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2011; 472:375-8; PMID:21460839; http://dx.doi.org/10.1038/nature09869 7.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genome Res 2014; 24:1650-64;PMID:25024163; http://dx.doi.org/10.1101/gr.172122.114 8. de Massy B. Initiation of meiotic recombination: how and where?,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
"Annu Rev Genet 2013; 47:563-99; PMID:24050176; http://dx.doi.org/10.1146/annurev-genet-110711-155423 9. Cooper TJ, Wardell K, Garcia V, Neale, MJ.",Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Exp Cell Res 2014; 329:124-31; PMID:25116420; http://dx.doi.org/10.1016/j.yexcr.2014.07.016 10.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Mol Cell Biol 2009; 29:3500-16; PMID:19380488; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genes Dev 2005; 19:255-69; PMID:15655113; http://dx.doi.org/10.1101/gad.32110518 T. J. COOPER ET AL.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Plant J 2015; 83:52-61; PMID:25925869; http://dx.doi.org/10.1111/tpj.12870 13.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Bioessays 2006; 28:45-56; PMID:16369948; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2009; 458 362-6; PMID:19092803; http://dx.doi.org/10.1038/nature07667 15.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Mol Cell Biol 1996; 16:2037-43;PMID:8628269; http://dx.doi.org/10.1128/MCB.16.5.2037 16.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nucleic Acids Res 2008; 36:984-97; PMID:18096626; http://dx.doi.org/10.1093/nar/gkm1082 18.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Mol Cell Biol 2007; 27:1868-80; PMID:17189430; http://dx.doi.org/10.1128/MCB.02063-06 19.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2002; 111:791-802; PMID:12526806; http://dx.doi.org/10.1016/S0092-8674(02)01167-4 22.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Chromosoma 2006; 115 175-94;PMID:16555016; http://dx.doi.org/10.1007/s00412-006-0055-7 23.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Curr Opin Genet Dev 2013; 23:147-55; PMID:23313097; http://dx.doi.org/10.1016/ j.gde.2012.12.002 24.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
EMBO J 2004; 23:1815-24; PMID:15044957; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Annu Rev Genet 1999; 603-754; PMID:10690419; http://dx.doi.org/10.1146/annurev.genet.33.1.603 26.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2011; 146:372-83; PMID:21816273; http://dx.doi.org/10.1016/j.cell.2011.07.003 27.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Mol Cell 2013; 49:43-54; PMID:23246437; http://dx.doi.org/10.1016/j.molcel.2012.11.008 28.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
EMBO J 2009; 28:99-111;PMID:19078966; http://dx.doi.org/10.1038/emboj.2008.25730.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell Cycle 2012; 11:1496-503; PMID:22433953; http://dx.doi.org/10.4161/cc.19733 31.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Elife 2015; 4:e07424; http://dx.doi.org/ 10.7554/eLife.07424 32.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
BMC Bioinfor-matics 2014; 15:391; PMID:25495332; http://dx.doi.org/10.1186/ s12859-014-0391-1 33.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
2008; 180:83-90; PMID:18180366; http://dx.doi.org/ 10.1083/jcb.200706136 34.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Biol 2004; 2:E259; PMID:15309048; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genes Cells 2014; 19:359-73; PMID:24635992; http://dx.doi.org/10.1111/gtc.12138 36.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2010; 143:924-37; PMID:21145459; http://dx.doi.org/10.1016/j.cell.2010.11.015 37.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Science 2010; 327: 836-40; PMID:20044539; http://dx.doi.org/10.1126/science.1183439 38.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Science 2010; 327:835; PMID:20044538; http://dx.doi.org/10.1126/science.1181495 39.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
2010; 11:104; PMID:20210982; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Biol 2011; 9:e1001176; PMID:22028627; http://dx.doi.org/ 10.1371/journal.pbio.1001176 41.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
EMBO J 2009; 28:2616-24; PMID:19644444; http://dx.doi.org/10.1038/emboj.2009.207 42.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nat Genet 2010; 42:859-63; PMID:20818382; http://dx.doi.org/10.1038/ng.658 43.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2012; 485:642-5; PMID:22660327; http://dx.doi.org/10.1038/nature11089 44.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS One 2014; 9:e85021; PMID:24454780; http://dx.doi.org/ 10.1371/journal.pone.0085021 45.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2015; 520:114-8; PMID:25539084; http://dx.doi.org/10.1038/nature13993CELL CYCLE 19,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Annu Rev Biochem 2015; 84:711-38; PMID:25580527; http://dx.doi.org/10.1146/annurev-biochem-060614-034335 48.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Open Biol 2013;3:130019; PMID:23902647; http://dx.doi.org/10.1098/rsob.130019 49.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Genet 2013; 9: e1003545; PMID:23825959; http://dx.doi.org/10.1371/journal.pgen.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2014; 510:241-6; PMID:24717437; http://dx.doi.org/ 10.1038/nature13120 51.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genes Dev 2013; 27:873-86; PMID:23599345; http://dx.doi.org/10.1101/gad.213652.113 52.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cold Spring Harb Perspect Biol 2015; 7:a016626; PMID:25986558; http://dx.doi.org/10.1101/cshperspect.a016626 53.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2010; 141:970-81; PMID:20550933; http://dx.doi.org/10.1016/j.cell.2010.04.038 55.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nat Rev Mol Cell Biol 2013; 14:197-210; http://dx.doi.org/10.1038/nrm3546 56.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2013; 152:1344-54; PMID:23498941; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
NatStruct Mol Biol 2014; 21:103-9; PMID:24336221; http://dx.doi.org/ 10.1038/nsmb.2737 58.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Curr Biol 2004; 14:1703-11; PMID:15458641; http://dx.doi.org/10.1016/j.cub.2004.09.047 59.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2014; 511:551-6; PMID:25043020; http://dx.doi.org/10.1038/nature13442 60.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 2006; 126:246-8; PMID:16873056; http://dx.doi.org/ 10.1016/j.cell.2006.07.010 61.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2002; 415:871-80; PMID:11859360; http://dx.doi.org/10.1038/nature724 63.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
"Science 1996; 274, 546:563-7; http://dx.doi.org/10.1126/ science.274.5287.546 64.",Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 1996; 86:159-71; PMID:8689683; http://dx.doi.org/10.1016/S0092-8674(00)80086-0 66.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nature 2011; 479:237-40; PMID:22002603; http://dx.doi.org/10.1038/nature10508 67.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Science 2011; 331:916-20; PMID:21330546; http://dx.doi.org/ 10.1126/science.1195774 68.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Chromo-soma 2007; 116:471-86; PMID:17558514; http://dx.doi.org/10.1007/ s00412-007-0111-y 71.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Genet 2011; 7:e1002305;PMID:21980306; http://dx.doi.org/10.1371/journal.pgen.1002305 73.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Cell 1991; 66:1239-56; PMID:1913808; http://dx.doi.org/10.1016/0092-8674(91)90046-2 74.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Annu Rev Genet 1998; 32:619-97; PMID:9928494; http://dx.doi.org/10.1146/annurev.genet.32.1.619 75.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genetics 2004; 168:35-48; PMID:15454525; http://dx.doi.org/10.1534/genetics.104.027789 76.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Genet 2013; 9:e1003984; PMID:24348265; http://dx.doi.org/10.1371/journal.pgen.1003984 78.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS One 2011; 6:e25498; http://dx.doi.org/10.1371/journal.pone.0025498 79.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genome Res 2012; 22:51-63;PMID:22006216; http://dx.doi.org/10.1101/gr.124123.111 80.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genetics 2014; 196:137-48;PMID:24172135; http://dx.doi.org/10.1534/genetics.113.158857 81.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
PLoS Genet 2012; 8: e1002905; PMID:23071443; http://dx.doi.org/10.1371/journal.pgen.1002905 83.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Genetics 2009; 182:459-69; PMID:19363124; http://dx.doi.org/10.1534/genetics.109.10125320 T. J. COOPER ET AL.,Non-OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nucleic Acids Res 2013; 41:3504-17; PMID:23382177; http://dx.doi.org/10.1093/ nar/gkt049 85.,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
Nat Genet 2013; 45:1327-36; PMID:24056716; http://dx.doi.org/10.1038/ng.2766 8 6 .,OADS,/arxiv_data1/oa_pdf/b8/f0/kccy-15-01-1093709.PMC4825777.pdf
"1, 117 –127 http://dx.doi.org/10.1080/15384101.2015.1121326",Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Cancer Res 2009; 69:8200-7; PMID:19826041; http://dx.doi.org/10.1158/0008-5472.CAN-09-1976 2.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Exp Cell Res 2011; 317:1541-7; PMID:21376036; http://dx.doi.org/10.1016/j.yexcr.2011.02.015 3.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Exp Gerontol 2011; 46:500-10;PMID:21382465; http://dx.doi.org/10.1016/j.exger.2011.02.012 4.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Int J Radiat Biol 2012; 88:393-404; PMID:22348537; http://dx.doi.org/10.3109/09553002.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Chem Cent J 2012; 6:18; PMID:22424056; http://dx.doi.org/ 10.1186/1752-153X-6-18 6.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nat Rev Mol Cell Biol 2007; 8:729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233 7.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Cell Death Dis 2013; 4:e911; PMID:24201810; http://dx.doi.org/10.1038/cddis.2013.445 9.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Aging Cell 2013; 12:489-98; PMID:23521863; http://dx.doi.org/10.1111/acel.12075 10.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Exp Gerontol 1992; 27:375-82; PMID:1459213;http://dx.doi.org/10.1016/0531-5565(92)90068-B 11.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Int J Biochem Cell Bio 2002; 34:1415-29; PMID:12200036; http://dx.doi.org/10.1016/S1357-2725 (02)00034-1 12.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Clin Invest 2004; 113:8-13; PMID:14702100; http://dx.doi.org/10.1172/JCI200420663 13.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Biochem Biophys Res Commun 2007; 362:707-11; PMID:17720141; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Biol Chem 2010; 285:29662-70; PMID:20639198; http://dx.doi.org/10.1074/jbc.M110.125138 1 5 .,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Trends Biochem Sci 2012; 37:15-22; PMID:22079189; http://dx.doi.org/10.1016/j.tibs.2011.10.002 16.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nature 2003; 421:499-506; PMID:12556884; http://dx.doi.org/10.1038/nature01368 17.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Cell Biol 2009; 187:977-990; PMID:20026654; http://dx.doi.org/10.1083/jcb.200906064 18.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Oncogene 2003; 22:9030-40; PMID:14663481; http://dx.doi.org/10.1038/sj.onc.1207116 19.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Science 1997; 277:831-4; PMID:9242615; http://dx.doi.org/10.1126/science.277.5327.831 20.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Genes Dev 1999; 13:1501-12; PMID:10385618; http://dx.doi.org/10.1101/gad.13.12.1501 21. d ’Adda di Fagagna F. Living on a break: cellular senescence as a DNA- damage response.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nat Rev Cancer 2008; 8:512-22; PMID:18574463; http://dx.doi.org/10.1038/nrc2440 22.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Feedback between p21 and reactive oxygen production is necessary for cell senescence Mol Syst Biol 2010; 6:347; PMID:20160708; http://dx.doi.org/10.1038/msb.2010.5 23.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nat Rev Mol Cell Biol 2008; 9:759-69;PMID:18813293; http://dx.doi.org/10.1038/nrm2514 25.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nature 2003; 426:194-8; PMID:14608368; http://dx.doi.org/10.1038/nature02118 27.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nat Chem Biol 2006; 2:369-74; PMID:16767085; http://dx.doi.org/10.1038/nchembio800 28.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
PLoS One 2014; 9:e104279; PMID:25093836; http://dx.doi.org/ 10.1371/journal.pone.0104279 29.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Cancer Res 2004; 64:9152-9; PMID:15604286; http://dx.doi.org/10.1158/0008-5472.CAN-04-2727 30.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Clin Cancer Res2008; 14:1877-87; PMID:18347191; http://dx.doi.org/10.1158/1078-0432.CCR-07-4298 31.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
RadiatOncol 2009; 4:51; PMID:19903334; http://dx.doi.org/10.1186/1748-717X-4-51 32.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nat Chem Biol 2012; 8:646-54; PMID:22660439; http://dx.doi.org/10.1038/nchembio.965 33.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Biol Chem 2005; 280:19635-40;PMID:15753076; http://dx.doi.org/10.1074/jbc.M502262200 34.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Int J Radiat Biol 2013; 89:501-11; PMID:23425510; http://dx.doi.org/10.3109/ 09553002.2013.775530 35.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Autophagy 2008; 4:810-4; PMID:18604159; http://dx.doi.org/10.4161/auto.6486 37.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Curr Opin Cell Bio 2010; 22:181-5; PMID:20044243; http://dx.doi.org/10.1016/j.ceb.2009.12.001 38.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Nature Cell Biol 2008; 10:676-87; PMID:18454141; http://dx.doi.org/10.1038/ncb1730 39.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Transl Med 2007; 5:57; PMID:18005405; http://dx.doi.org/10.1186/1479-5876-5-57 40.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Cell Transpl 2008; 17:303-11; PMID:18522233; http://dx.doi.org/10.3727/096368908784153922 41.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Chro- mosoma 1997; 106:348-60; PMID:9362543; http://dx.doi.org/10.1007/s004120050256 43.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Mol Biol Cell 2001; 12:1315-28; PMID:11359924; http://dx.doi.org/10.1091/mbc.12.5.1315 44.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Science 1999;285:1733-7; PMID:10481009; http://dx.doi.org/10.1126/ science.285.5434.1733 46.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Am J Pathol2009; 174:423-35; PMID:19147823; http://dx.doi.org/10.2353/ ajpath.2009.080332 49.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
FEBS J 2011; 278:427-41; PMID:21182594; http://dx.doi.org/10.1111/j.1742-4658.2010.07975.x 50.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Virol 2011; 85:6293-308; PMID:21490089; http://dx.doi.org/10.1128/JVI.00001-11 51.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Autophagy 2007; 3:542-5; PMID:17611390; http://dx.doi.org/10.4161/auto.4600 52.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Cell Sci 2011; 124:161-70; PMID:21187343; http://dx.doi.org/10.1242/jcs.064576 53.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Science 2011; 331:456-61; PMID:21205641; http://dx.doi.org/10.1126/science.1196371 54.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Free Radic Res 2008; 42:625-32; PMID:18608517; http://dx.doi.org/ 10.1080/10715760802244768 55.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Pharmacol Ther 2015; 149:124-38; PMID:25512053; http://dx.doi.org/ 10.1016/j.pharmthera.2014.12.001 57.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Mol Cell Biol 2002; 22:1049-59; PMID:11809797; http://dx.doi.org/10.1128/MCB.22.4.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Stem Cells 2009; 27:1822-35;PMID:19544417; http://dx.doi.org/10.1002/stem.123 59.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Oncogene 2007; 26:5833-39; PMID:17384683; http://dx.doi.org/10.1038/sj.onc.1210402 60.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
Biochem J.2012; 446:373-81; PMID:22686412; http://dx.doi.org/10.1042/BJ2012038561.,Non-OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
J Cell Biol 2007; 176:749-55; PMID:17353355;http://dx.doi.org/10.1083/jcb.200612047 62.,OADS,/arxiv_data1/oa_pdf/2d/7d/kccy-15-01-1121326.PMC4825783.pdf
